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Introduction
The term “epigenetics” was coined for the first time by Conrad Waddington (1905–
1975), as “the branch of biology which studies the causal interactions between genes 
and their products, which brings the phenotype into being” (Waddington, 1942). As the 
name indicates epi- (Greek: επί- over, above, outer) –genetics adds an additional layer 
of information to the genomic information that can explain heritable changes while 
leaving the DNA sequence unchanged. These additional layers of information often 
include alterations in the chromatin template. Chromatin is a complex combination of 
DNA and histone proteins which are packaged in defined units called nucleosomes. 
Nucleosomes are the building blocks of chromatin comprising of 147bp of DNA 
wrapped around a histone octamer comprising of a doublet of each of the core histone 
proteins H2A, H2B, H3 and H4. In the last decade, the area of epigenomics grasped 
widespread attention and a plethora of studies revealed various factors, including 
histone modifications, DNA methylation, DNA accessibility and non coding RNAs 
as key epigenetic decorations setting up complex chromatin environments in a given 
cell type. Most of the epigenetic regulation is derived from the covalent and/or non-
covalent modifications occurring either on histone proteins or directly on the DNA 
template, along with nucleosome positioning and (non-coding) RNA transcription. In 
turn the chromatin conformation is rendered accessible (euchromatin) or inaccessible 
(heterochromatin) for various nuclear activities. In this chapter an overview of 
chromatin architecture and the regulatory factors shaping the chromatin landscape 
is presented. Moreover, roles of the epigenetic modifiers in the development of 
hematological malignancies, specifically with respect to myeloid leukemias are 
introduced.
Chromatin accessibility
In eukaryotes chromatin assembly is governed by a series of events starting from the 
deposition of histone proteins on DNA to form nucleosomes, nucleosome array higher 
order folding and histone post translational modifications that establish a particular 
chromatin state. Furthermore, chromatin remodelers and other chromatin associated 
proteins distributions give rise to different functional domains (Polo and Almouzni, 
2006). Based on the type of chromatin modifications present, variable transcription 
factors get access to the DNA and different biological pathways are functionally set. 
Due to the complex nature of interactions between different chromatin regions as well 
as transcription factors it is still quite challenging to elucidate the exact mechanism 
of action that renders chromatin accessible or inaccessible (Li and Reinberg, 2011; 
Loden and van Steensel, 2005; Singh Sandhu et al., 2011). Conventional assays based 
on restriction enzymes, DNaseI, MNase or UV treatment have been used to assess the 
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chromatin accessibility status (Gross and Garrard, 1988). However, with the recent 
advancement from the technological aspects and introduction of next generation 
sequencing (NGS), various genome-wide studies have attempted to present further 
insights into chromatin organization and the factors involved (de Wit and van Steensel, 
2009; Schones and Zhao, 2008). Accessibility dynamics are important especially at 
the regulatory chromatin regions involved in the process of cellular differentiation 
and development as evident by some genome-wide studies mapping chromatin 
accessibility (Boyle et al., 2008; Gargiulo et al., 2009; Thomas et al., 2011; Zhang et 
al., 2011) (Table 1).
Table 1. Methods for genome-wide chromatin accessibility mapping.
Name Method Properties
Nuclease Accessible site 
sequencing
(NA-seq)
Restriction enzymes
NlaIII, HpaII, MspI
Sequence specific cutting, identifies regulatory 
regions ranging from promoters to enhancers 
depending upon enzymes used
DNaseI Hypersensitive site 
sequencing
(DNase-seq)
DNaseI
Identifies the accessibility pattern in regulatory 
regions based on their sensitivity to DNaseI 
cleavage
Formaldehyde assisted 
identification of regulatory 
regions
(FAIRE-seq)
Formaldehyde 
crosslinking and 
sonication
Method involves formaldehyde crosslinking 
and successive chromatin sonication. 
Accessible regions are identified by analyzing 
non-crosslinked chromatin fragments
Genome-wide chromatin accessibility patterns can help to identify potential regions 
involved in transcriptional activities, as well as the genomic footprints which escaped 
endonuclease cleavage because of the binding of the trans-acting factors (Hesselberth 
et al., 2009). Overall, the knowledge of the chromatin accessibility landscape of 
a particular cell type can facilitate the understanding of molecular mechanisms 
underlying different biological pathways.
Covalent chromatin modifications 
Histone tails protruding out of the nucleosomes can undergo different kinds of 
covalent post translational modifications. Until now, more than 60 modified amino 
acid residues bearing a wide range of modifications, ranging from methylation, 
acetylation, phosphorylation, ubiquitylation, sumoylation, to ADP ribosylation have 
been described for histone proteins (Kouzarides, 2007; Tan et al., 2011). These histone 
modifications are the basis of the “histone code” hypothesis according to which the 
combinatorial effect of all these modifications is a key factor which determines the 
biochemical outcome in a particular chromatin environment (Jenuwein and Allis, 
2001; Strahl and Allis, 2000). However, the authenticity of the term “histone code” 
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and the understanding of the precise mechanism by which this histone code governs 
DNA-histone interactions remain elusive. 
Different classes of enzymes or “writers” are associated with the deposition of these 
histone modifications. Depending upon the kind of modifications deposited different 
“readers” or “effectors” can then further define the functional outcome of these 
modifications, for example via alteration of the local chromatin environment for 
proper (de)regulation of the gene expression programs (Chi et al., 2010). Moreover, 
all these histone modification are subjected to reversibility and depending upon the 
functional response required, they can be removed by “erasers”. These chromatin 
associated activities are co-ordinated through the combinatorial effects of different 
proteins having specialized motifs responsible for various chromatin modifying 
activities. In fact, ‘reader’ protein motifs are often found in conjunction with ‘writer’ 
and ‘eraser’ motifs in the same polypeptide or in distinct proteins that form complexes 
together. This provides a conceptual framework for a ‘signal transduction’ model 
of the histone code, whereby one event leads to another, ultimately tailoring local 
chromatin properties to suit the cell’s needs (Chi et al., 2010; Ruthenburg et al., 2007; 
Yun et al., 2011). A further level of complexity is caused by the fact that the ‘writers’ 
and ‘erasers’ of the histone code also target non-histone proteins such as transcription 
factors and other ‘readers’, ‘writers’ and ‘erasers’(Lohrum et al., 2007).
Acetylation
Although research on histone modifications has only gained broad interest over 
the last two decade, it was already known for several decades that histones can be 
post translationally altered. For example, already more than 40 years ago histone 
acetylation was identified and suggested to have a link with transcriptional activity 
(Allfrey et al., 1964). Later, evidence showed that acetylation can occur at all histones 
and, especially acetylated H3 and H4 are associated with a more accessible chromatin 
structure and active transcription (Sealy and Chalkley, 1978; Struhl, 1998; Vidali et 
al., 1978). 
The enzymes involved in setting the acetylation mark are called histone 
acetyltransferases (HATs) and the enzymes that remove the mark are known as histone 
deacetylases (HDACs) (Wang et al., 2009). Alterations in the acetylome, for example 
through mutations of HATs or HDACs, or through aberrant HDAC recruitment have 
been reported in various cancers, and therefore have been proposed as a potentially 
important drug targets (Dekker and Haisma, 2009; Martens et al., 2010; Ropero and 
Esteller, 2007; Secrist et al., 2003).
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Methylation
Methylation is another important histone modification that mostly occurs at lysine 
and arginine residues. Histone methyl transferases (HMTs) are the enzymes 
responsible for the deposition of methylation mark (Zhang and Reinberg, 2001). 
The locations and number of methyl groups added on a histone amino acid are of 
crucial importance for the biological response. For example, methylation of the 
H3K4 residue is associated with an accessible chromatin conformation and leads to 
active transcription, while methylation at lysines 9 or 27 of histone H3 are associated 
with transcriptionally inactive chromatin and probably a more compact chromatin 
conformation (Barski et al., 2007). In addition, variations in the number of methyl 
groups on the lysine and arginine residues are known to result in different biochemical 
effects on the chromatin template. For example, H3K4me1 (histone H3 lysine 4 mono 
methylation) is associated with enhancer regions located mostly in intergenic regions 
(Heintzman et al., 2009; Heintzman et al., 2007) while H3K4me3 (histone H3 lysine 
4 trimethylation) is associated with (mostly) active gene promoters (Santos-Rosa et 
al., 2002). Histone demethylases are the enzymes responsible for removing specific 
methyl groups (Mosammaparast and Shi, 2010).
Histone variants
Apart from the histone modifications themselves, replacement of some of the canonical 
histone proteins with histone variants can also alter chromatin compaction and 
regulate transcriptional activity (Sarma and Reinberg, 2005). Various histone variants 
have been described in mammals, for example, the histone H3 variants, including 
CENP-A and H3.3 and the H2A variant, H2A.X, which is involved in DNA damage 
response (Talbert and Henikoff, 2010). Another important H2A variant is H2A.Z, 
which is mostly found at accessible chromatin regions (Sarma and Reinberg, 2005). 
Overall the type and location of histone modifications as well as presence of different 
histone variants are the main predictors of the degree of chromatin compaction and 
execution of gene expression programs. 
DNA methylation and chromatin silencing
DNA methylation is another important and well characterized epigenetic mark. 
DNA methylation occurs at the 5th position of the cytosine pyrimidine ring (5mC) 
in CpG dinucleotides and is a prevalent epigenetic modification that directly targets 
DNA. DNA methylation is implicated in gene silencing and is indispensable in a 
wide variety of processes including normal cell development, maintenance of 
pluripotent stem cells, imprinting and X-chromosome inactivation (Bird, 2002). 
The DNA methyltransferases DNMT1, DNMT3A and DNMT3B are responsible for 
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maintenance (DNMT1) and deposition (DNMT3A and 3B) of the DNA methylation 
pattern (Goll and Bestor, 2005). In vivo studies revealed the occurrence of several 
developmental and growth defects in mouse embryos deficient for these DNMTs (Li 
et al., 1992; Okano et al., 1999). Moreover, in embryonic stem cells which represent 
the developmentally ground state of cells, DNA methylation has been shown to 
play a key role in maintaining cell pluripotency by controlling downstream cell fate 
determining genes (Altun et al., 2010; Broske et al., 2009; Meissner et al., 2008). A 
crosstalk between DNA methylation and histone modifications such as H3K9me3 and 
H3K27me3 is also reported to regulate the transcriptional events at different genomic 
loci (Kondo, 2009). Furthermore, DNA methylation and histone modification levels 
are also found altered in several cancers and hematological malignancies (Chi et al., 
2010; Figueroa et al., 2010).
Although, DNA methylation has been known for over 40 years, only recently 
another epigenetic modification on the DNA template has been discovered, namely 
5 hydroxymethylcytosine (5hmC) (Matarese et al., 2011; Scarano et al., 2005). The 
5hmC mark is essentially an oxidative product of 5mC and the enzymes responsible 
for setting this modification belong to the TET family (Tahiliani et al., 2009). 
Although levels of 5hmC are found to be strongly altered in several human cancers 
(Jin et al., 2011) and mutations in the TET family of proteins have been implicated in 
various myeloid malignancies (Delhommeau et al., 2009; Langemeijer et al., 2009), 
the exact biological role of this modification is not yet clear. In conclusion, all the 
above mentioned chromatin modifications can create an epigenetic pattern which can 
be read by different transcription factors and chromatin modifiers to set up a closed or 
accessible chromosomal conformation, which is required to govern the proper gene 
expression programs (Figure 1). 
Non-Coding RNAs and transcriptional regulation
Non-coding RNAs (ncRNAs) are functionally distinct RNA molecules which are not 
eventually translated into a protein product. In cells, ncRNAs have been shown to be 
involved in regulation of mRNA stability and biochemical fate (Mattick and Makunin, 
2006). Non-coding RNAs include various RNA molecules, ranging from transfer 
RNAs (tRNA), ribosomal RNAs (rRNA) and snoRNAs to long non-coding RNAs 
as well as microRNAs (miRNA) with specialized biological functions. The exact 
number of the non-coding RNAs in the human genome is not yet known. Although, 
bioinformatic algorithms have predicted a large number of these RNAs (Birney et al., 
2007), however, more functional studies are needed to find out the role of these non-
coding RNAs in cells. 
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Figure 1. Model of the chromatin structure in a cell. 
Depicted above are the Heterochromatin (inaccessible) and Euchromatin (accessible) 
chromatin conformations. The inaccessible chromatin conformation is attained by different co-
repressor complexes, repressive histone modifications (pink) and DNA methylation (black). On 
the other hand, accessible chromatin structure (euchromatin) associated with transcriptional 
events requires the involvement of co-activator complexes and the active histone modifications 
(yellow).
Non-coding RNAs have also been linked to human diseases (Esteller, 2011; Taft et 
al., 2010). Over the last decade miRNAs have emerged as one of the most extensively 
studied non-coding RNA class. They have been proposed as key regulators of normal 
cellular development and were found to be expressed in aberrant fashion in various 
cancers (Liang et al., 2007; Lu et al., 2008; Trang et al., 2008). 
MicroRNAs in epigenetic regulation
MicroRNAs are small, approximately 18-25 nucleotide long, non protein coding RNA 
molecules derived from their long primary transcripts (pri-miRNA) in a step-wise 
process. First the miRNA coding genes are transcribed to long pri-miRNAs which 
are processed in the nucleus by RNAse III Drosha into stem loop precursors called 
as pre-miRNAs (Lee et al., 2003). In the next step these pre-miRNAs are further 
processed in the cytoplasm by Dicer enzyme to mature miRNAs (Lee et al., 2004). 
Mature miRNAs bind to a small “seed” region in the mRNA of their respective target 
gene and negatively regulate its expression by degrading the mRNA or inhibiting 
its translation. MicroRNAs are found in both animals (Lagos-Quintana et al., 2001) 
and plant genomes (Reinhart et al., 2002). Since 1993 when the first miRNA was 
described in C. elegans (Lee et al., 1993), they have been extensively investigated 
and are nowadays in the limelight because of their suggestive roles in a wide range of 
biological processes (Chen et al., 2004; Lim et al., 2005). As miRNAs are involved 
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in the regulation of a wide spread of biological processes, their deregulation has also 
been reported in several diseases ranging from hematopoietic malignancies to several 
cancers (Kluiver et al., 2006; Lu et al., 2005). More than 1000 miRNAs have been 
identified so far, and they could be involved in regulation of as much as 60% of 
the human mRNAs (Martignani et al., 2011). miRNA expression is quantified by 
methodologies such as quantitative RT-PCR, miRNA expression arrays and high 
throughput sequencing (Dixon-McIver et al., 2008; Krichevsky et al., 2003; Liu et 
al., 2004; Lu et al., 2005; Morin et al., 2008). Indeed, mis-regulation of miRNA is 
commonly found in diseases. For example, miRNAs can be located at fragile sites 
which are either deleted or duplicated in various cancers. These alterations can 
enhance tumor progression either by acting on a tumor suppressor gene (when the 
oncogenic miRNA is over expressed) or by over expression of an oncogene (when the 
tumor suppressor miRNA is deleted) (Zhang et al., 2007). In addition, one miRNA can 
target several genes and one gene can have binding sites for several miRNAs, enabling 
a complex pattern of post transcriptional regulation of protein expression (John et al., 
2004). Finally, due to the accumulated evidence about the importance of miRNAs 
in cancer progression they have been identified as potential biomarkers and even 
therapeutic targets for cancer treatment (Lovat et al., 2011). Overall, identification 
of the non-coding RNA molecules and their biological function can have various 
implications in developing new treatment modalities against multiple diseases.
Genome-wide analysis of epigenetic modifications and chromatin conformation 
The recent advancements in high throughout sequencing have allowed researchers 
to overcome several experimental barriers to study chromatin features in depth. For 
example Chromatin immuno precipitation coupled to high throughput sequencing 
(ChIP-seq) is nowadays widely used for profiling genome-wide histone modification 
patterns and protein DNA interactions (Barski et al., 2007; Johnson et al., 2007). 
ChIP sequencing is based on the use of an antibody directed against the modification 
of interest, after which the captured DNA is sonicated and sequenced using a high 
throughput sequencing platform. For analysis of global DNA methylation patterns 
techniques such as Methyl DNA chromatin immunoprecipitation (MeDIP) and 
MethylCap are used to enrich for methylated DNA fractions that can be investigated 
further via next generation sequencing (NGS), while even the methylation level of all 
individual CpGs in the genome can be analyzed using Bisulfite sequencing (Bock et 
al., 2010; Lister et al., 2009). 
In addition to these modifications on the DNA and the histones also the chromatin 
accessibility architecture in a given cell type is of utmost importance to fully 
understand the epigenetic mechanisms in normal and disease states of a cell. Use 
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of different nucleases like restriction enzymes or DNaseI are common practice for 
mapping specific accessible chromatin regions, in addition these techniques have been 
translated into genome-wide procedures (Boyle et al., 2008; Gargiulo et al., 2009). In 
addition to the use of nucleases, another technique, called FAIRE (Formaldehyde-
Assisted Isolation of Regulatory Elements) can be used to identify the accessible 
chromatin regions associated with regulatory activities (Gaulton et al., 2010; 
Giresi et al., 2007) (Table 1). Overall, the chromatin landscape of cells in normal 
or diseased states is a combinatorial effect of the (mal)functioning of the enzymes 
responsible for chromatin modifications and either hypo-or-hyper deposition of all the 
above mentioned and other epigenetic marks. Therefore, by making use of massive 
parallel sequencing technologies the role of all these epigenetic factors in setting 
up a particular chromatin environment and proper execution of various biological 
phenomena like development of embryonic stem cells, X-chromosome inactivation, 
genetic imprinting, and lineage specification can now be very well documented, not 
only during normal development and differentiation, but also under environmentally 
conditioned or pathologically perturbed settings. 
Epigenetic regulation of normal and malignant Hematopoiesis
Hematopoiesis, the process of blood development, is one of the best characterized 
multilineage developmental systems. All cell types found in blood originate 
from hematopoietic stem cells (HSCs), which give rise through a hierarchical 
differentiation process to all these specialized cell types. The HSCs have the potential 
to self renew as well as to terminally differentiate into all kinds of blood cells (Figure 
2). Hematopoiesis is a continuous process as not only the pool of pluripotent stem 
cells is maintained throughout the life, but all kinds of specialized blood cells are 
also produced during the entire life span of a human. This whole system of blood 
cell formation not only involves a complex signaling cascade, but is also under strict 
epigenetic control allowing the timely activation of the correct gene expression 
programs which lead to the right blood cell composition. Starting from HSCs in the 
course of development precursor cells with restricted pluripotency are formed, the 
main branches being the lymphoid compartment that gives rise to B and T cells and 
the myeloid compartment that gives rise to monocytes, macrophages, erythrocytes and 
megakaryocytes (Kondo, 2010; Laiosa et al., 2006). These terminally differentiated 
blood components comprise the immunological system, which provides the defense 
mechanism to the body throughout the life span. Classically the immune system is 
categorized in two subdivisions which are the innate and adaptive immune systems 
(Table 2).
General Introduction
21
Table 2. Types of the Immune responses.
Adaptive Immune Response Innate Immune Response
Pathogen and antigen specific response Response is non-specific, antigen independent
Lag time between exposure and maximal response Exposure leads to immediate maximal response
Exposure leads to immunological memory No immunological memory
Found only in vertebrates Found in nearly all forms of life
Although both systems provide defense against foreign invasion, they differ in the 
cellular components used and the response generated (Murphy, 2012). For example T 
and B cells make up the adaptive immune compartment where the response to foreign 
invader is tailored via chromosome recombination and cellularly maintained to keep 
the memory of previous encounters to provide a memory based response for future 
infections. By contrast, the innate immune response comprises of monocytes and 
macrophages and the response generated by this system is more general and non-
specific. Different studies have suggested a tight epigenetic regulation comprising of 
a complex interplay between cis elements and trans factors including transcription 
factors and chromatin-modifying enzymes to give rise to all these specialized cells 
(Cedar and Bergman, 2011; Weishaupt et al., 2010). 
With the passage of time, a better understanding of molecular mechanisms of 
hematopoietic cell fate determination and differentiation by different transcription 
factors like PU.1, RUNX1, GATA1 have been documented (Burda et al., 2010; 
Iwasaki et al., 2005; Kastner and Chan, 2008; Speck and Gilliland, 2002). As such, it 
became clear that any aberrant change which can disturb the delicate balance between 
proliferation, differentiation and apoptosis can influence the normal hematopoietic 
development and can lead to the onset of hematopoietic diseases such as leukemia. 
Depending upon the type of hematopoietic compartment that is perturbed, this can 
either lead to lymphoid or myeloid abnormalities/malignancies. Several genetic 
aberrations involving key transcription factors like chromosomal rearrangements 
involving PML and RARα, or AML1 and ETO (Sell, 2005), mutations such as 
DNMT3a (Ley et al., 2010; Takahashi, 2011), and miRNA deletions such as miR15-
16 (Calin et al., 2008) have been linked to the cause of these malignancies. It is clear 
that knowing both the binding pattern of a particular transcription factor as well as 
understanding the underlying chromatin architecture can help to better comprehend 
how these factors regulate cell fate in different hematopoietic lineages. 
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Figure 2. Schematic overview of the hematopoietic system. 
The process of blood cell formation starts from a hematopoietic stem cell and gives rise to 
the two main blood cell compartments lymphoid and myeloid. The lymphoid and myeloid 
progenitors give rise to all kind of specialized blood cells. Figure reproduced and modifi ed 
from (Jos Domen et al., 2006).
 
Acute myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneous malignancy of the myeloid 
lineage of the hematopoietic system in which rapid expansion and accumulation of 
the immature myeloid cells interferes with normal blood cell formation (Lowenberg 
et al., 1999). Although AML is a rare disease, its incidence is expected to increase 
as the population ages (Deschler and Lubbert, 2006). The main symptoms of AML 
include fatigue, unusual bleeding, fever, multiple infections, aching bones and pain in 
the joints. Due to the high proliferative nature and ability to expand, AML can be fatal 
within weeks if left untreated. It is thought that transformation from a pre-leukemic 
state to a fully functional leukemia involves the combined action of genetic aberration 
and other aberrations like changes to the chromatin modifying machinery (Blum and 
Marcucci, 2005; Plass et al., 2008) or altered miRNA expression (Havelange et al., 
2009). Overall, a fully transformed leukemic state results from the combinatorial effect 
exerted by non-reversible genetic aberrations and potentially reversible epigenetic 
chromatin features (Uribesalgo and Di Croce, 2011). AMLs can be divided into 
subtypes according to French-American-British (FAB) classifi cation (Bennett et al., 
1976). This classifi cation of AMLs is mainly based on blast morphology. However, 
with the advancements in the fi eld also genetic characteristics have been associated 
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with these subtypes including chromosomal translocations (generating fusion 
proteins), such as PML-RARα with M3, AML1-ETO with M2 and CBFβ-MYH with 
M4 (Table 3). These recurrent genetic aberrations have important prognostic features 
for a majority of AML patients, however, a large fraction of AML cases do not have 
an abnormal karyotype (Valk et al., 2004).
In recent years, due to the use of more sophisticated high throughput sequencing 
technologies like ChIP-seq and transcriptome profiling, the role of these leukemia 
associated aberrations and other genetic players like transcription factors, chromatin 
modifying enzymes and miRNAs has been characterized (Bonadies et al., 2011; 
Martens and Stunnenberg, 2010; Rice et al., 2007; Wouters et al., 2009). This 
increasing understanding of the molecular mechanisms and the genes involved has 
opened the way for new treatment modalities based on target drug delivery for both 
the genetic and epigenetic culprits of some of the acute myeloid leukemias. However, 
AML remains a deadly disease with a majority of the patients ultimately succumbing 
(Appelbaum et al., 2001), making it essential to further uncover the molecular 
mechanisms that underlie this disease.
Table 3. FAB classification of AML and associated chromosomal abnormalities. 
FAB subtype Description Comments
M0 Undifferentiated Myeloperoxidase negative, myeloid markers positive
M1 Myeoloblastic without maturation Some evidence of granulocytic differentiation
M2 Myeoloblastic with maturation Divided into those with t(8;21) AML1-ETO fusion and those without
M3 Promyelocytic APL; most cases have t(15;17) PML-RARα or 
another translocation involving RARα
M4 & M4
EO
Myelomonocytic with bone-marrow 
eosinophilia
Characterized by inversion of chromosome 
16 involving CBFβ, which normally forms a 
heterodimer with AML1
M5 Monocytic Abnormalities involving 11q23 (MLL) 
M6 Erythroleukemia
M7 Megakaryoblastic GATA1 mutations in those associated with Down’s Syndrome
Oncofusion proteins and epigenetic landscape in AML
Amongst the most frequently found genetic aberrations in AML cases are the non-
random chromosomal translocations. These aberrations can result in the fusion of 
two different genes located on the translocated chromosomes, resulting in oncofusion 
proteins that have altered activities compared to the two wild type genes. In most cases 
these rearrangements juxtapose a DNA binding transcription factor with a protein that 
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has different function. As a result the fusion protein binds to DNA with the DNA binding 
motif of the transcription factor and due to its fusion partner, aberrantly regulates gene 
expression, often key hematopoietic regulators (Martens and Stunnenberg, 2010). 
These oncofusion proteins have been shown as main prognostic features of certain 
AML types, and resolving their molecular function in some cases has already led to the 
successful treatment of the leukemia subtype (Kumar, 2011). In most cases expression 
of the oncofusion proteins results in rapid expansion of premature blood cells with a 
differentiation blockage. Overall, leukemia associated oncofusion proteins have been 
suggested to alter the chromatin landscape by directly or indirectly interacting with 
transcription factors and histone modifying enzymes (Look, 1997). One of the best 
studied oncofusion protein associated with AML is PML-RARα, which is associated 
with the AML subtype called acute promyelocytic leukemia. Acute promyelocytic 
leukemia (APL) is an AML subtype (M3), characterized by the accumulation of 
immature granulocytes. Chromosomal translocation associated with APL involve 
fusions of the RARα on chromosome 17 with different fusion partners like PML, 
PLZF and NPM (Redner, 2002). PML-RARα is present in greater than 95% of the 
cases (Lo-Coco and Cicconi, 2011). This translocation results in the fusion of the 
PML gene on chromosome 15 with the RARα gene on chromosome 17 (de The et al., 
1990). The resultant chimeric protein retains the DNA binding domain of the RARα 
gene and the oligomerization domain of the PML gene, both of them are important 
for its transforming potential. PML-RARα shows a diverse repertoire of binding 
mainly at non-canonical retinoic acid response elements (RAREs) (Kamashev et al., 
2004; Martens et al., 2010). In normal mode, RARα plays a pivotal role in myeloid 
development. It binds to RAREs alone or in the form of a heterodimer with Retinoid X 
receptor (RXR) (Melnick and Licht, 1999). Transcriptional repression caused by the 
binding of this heterodimer and associated co-repressor complexes like N-CoR and 
SMRT is relieved upon ligand (RA) binding and leads to recruitment of co-activator 
complexes, resulting in gene activation (Jepsen and Rosenfeld, 2002). In the case 
of acute promyelocytic leukemia (APL), similarly to wild type RARα, PML-RARα 
recruits co-repressor complexes (Kamashev et al., 2004; Nagy et al., 1999) bearing 
HDAC activity (Lin et al., 1998), albeit in a more constitutive manner. This leads to 
continuous repression of important differentiation regulators, a resultant differentiation 
blockage and accumulation of premature granulocytes. Physiological doses of RA 
(10-9 to 10-7 M) are unable to release this repressive mode. However, pharmacological 
doses (10-6 M) can effectively release this repression and trigger the differentiation 
process. The simultaneous administration of all trans retinoic acid (ATRA) and 
anthracycline-based chemotherapy is currently considered as the standard treatment 
for diagnosed APL patients, although the use of arsenic trioxide is also in practice 
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(Sanz et al., 2009). As epigenetic perturbations also contribute significantly to the 
development of APL (Matsushita et al., 2006; Villa et al., 2004) additional treatment 
with ‘epi’-drugs like HDAC inhibitors has also been considered for APL treatment 
(Ferrara et al., 2001; Mai and Altucci, 2009). Recruitment of epigenetic modifiers 
like histone deacetylase activity is also found as a common mechanism of action in 
other AML associated oncofusion proteins like AML1-ETO t(8,21) (Gelmetti et al., 
1998; Grignani et al., 1998). Although there are similarities in the mode of action of 
different oncofusion proteins their leukemic repertoire is characteristic for different 
subtypes and clearly dependent on the transcription factors involved. 
In This Thesis
Studying the chromatin architecture and epigenetic features that render it compact or 
open is of utmost importance to fully understand the nuclear organization in a cell. 
This thesis focuses on the hematopoietic system and describes the chromatin features 
associated with acute myeloid leukemia as well as the influence of the epigenetic 
environment on terminally differentiated blood cells. Chapter 2 mainly discusses the 
functional aspects of the hallmark APL oncofusion protein PML-RARα, the epigenetic 
landscape associated with the PML-RARα genome-wide binding spectrum, the main 
gene targets and pathways of PML-RARα and its crosstalk with other transcription 
factors. Continuing on this aspect, work done in chapter 3 describes the genome-wide 
chromatin accessibility maps in APL but also in different acute myeloid leukemia 
(AML) cells. It focuses on the chromatin changes between undifferentiated and 
differentiated APL cells and in patient blasts. The results shown in this chapter suggest 
that oncofusion proteins localize to accessible chromatin regions. Apart from that 
there are specific histone modification patterns associated with functional accessible 
elements in APL cells and it is shown that chromatin accessibility together with p300 
binding and histone acetylation can serve as a characteristic mark of the genome-wide 
AML1-ETO and PML-RARα binding sites. Chapter 4 describes the influence of the 
epigenetic environment in generating “trained immunity” in monocytes, which are 
specialized blood cells that are part of the innate immune system. This study shows 
that C. albicans and beta-glucans induce functional reprogramming of monocytes, 
leading to enhanced cytokine production in vivo and in vitro. Results in this chapter 
show that monocyte training by beta-glucans is mediated by epigenetic reprogramming 
through stable and genome-wide changes in histone methylation at histone 3 lysine 4 
trimethylation with the specific induction of epigenetic changes in genes associated 
with innate immunity. In chapter 5 genome-wide strand specific RNA-seq analysis is 
done to identify the pri-miRNAs that are expressed in NB4 and SKNO-1 cell types, 
which represent the AML M3 and M2 subtypes respectively. Here, we identified a 
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set of > 100 miRNA transcripts, 43 of them showed dynamic expression between 
these two AML subtypes. Annotation of the validated target genes of these miRNAs 
gives a view of the miRNA (de)regulated pathways in PML-RARα and AML1-ETO 
expressing subtypes of AML.
Together, this thesis provides important insights into chromatin architecture of the 
AML genome and the epigenetic features which orchestrate the chromatin landscape 
in different blood cells.
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Abstract
PML-RAR (retinoic acid receptor) α is the hallmark protein of acute promyelocytic 
leukemia, a highly malignant subtype of acute myeloid leukemia that accounts for 
approximately 10% of all AML cases. Recently, several studies have been set out to 
obtain a comprehensive genome-wide view of the molecular actions of this chimeric 
protein. In this review we highlight the new insights that arose from these studies, in 
particular focusing on newly identified PML-RARα target genes, its interplay with 
RXR and deregulation of epigenetic modifications. 
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Introduction
Acute promyelocytic leukemia (APL) is a distinctive subtype of acute myeloid 
leukemia (AML) that accounts for approximately 10% of all AML cases (Jing, 2004). 
The disease represents a highly malignant form of leukemia with high bleeding 
tendency and a fatal course of only few weeks (Wang and Chen, 2008). The main 
diagnostic feature of APL is an aberrant chromosomal translocation that juxtaposes 
the PML gene on chromosome 15 and the RARα gene on chromosome 17 (Kakizuka 
et al., 1991). The resultant chimeric protein, which is found in over 95% of human 
APLs (Di Croce, 2005), retains the DNA binding and ligand binding domains of 
RARα and the multimerization domain of PML. In normal cells PML is a main 
constituent of nuclear bodies, which are matrix associated multiprotein containing 
domains involved in various biological functions like DNA-damage response and 
microorganism resistance through regulation of a wide range of proteins, amongst 
which are various transcription factors (Lallemand-Breitenbach and de The, 2010). 
In contrast, in APL, the expression of PML-RARα disrupts the localization of the 
wild type PML from nuclear bodies to numerous micro speckles (Brown et al., 2009) 
and induces a maturation block at the promyelocytic level (Wang and Chen, 2008). 
All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are the two most important 
drugs in clinical use for the treatment of early diagnosed APL. Both ATRA and ATO 
degrade the PML-RARα fusion protein by acting on the RARα and PML moieties, 
respectively. ATRA mainly degrades the protein through proteosome mediated 
pathways (Zhu et al., 1999) and caspases (Nervi et al., 1998), while ATO-induced 
degradation is initiated through sumoylation of the PML moiety. Both treatments 
ultimately lead to restoration of PML nuclear bodies (Lallemand-Breitenbach et al., 
2008; Zhang et al., 2010), but whether this is important for curing the disease is an 
open question.
Various mechanisms have been proposed for PML-RARα functioning. It has been 
suggested that PML-RARα can form homodimers without RXR (Minucci et al., 2000) 
or that it forms PML-RARα oligomers that heterodimerise with RXR (Jansen et al., 
1995; Perez et al., 1993). In addition, it has been suggested that during transformation 
PML-RARα induces a multitude of alterations in the chromatin architecture. These 
alterations are achieved through the recruitment of various epigenetic-modifying 
factors like histone deacetylase complexes such as SMRT (Lin et al., 1998) and 
N-CoR (Grignani et al., 1998) and DNA methyltransferases (Di Croce et al., 2002). 
In addition, recent evidence suggests co-recruitment of the histone methyltransferases 
SUV39H1 and polycomb repressor complexes which dictate the epigenetic state of 
H3K9 (Carbone et al., 2006) and H3K27 (Villa et al., 2007) respectively. Unfortunately 
most of these studies showed epigenetic alterations only around a limited set of binding 
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regions, in most cases the RARβ promoter. This was largely due to unavailability of 
the genome-wide PML-RARα target site repertoire. However, the recent advances 
in high throughput tools have, for the first time, made it possible to look at the 
genome-wide actions of PML-RARα and different epigenetic marks associated with 
its binding. Indeed, two recent studies have provided a more global picture of PML-
RARα functioning by identifying binding regions of PML-RARα using state-of-the-
art ChIP-seq and ChIP-on-chip technologies. Importantly, the new technologies even 
allowed extension from the commonly used model cell lines to primary APL blasts, 
highlighting the new opportunities that have now become available.
In this review we will focus on the various aspects of PML-RARα functioning with 
respect to its genome-wide binding spectrum, its interplay with RXR and its regulation 
of various epigenetic modifications. In addition we will discuss some of the newly 
identified target genes and target pathways of PML-RARα.
Altered RAR signaling in APL cells 
All-trans retinoic acid (ATRA) belongs to the group of vitamin A -derived substances 
and binds three major RARs, RARα, β and γ. The full execution of the ATRA 
signaling pathway operates by inducibly controlling the expression of the genes that 
have a direct repeat with spacing 2 or 5 (DR2 or DR5) in their promoter (de The et al., 
1991). Retinoid signaling has a key role in various developmental and differentiation 
processes. According to the classical model, RAR and RXR, another nuclear receptor, 
heterodimerise under non-ATRA conditions, recruit co-repressors and silence target 
gene expression. In this model, RAR binding to ATRA results in a conformational 
change in the RXR-RAR heterodimer, allowing recruitment of gene-activating 
complexes and resultant gene expression. In APL, PML-RARα is thought to behave 
functionally as an altered RARα that has lost the potential to respond to fluctuations in 
physiological ATRA concentration, and as a result acts as a constitutive transcriptional 
repressor for DR2- or DR5- containing genes. Strikingly, recent studies that analyzed 
the genome-wide PML-RARα binding sites not only identified DR2 and DR5 elements 
as the primary PML-RARα response elements, but also regions containing DR1, 
DR3 and DR4 motifs and even more atypical DR motifs with various spacing and 
orientation were detected (Martens et al., 2010) thereby extending in vivo previous in 
vitro data (Kamashev et al., 2004). This rather diverse repertoire of response elements 
present at PML-RARα binding sites underscores the idea of a gain of DNA binding 
capacity as an essential feature of PML-RARα mediated transformation. In addition 
to this extended binding potential, global binding data of PML-RARα using ChIP-seq 
revealed PML-RARα binding to the RARα, RARβ and RARα genes itself (Table 
1), suggesting that expression of these proteins is directly regulated by PML-RARα 
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(Martens et al., 2010). All these data suggest that PML-RARα affects ATRA signaling 
at multiple levels: first by regulating expression of the genes involved in transmitting 
the ATRA signals, second through an altered regulation of classical DR2- and DR5- 
containing RAR/RXR target genes and third through an extension of the (PML-)RAR 
binding potential towards more degenerate DR-containing regulatory sites. 
Table 1. Binding targets of PML-RARα (HG 18).
Gene name Chromosome Start PML-RARα peak End PML-RARα peak Peak location
GFI1 chr1 92714254 92714749 Gene body 
RUNX1 chr21 35159419 35160205 Gene body 
RUNX3 chr1 25221279 25222212 Distant 
JUND chr19 18263175 18264260 UpstreamFar 
JUNB chr19 12760448 12760879 UpstreamNear 
GATA2 chr3 129725052 129725491 Distant 
SETDB1 chr1 149165218 149165613 UpstreamNear 
DNMT3A chr2 25377769 25378201 Gene body 
JMJD1A chr2 86521292 86521853 UpstreamNear 
HDAC4 chr2 239913436 239913935 Gene body 
HDAC9 chr7 18323574 18323895 Distant 
JMJD3 chr17 7682360 7683526 UpstreamNear 
PU.1 (SPI1) chr11 47337456 47338471 Gene body 
RARA chr17 35762690 35763210 Gene body 
RARB chr3 25444370 25444950 UpstreamNear 
RARG chr12 51897334 51897732 Gene body 
PML-RARα heterodimerizes with RXR 
Although oligomerization of the RARα fusion proteins has been considered to be a 
crucial requirement to their oncogenic potential (Minucci et al., 2000), several studies 
support a role of RXR in the PML-RARα transformation process. RXR was already 
described as part of the PML-RARα oncogenic complex in in vitro settings (Kamashev 
et al., 2004). In addition, recent studies highlighted the importance of RXR in PML-
RARα mediated transcriptional repression (Zeisig et al., 2007; Zhu et al., 2007). 
These studies showed that impaired RXR binding by PML-RARα mutants impairs 
APL development in transgenic mice while still retaining transforming potential in 
vitro. Furthermore, they showed that silencing of RXR by shRNA suppresses the 
RARα fusion-mediated transformation in vitro. These studies were corroborated and 
extended by the identification of genome-wide association of RXR with PML-RARα 
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(Martens et al., 2010). For 99% of PML-RARα binding sites, association of RXR was 
detected. Together these studies highlight the importance of RXR in the PML-RARα 
mediated transformation process. It may therefore be interesting to also test RXR 
antagonists (Altucci et al., 2007) in this subtype of AML.
PML-RARα cross talks with other transcription factors
Apart from interacting with RXR, PML-RARα has been suggested to interact 
with many other proteins. Amongst these are various key hematopoietic regulatory 
transcription factors such as GATA-2, PU.1 and AP-1 factors (Table 1). PML-RARα 
is proposed to be involved in inhibition of AP-1 transcriptional activity in an ATRA 
dependent manner. This is illustrated by the observation that PML-RARα interacts 
with c-Jun and c-Fos and that the repressive effect on AP1 target sites is reversed 
by ATRA treatment (Doucas et al., 1993). There is also evidence of a physical 
association of GATA2 with PML-RARα. This interaction is suggested to result in 
enhanced GATA-2 dependent transactivation capacity (Tsuzuki et al., 2000). In line 
with these two studies is the observation that PML-RARα binding was detected near 
several AP1 factors, such as JUNB and JUND, but also GATA2 (Martens et al., 2010), 
suggesting that these factors are affected both at the level of their expression as in their 
targeting capacities. In addition, we observed PML-RARα binding at several other 
key regulators of hematopoiesis such as PU.1 (see below) RUNX1, RUNX3 and GFI1 
(Table 1). This extends the observation that PML-RARα regulates the classical targets 
of the retinoic acid signaling pathway to many other key players in hematopoiesis. 
Binding of PML-RARα with PU.1
PU.1 is a protein that is essential for the hematopoietic differentiation process. PU.1 
mutants lead to embryonic lethality at a late gestational stage (Scott et al., 1994). Mice 
that have homozygous disruption of the DNA binding domain of PU.1 have severe 
septicemia and die within 48 h of their birth (McKercher et al., 1996). In addition, 
PU.1 has been shown to be essential for reprogramming B-cells into the myeloid 
lineage (Xie et al., 2004). Already in 2006 it was proposed that PML-RARα interacts 
with PU.1 and that the action of PU.1 is suppressed upon expression of PML-RARα, 
thereby resulting in a differentiation block (Mueller et al., 2006). In these studies, 
ATRA treatment and the ensuing PML-RARα degradation resulted in restoration 
of PU.1 expression and a release of the differentiation block. These studies already 
hinted at the molecular interplay of PU.1 with PML-RARα. A recent study based 
on genome-wide binding of PML-RARα using ChIP-sequencing in a PML-RARα 
inducible cell model further shed light on the PU.1 and PML-RARα interaction 
(Wang et al., 2010). In this study more than 84% of the detected PU.1 motifs were 
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found in close vicinity of variably spaced direct repeats (DRs). Further functional 
analysis suggested that the binding of PML-RARα to the regions containing both 
PU.1 and DRs is prerequisite for subsequent repression of chromatin at PU.1 targeted 
regions. In addition to these observations, the PU.1 gene was found as a direct target 
of PML-RARα (Martens et al., 2010). Interestingly, binding of PML-RARα was not 
detected at the promoter regions but rather in the third intron of the PU.1 gene (Table 
1). As this intronic region has also been reported to contain the transcription start site 
of an antisense transcript that acts as a putative negative regulator of PU.1 expression 
(Ebralidze et al., 2008), these results identify for the first time PML-RARα-mediated 
regulation of a non-coding transcript. 
PML-RARα affects the epigenome
Multiple studies have suggested that central to oncogenic transformation in APLs is 
the PML-RARα-induced mis-targeting of the epigenetic machinery, thereby causing 
a perturbation of the normal epigenetic landscape. Genome-wide binding analysis of 
PML-RARα (Martens et al., 2010) revealed that various enzymes that can set different 
chromatin modifications are targeted by PML-RARα including JMJD3 (H3K27me3 
demethylation), SETDB1, JMJD1A (H3K9 modifiers), deacetylases like HDAC4 and 
9 and genes involved in DNA methylation, such as DNMT3A (Table 1). These findings 
suggested that PML-RARα expression has the potential to confer a genome-wide 
alteration in epigenetic make-up. In addition to the direct transcriptional regulation of 
epigenetic enzymes, different labs have explored the epigenetic marks that are recruited 
by PML-RARα itself. Histone marks like H3K27me3 and H3K9me3, as well as DNA 
methylation, have been proposed to be positively correlated with PML-RARα binding, 
whereas H3 acetylation was associated with loss of PML-RAR binding. The dynamic 
changes of DNA methylation, H3K9me3 and H3K27me3 functioning are suggested to 
be regulated by DNA methyltransferases, histone methyltransferase (SUV39H1) and 
polycomb repressive complex 2 (PRC2), respectively, and all these proteins have been 
suggested to interact with the PML-RARα complex in several independent studies 
(Di Croce et al., 2002; Carbone et al., 2006; Villa et al., 2007). H3 acetylation was the 
first chromatin modification associated with PML-RARα binding and is a mark which 
is negatively correlated with PML-RARα binding. Mechanistically, this is thought to 
be achieved through PML-RARα-mediated recruitment of HDACs (Lin et al., 1998; 
Grignani et al., 1998). Indeed, in vivo studies could show that there is a significant 
increase of H3 acetylation upon ATRA- mediated degradation of PML-RARα at the 
RARβ promoter (Villa et al., 2007). Still, the limiting factor to this observation and 
also other studies that investigated epigenetic marks was the number of PML-RARα 
binding regions addressed and, therefore the generality of the proposed mechanisms. 
Chapter 2
40
The recent genome-wide interrogation of APL (Martens et al., 2010) allowed for the 
first time expansion to all binding regions of PML-RARα. This showed that there 
was a significant regulation of local H3 acetylation at more than 80% of PML-RARα 
binding regions, illustrated by the observation that H3 acetylation levels at these 
sites were significantly elevated upon ATRA-induced PML-RARα degradation. In 
contrast, changes in other epigenetic marks such as H3K9me3, H3K27me3 and DNA 
methylation could not be generalized towards all PML-RARα binding sites, as the 
vast majority of sites did not show a significant change after ATRA treatment. These 
findings are of significant worth, as they point out the importance of the role of histone 
deacetylases in maintenance of repressed chromatin architecture at PML-RARα 
binding sites. This sanctions the idea of making HDACs direct targets for therapeutic 
treatment of APL by using specific inhibitors for these proteins.
Outlook
In this review, we focused on two recent studies that describe a global analysis of PML-
RARα (Martens et al., 2010; Wang et al., 2010). Both studies have shown near 3000 
genome-wide direct targets of PML-RARα by using high throughput sequencing and 
array-based technologies, and provided a significant step forward in understanding 
PML-RARα mediated leukemogenesis. Although these studies used independent 
platforms, several common conclusions were drawn (Figure 1). One of these is the 
extended binding repertoire of PML-RARα in comparison with the non-fused RAR. 
Indeed, direct, inverted and everted repeats with various spacing and orientation were 
detected in vivo for PML-RARα binding sites in comparison with the classical DR2 
and DR5 motifs that are hallmarks of heterodimerized RARα/RXR binding regions. 
In addition to the DR motifs, the discovery of  DNA motifs for PU.1 resulted in the 
finding that PU.1 colocalizes with PML-RAR. 
The above studies highlighted the fact that PML-RARα does not only bind to the 
promoter regions of target genes but also has a rather diverse repertoire of binding 
sites. This complex binding spectrum suggests a potential influence on long range 
chromosomal interactions by PML-RARα. The wide-ranging molecular alterations 
induced by PML-RARα are further illustrated by the fact that PML-RARα regulates 
several key regulators of normal hematopoiesis such as PU.1, GATA-2, RUNX1 
and many others, as well as different pathways like RAR signaling. In addition, 
exploration of the epigenetic environment of the APL genome before and after ATRA 
treatment gave significant insights into PML-RARα chromatin regulation. An inverse 
correlation of PML-RARα with H3 acetylation was revealed at the PML-RARα 
binding sites themselves, while the genome-wide epigenetic environment was also 
significantly remodeled. Still, more in-depth functional studies are needed to provide 
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an answer as to whether histone H3 acetylation levels or other epigenetic markings are 
crucial in the PML-RARα induced transformation process. Nevertheless, current data 
already hints at potential drug targets such as acetyltransferases and deacetylases, as 
well as RXR for treatment of APL. 
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Figure 1. Model of PML-RARα binding.
(A) PML-RARα in conjunction with RXR and PU.1 binds DR motifs and recruits repressor 
complexes, resulting in histone hypoacetylation and transcriptional silencing. (B) All-trans 
retinoic acid (ATRA) or arsenic trioxide (ATO) mediates degradation of PML-RARα, which is 
replaced by the RARα/RXR heterodimer, resulting in recruitment of activating complexes and 
transcriptional activation. HAT, histone acetyltransferase; HDAC, histone deacetylase.
Despite the wealth of important insights on PML-RARα functioning provided by the 
above studies, the question still remains as to what the crucial determinant for PML-
RARα binding to a particular region actually is. Is it the underlying motif, interaction 
with other transcription factors, the chromatin accessibility, or a combination of 
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all three? In order to obtain a better comprehension of normal hematopoiesis and 
leukemia it will be important to address these crucial questions. At the same time, 
deeper insight is required into the molecular behavior of other oncofusion proteins 
that harbor functional properties similar to PML-RARα’s such as AML1-ETO which 
is the result of the t(8;21) chromosomal translocation, or the inv (16) translocation 
that gives rise to the CBFβ-MYH11 oncofusion protein (Martens et al., 2010). 
A comparative analysis of the molecular actions of several oncofusion proteins is 
expected to uncover some of the more general mechanisms that are used by these 
proteins to transform cells.
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Abstract
Chromatin accessibility plays a key role in regulating cell type specific gene expression 
during hematopoiesis, but has also been suggested to be aberrantly regulated during 
leukemogenesis. To understand the leukemogenic chromatin signature we analyzed 
acute promyelocytic leukemia (APL), a subtype of leukemia characterized by 
the expression of RARα-fusion proteins such as PML-RARα. We used nuclease 
accessibility sequencing in cell lines as well as patient blasts to identify accessible 
DNA elements and identified over 100,000 accessible regions in each case. Using 
ChIP-seq we identified H2A.Z as a histone modification generally associated with 
these accessible regions while unsupervised clustering analysis of other chromatin 
features including DNA methylation, H2A.Zac, H3ac, H3K9me3, H3K27me3 and 
the regulatory factor p300 distinguished six distinct clusters of accessible sites, 
each with a characteristic functional make-up. Of these, PML-RARα binding was 
found specifically at accessible chromatin regions characterized by p300 binding and 
hypoacetylated histones. Identifying regions with a similar epigenetic make up in 
t(8;21) AML cells, another subtype of AMLs, revealed that these regions are occupied 
by the oncofusion protein AML1-ETO. Together our results suggest that oncofusion 
proteins localize to accessible regions and that chromatin accessibility together with 
p300 binding and histone acetylation characterize AML1-ETO and PML-RARα 
binding sites.
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Introduction
Cell specific gene expression is regulated through a vast suite of epigenetic marks such 
as chromatin modifications and DNA accessibility (Bernstein et al., 2007). Recently, 
genome-wide histone modification patterns have been extensively investigated in 
different cell types and organisms to understand the global histone marking and its 
influence on underlying biological processes (Barski et al., 2007; Liu et al., 2005; 
Pokholok et al., 2005; Roh et al., 2006). In the context of hematopoietic development 
and leukemia various groups set out to characterize the global histone modification 
landscape (Di Croce, 2005; Martens et al., 2010; Roh et al., 2006). Although thought 
to be equally important, less effort has been put in understanding the role of DNA 
accessibility (Sekinger et al., 2005). High accessibility owing to poor nucleosome 
occupancy has been suggested as a hallmark of (most) functional elements in the 
genome (Crawford et al., 2006; Gross and Garrard, 1988; Wu, 1980), highlighting its 
functional importance and endorsing more in-depth study of the global accessibility 
landscape. 
Hematopoiesis is a complex differentiation system and it is tightly regulated 
by the interplay between cis elements and trans factors including transcription 
factors and chromatin-modifying enzymes. Knowing both the binding pattern of 
a particular transcription factor as well as understanding the underlying chromatin 
has the potential to lead to better comprehension on how these factors regulate the 
different hematopoietic lineages as well as how the histone and accessibility patterns 
are changed in the context of leukemia. Different AML associated oncoproteins 
like PML-RARα t(15;17) and AML1-ETO t(8;21) are known to recruit repressive 
complexes, influencing different histone modification patterns and thereby altering 
the chromatin landscape underlining the importance of chromatin dynamics in the 
context of different types of leukemia. 
To determine the accessibility landscape a variety of techniques are available, 
including assays based on restriction enzymes and DNaseI (Gross and Garrard, 
1988). Coupling these techniques with state-of-the-art high throughput sequencing 
technologies has made it possible to obtain high resolution pictures of the overall 
chromatin architecture and its dynamics with respect to different cellular phenomena. 
Indeed, high throughput studies based on the use of enzymatic activities (Boyle et al., 
2008a; Gargiulo et al., 2009; John et al., 2011), or chromatin sonication (Gaulton et 
al., 2010; Giresi et al., 2007), have shed light on chromatin organization of primary 
cells such as CD4+ T and CD34+ cells, mouse model cell lines and human pancreatic 
islets. 
Acute promyelocytic leukemia (APL), is a subtype of acute myeloid leukemia (AML) 
in which the epigenetic landscape is perturbed by the expression of the oncofusion 
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protein PML-RARα (Saeed et al., 2011). The ability of PML-RARα to distort the 
normal functioning of different chromatin modifying factors can lead to changes in 
the local chromatin environment and hence the underlying DNA accessibility. Recent 
global studies of APL cells have given a comprehensive analysis of genome-wide 
PML-RARα binding sites and the all-trans retinoic acid (ATRA) induced changes in 
histone and DNA methylation profiles (Martens et al., 2010; Wang et al., 2010). These 
studies showed that upon degradation of PML-RARα dramatic changes in histone 
modification patterns occur. Although these changes are expected to correlate with 
the accessibility landscape of the cells, it is currently unknown whether the epigenetic 
changes drive or follow changes in genome-wide accessibility and to what extent 
these chromatin alterations can be found in other oncoprotein-expressing AMLs. 
Nuclease accessibility coupled with high throughput sequencing (NA-seq) has recently 
been introduced as a novel tool for the detailed structural analysis of chromatin 
alterations during differentiation of primary human CD34+ cells towards myeloid 
differentiation (Gargiulo et al., 2009). In this study, we have established genome-
wide nuclease accessibility maps for APL and AML cells using NA-seq methodology, 
and the changes occurring during ATRA induced differentiation. In addition, we have 
analyzed the patterns of different epigenetic modifications such as H2A.Z, H2A.
Zac, H3ac, H3K4me3, H3K4me1, H3K9me3, RNAPll and the regulatory factor 
p300. Our analysis allowed the identification of specific accessibility clusters in 
APL which represent different functional clusters, based on co-occurrence of these 
factors. We also found that PML-RARα binds specific response elements in open 
chromatin regions and that PML-RARα bound response elements show an increased 
accessibility upon ATRA treatment. Examining t(8;21) cells for the presence of the 
chromatin signature identified at PML-RARα binding sites allowed the identification 
of AML1-ETO binding sites. Together these results suggest that oncoproteins localize 
to accessible regions and that chromatin accessibility together with a set of specific 
chromatin modifications are characteristics of AML1-ETO and PML-RARα binding 
sites.
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Methods
Cell culture and preparation of accessible libraries
NB4 and SKNO-1 cells were cultured in RPMI medium along with FCS at 370C. 
For differentiation NB4 cells were treated for 48 hrs with 10 µM ATRA. For NA-seq 
DNA regions were isolated essentially as described before (Gargiulo et al., 2009). In 
brief, isolated nuclei were treated with Nlalll and Hpall enzymes, purified DNA was 
reduced in size by using Sau3AI and processed for sequencing. As a control similar 
libraries of total genomic DNA were prepared (see also Supplementary Methods).
Illumina sequencing of accessible libraries
Libraries were ligated to specialized adapters A and B (Supplementary Table S1) 
having the sticky ends corresponding to Nlalll at one side and Sau3Al on the other 
side. 150-600bp size selected fragments were purified and Nlalll containing fragments 
were purified using a biotin-streptavidin capture (Basheer et al., 2009). PCR amplified 
accessible libraries were sequenced using the illumina solexa platform. For the Hpall 
libraries the same procedure was carried out. Sequenced reads were mapped to the 
human genome HG18 using ELAND (see also Supplementary Methods). 
NA-seq data analysis 
Accessible regions were defined by merging all the uniquely mapped sequence reads 
within contiguous 300bp windows from all the sequencing runs of Nlalll-Sau3AI 
libraries. Tags were counted in these regions from each of the accessible libraries and 
genomic controls. Using the Fisher test (Bock et al., 2010; Gu et al., 2010) regions 
having more than a 2 fold difference between the accessible libraries over the naked 
genomic DNA were called accessible. Correction for multiple testing was applied 
using the q-value method (Storey and Tibshirani, 2003). Biological replicates were 
generated for all the libraries and the total number of accessible regions in proliferating 
NB4 cells was the added sum of all the replicates. For comparison of NA-seq data 
of different AML patient blasts we used the Fisher test with a fold change of 1.2 
and a q-value of 0.5. Genomic annotation of the accessible regions and enrichment 
analysis were performed using the Genomatix (http://www.genomatix.de) tools from 
RegionMiner “Annotation and Statistics” and “GenomeInspector”, respectively. All 
NA-seq and ChIP-seq raw data files have been submitted to GEO (accession number: 
GSE30254); genomic locations of all accessible regions identified in this study are 
provided in Supplementary Table S3.
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CATCH clustering analysis
Epigenetic marks were clustered using the CATCH clustering algorithm (Nielsen et al., 
2012) (http://catch.cmbi.ru.nl). Clustering was performed using the highly accessible 
fraction of NA-seq identified regions in proliferating NB4 cells. CATCH was run with 
default settings and a resolution of 20bp. Two major clusters were identified of which 
one was further defined into sub clusters (see also Supplementary Methods).
Analysis of ATRA treated NA-seq libraries
To define differential accessibility regions between ATRA-treated and non-treated 
NB4 cells, accessible regions were further merged within 700bp windows (see also 
Supplementary Methods). The Fisher test was used with a q-value of 1e-06 and a fold 
change of greater than 2. The same threshold settings were applied both for the Nlalll 
and Hpall libraries.
Patient blasts 
APL blasts were obtained from a patient with newly diagnosed AML having t(15;17). 
The sample consisted of more than 80% bone marrow invasion and was a typical 
FAB M3. AML FAB M1 blasts were obtained from patients with newly diagnosed 
AML having no translocation. These studies were approved by the S.U.N. Ethical 
Committee (7028032003).
Browser visualization of NA-Seq libraries
F-seq (Boyle et al., 2008b) was used for genome browser visualization of all NA-seq 
libraries.
Chromatin immunoprecipitation
For ChIP, NB4 cells were cultured as described before (Martens et al., 2010). ChIPs 
were performed using antibodies against H2A.Z, H2A.Zac (Abcam), p300 (Santa 
Cruz), H3K4me1 (Diagenode) and H3K4me3 (Diagenode) and ChIPed DNA was 
further processed for Illumina High throughput sequencing as described (Martens et 
al., 2010).
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Results
Genome-wide mapping of the accessible regions in APL cells 
Chromatin accessibility is thought to be a main determinant in regulating gene 
expression during hematopoiesis, as it allows or prohibits the interaction of transcription 
modulating factors with DNA. To map the nuclease accessible epigenome in acute 
promyelocytic leukemia (APL) we used the nuclease accessible site sequencing (NA-
seq) technique (Gargiulo et al., 2009). For this, we generated restriction enzyme (RE) 
accessibility libraries through treatment of NB4 cell (Lanotte et al., 1991) nuclei with 
the 4 base pair cutter restriction enzymes Nlalll (CATG) or Hpall (CCGG), which 
are known to provide significant coverage of the human genome (Gargiulo et al., 
2009). After this the DNA fragments were further shortened in vitro by using a 
second enzyme, Sau3AI (GATC). The sticky end containing fragments were ligated 
to linkers and sequenced on the Illumina platform (see Methods & Figure S1A). 
After sequencing, tags were selected using the recognition motifs for the respective 
enzymes at the start of the sequence tag, thereby removing all non-specific sequences. 
Biological replicates were generated and they showed for all data sets a very high 
Pearson correlation > 0.95 (Figure S1B), highlighting the reproducibility of the assay. 
As a control, naked genomic DNA was treated with the same enzymes and further 
processed for sequencing. To identify the accessible regions that were captured in our 
libraries we merged all the uniquely mapped tags within 300bp windows and defined 
accessible regions using the exact Fisher test (Bock et al., 2010; Gu et al., 2010), a 
multiple testing correction using the q-value method (Storey and Tibshirani, 2003), 
and a threshold at a fold difference of 2. This analysis revealed 82,257 Nlalll and 
24,912 Hpall marked nuclease accessible regions in proliferating NB4 cells (Table 
1A), for example at several key hematopoietic regulators such as SPI1 and TAL1 
(Figure 1A). Interestingly, most of these regions were enzyme specific, as only 4507 
regions overlap between the NlaIII and HpaII sets (Figure S1C). 
To validate the results we compared the accessible sites detected in NB4 cells with 
publically available DNasel data sets from NB4 cells (http://genome.ucsc.edu/cgi-
bin/hgTrackUi?hgsid= 189871639&c=chr21&g=wg EncodeUwDnase). For this, we 
scanned our data set to examine whether a DNasel hotspot could be detected within 
1 to 5kb regions spanning the middle of the NA-seq accessible regions. We found 
a very significant enrichment of DNasel hotspots in our NA-seq data set (Figure 
1B), with 78% (243,781) of DNaseI-identified regions within a 5 kb distance of the 
NA-seq regions (see Methods). Nearly all (99%) HpaII NA-seq regions overlapped 
with DNaseI hotspots, while only 66% of NlaIII regions overlapped (Figure 1C&D). 
These NA-seq ‘unique’ regions (34% of Nlalll plus 1% of Hpall regions) were 
generally non-promoter regions (Figure 1E). Although they do not overlap with the 
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publically available DNaseI hotspots we did not disqualify these regions since they 
showed a reproducible tag intensity among replicate experiments (Figure 1F) and 
since experimental system-specific parameters may impact the analysis resulting in 
apparent discrepancies between DNaseI and NA-seq, as previously noted between 
DNaseI and FAIRE (Song et al., 2011).
Examining the genomic distribution of the NA-seq regions revealed that 94% of Nlalll 
sites represent non-promoter regions, while 6% are found within 500 bp upstream 
of transcription start sites (Figure 1E). Compared to the entire genome, for which 
1.8% marks promoter regions using these settings, this still represents a three-fold 
enrichment. By contrast, Hpall accessible regions are enriched 27-fold for promoters, 
in line with the expectation that the methylation sensitive restriction enzyme HpaII 
(CCGG) will preferentially cut within CpG islands of (most likely) active genes.
Table1. Total number of NA-seq defined accessible regions.
A. Accessible regions marked by either Nlalll or Hpall enzymes in proliferating and ATRA 
differentiated NB4 cells.
NAS Library type Accessible regions
Nlalll NB4 cells -  ATRA 82,257
Nlalll NB4 cells + ATRA 85,054
Hpall NB4 cells - ATRA 24,912
Hpall NB4 cells + ATRA 27,752
B.  Number of high, medium and low accessible regions based on p-value partitioning.
Nlalll accessible 
libraries
High
(p-value < 0.0001)
Medium
(p-value < 0.005)
Low
(p-value > 0.005)
NB4 cells - ATRA 10,385 28,464 43,408
NB4 cells + ATRA 12,460 28,793 43,801
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Figure 1. Identification of accessible regions in Acute Promyelocytic Leukemia cells.
(A) Overview of the accessible regions at the SPI1and TAL1 genes in NB4 cells identified by 
NA-seq using Nlalll and Hpall. (B) Enrichment of DNaseI hotspots within the NA-seq dataset. 
Enrichment was computed with a lowered threshold and different distances from the middle of the 
regions defined by NA-seq (see Supplementary Methods). The number of overlapping regions for 
every size window are indicated. (C-D) Enrichment plots of NA-seq regions within a window of 
± 5kb of DNaseI-defined accessible regions in NB4 cells. The inset pie charts show the percentage 
of NA-seq regions that overlap with the DNAseI data set. The HpaII data is shown in (C) while 
the NlaIII data is shown in (D). (E) Genomic distribution of the unique and DNaseI hotspots 
overlapping NA-seq regions. Accessible sites were examined for their presence in promoter (-500 
bp up to 100bp downstream of TSS), gene body (intron and exon) or intergenic (everything else) 
regions. Analysis was performed using “Genomatix” tool for annotation and statistics, whereby 
1.8% of the human genome consists of promoters, 44% gene bodies and 54% intergenic regions. 
(F) Intensity plot showing tag enrichment from two biological replicates within ± 5kb windows 
from the center of the NA-seq regions that do not overlap with the DNaseI hotspots used to 
generate panels B-D (left). The same number of random regions was plotted as control (right). 
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PML-RARα binds at accessible regions 
PML-RARα is the hallmark oncofusion protein associated with APL (de The et al., 
1991). ATRA treatment causes degradation of PML-RARα in NB4 cells which leads 
to loss of proliferative capacity. Recently the genome-wide binding pattern of PML-
RARα was identified in NB4 cells (Martens et al., 2010; Saeed et al., 2011). As PML-
RARα has been suggested to induce a repressive chromatin environment (Carbone 
et al., 2006; Martens et al., 2010; Villa et al., 2007), we wondered whether PML-
RARα binding sites would comprise inaccessible regions. Interestingly we found 
that the vast majority of PML-RARα binding sites overlap with accessible regions in 
proliferating NB4 cells (Figure 2A), suggesting that the repressive capacity of PML-
RARα is not translated towards chromatin accessibility. As degradation of PML-
RARα using ATRA triggers APL cell differentiation towards granulocytes (Breitman 
et al., 1981) it allows to investigate whether the accessibility at PML-RARα binding 
sites is altered during this process. For this we first treated NB4 cells with ATRA and 
identified 85,054 Nlalll and 27,752 Hpall accessible regions in these differentiated 
cells (Table 1A). By applying the Fisher test and a stringent threshold for multiple 
correction (q= 1e-06), we identified approximately 2,900 regions which showed more 
than 2-fold increased accessibility upon ATRA induced differentiation (for example at 
the LMO2 gene) and almost 2,300 regions that showed reduction in accessibility (for 
example the RUNX1 gene)(Figure 2B&C). Genomic annotation of these dynamically 
accessible regions revealed that a substantial number of accessible promoters are 
specific for proliferating NB4 cells and that sites specific for differentiated NB4 cells 
can be mostly found in non-promoter regions (Figure 2D). 
To determine whether differentially expressed genes show differences in accessibility 
we interrogated the promoter regions of previously identified up (1000) and down 
(900) regulated genes in ATRA treated NB4 cells (Martens et al., 2010) and found 
enrichment of accessible regions at the center of all of these (Figure S2A&B). Generally 
the promoter regions showed a stable accessibility status both in the proliferative as 
well as differentiated states, irrespective of expression dynamics of the corresponding 
genes (Figure S2A&B), except for a subset of approximately 100 promoters, for 
example CCL2 and GFI1, which overlap with our dynamically changing accessible 
regions (Figure S2C&D). Together these results suggest that changes in accessibility 
can influence gene expression, but that other factors are involved in fine-tuning 
resulting gene expression.
Analysis of PML-RARα binding in relation to dynamically accessible regions 
revealed 134 PML-RARα binding regions which had greater than 2 fold increased 
accessibility upon ATRA induced differentiation, while 213 PML-RARα regions 
showed the opposite pattern and overlapped with decreased accessibility regions. 
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Figure 2. Dynamic accessible regions and PML-RARα binding.
(A) Enrichment of the accessible regions over the PML-RARα binding sites before (blue) and 
after (green) ATRA treatment. The plot represents the number of accessible regions enriched over 
a distance of ±10 kb starting from the middle of the PML-RARα binding sites. (B) Overview 
of the LMO2 gene region in proliferating (blue) and ATRA treated (green) NB4 cells. The 
depicted region shows an increase in accessibility upon ATRA treatment. (C) Overview of the 
RUNX1 gene region in proliferating (blue) and ATRA treated (green) NB4 cells. The depicted 
region shows a decrease in accessibility upon ATRA treatment. (D) Genomic annotation of 
approximately 2300 and 2900 sites that display dynamic accessibility, respectively gaining 
signal in proliferating and in ATRA differentiated NB4 cells. Accessible sites were sorted in 
promoter (-500 bp up to 100bp downstream of TSS), gene body (intron and exon) or intergenic 
(everything else) regions. Analysis was performed using “Genomatix” tool for annotation and 
statistics. (E) Overview of NA-seq (Nlalll plus Hpall) data at the PML-RARα targets RARβ 
and SPI1 showing accessibility changes upon ATRA treatment. PML ChIP-seq indicating 
PML-RARα binding sites, is plotted in red. NA-seq data in untreated cells is plotted in blue 
while NA-seq data for ATRA treated cells it is plotted in green. (F) DR motif analysis for PML-
RARα binding sites which show gain of accessibility after ATRA treatment (NB4+ATRA), and 
for PML-RARα binding sites which loose accessibility (NB4-ATRA).
Chapter 3
56
Regions that showed high increase in accessibility include well known PML-RARα 
targets such as the RARβ and SPI1 promoters (Figure 2E). Interestingly, for the SPI1 
gene we noticed decreased accessibility at the PML-RARα binding site in the 3rd 
intron of the SPI1 gene (Figure 2E), a region that has been described as the TSS of a 
negative regulating non-coding RNA for expression of SPI1 (Ebralidze et al., 2008).
As it is thought that upon ATRA treatment PML-RARα, which shows promiscuous 
binding towards all variants of DR motifs AGGTCA(n)n (Martens et al., 2010), 
degrades and is replaced by the heterodimer RAR:RXR, which preferentially binds 
the DR2 (AGGTCA(n)2AGGTCA) and DR5 (AGGTCA(n)5AGGTCA) motifs, we 
investigated the presence of the DR response elements within the dynamic accessible 
regions. This analysis showed high enrichment for the retinoic acid response elements 
DR2 and DR5 in the accessible sites after ATRA treatment, while DR1 and DR4 
repeats were enriched at accessible sites occupied by PML-RARα before ATRA 
induced differentiation (Figure 2F). Together, these results show that PML-RARα 
binds to open chromatin regions and that genomic regions containing DR2 and DR5 
are preferentially opened upon ATRA treatment, suggesting that at these positions 
PML-RARα is replaced by RAR:RXR. 
Accessibility landscape in patient blasts and other leukemic subtypes
To further validate the NA-seq marked regions we created a NA-seq library using 
the Nlalll enzyme in untreated APL patient blasts and found many similarities in the 
genomic location of accessible sites, for example at the RPS17 and CR1 genomic 
loci (Figure 3A). We examined the APL tag density in the high, medium and low 
accessible regions identified in proliferating NB4 cells (Table 1B) and found a similar 
pattern of accessibility in terms of tag density in APL blasts as in NB4 cells (Figure 
3B), while in comparison with a previously published NA-seq data set from CD34+ 
cells (Gargiulo et al., 2009) we found an overlap with 60,178 (~54%) of our accessible 
regions identified in NB4 cells (Figure 3C), indicating differences in accessible 
regions between the APL and CD34+ cell types.
To assess the variability in accessibility between different AMLs we also generated 
an accessibility profile in SKNO-1 cells, which represent an AML M2 subtype and 
harbor a t(8,21) translocation. Comparison of NB4 and SKNO-1 accessible regions 
showed a very high overlap of 83% at Hpall marked accessible promoters between the 
two cell types (Figure 3D). This significant overlap was also observed for the NlaIII 
marked promoters (Figure S3) while for the entire NlaIII set, comprising mostly non-
promoter regions, an overlap of only 34% was found (Figure 3D). This difference 
in accessibility architecture at Nlalll-marked non-promoter elements as compared to 
HpaII-marked promoter elements suggests that especially the non-promoter elements 
comprise the crucial functional regions that regulate cell type identity.
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Figure 3. Differential accessibility between leukemic subtypes.
(A) Overview of Nlalll-identified accessible regions at the RPS17 and CR1 genomic regions 
in APL (purple) as well as in NB4 cells (blue). (B) Correlation of accessible regions (high, 
medium, low) and a set of randomly chosen regions in proliferating NB4 cells with the 
accessibility library in an APL patient sample. Box plot showing the normalized tag count for 
NB4 proliferating cells and for an APL patient sample (pz258) in accessible regions as defined 
in NB4 cells. (C) Enrichment of accessible regions defined by NA-seq in CD34+ cells within 
NA-seq defined NB4 accessible regions. Enrichment was investigated from the middle of the 
NB4 NA-seq data set to a distance of ± 5kb. (D) Overlap of accessible regions defined by NA-
seq in APL (NB4 cells) and t(8;21) AML (SKNO-1 cells). The HpaII data is presented in the 
left panel, the NlaIII data in the right panel). (E) Correlation of accessibility between different 
AML patient samples. In scatter plots the NA-seq tag count was plotted in windows of 1.2 Mb 
over the whole genome (Blue). Differential accessible regions between M1 and M3 patients 
(see Methods) and bound by PML-RARα are highlighted (brown). The correlation coefficient 
between pairs of datasets is depicted in the upper left corner of each scatter plot.
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To further analyze the heterogeneity between different AML patients, we generated 
genome-wide NlaIII accessibility profiles of two AML M1 patient cells. As the 
limited amount of material precluded sequencing of genomic DNA for these AML 
patients, and hence the analysis as described for NB4, we plotted as an alternative the 
accessibility tag distribution over 1.2 Mb windows (Gargiulo et al., 2009) in the whole 
genome from all three patient samples (two AMLs M1 and one APL M3). We noticed 
a very high correlation between the tag distribution in the two AML M1 patients with 
an r value of 0.93, while the r value is lower when we compare the tag distribution 
between M1 and M3 patient blasts (Figure 3E), again suggesting cell type specificity 
in accessible sites.
To identify the regions which show differences in accessibility pattern between the 
M1 and M3 AML subtypes we used the Fisher test (see Methods). Examining the 
regions which showed differential accessibility patterns between APL and AML M1 
subtypes showed a high overlap (>74%) with our previously published (Martens et 
al., 2010) genome-wide PML-RARα binding sites, specifically for the regions which 
show increased accessibility in APL patients as compared to the AML M1 blasts 
(Figure 3E), suggesting that the difference in accessibility pattern between APL and 
other AML subtypes might to a large extend be connected to expression of the PML-
RARα oncofusion protein.
Epigenetic landscape over regulatory regions in APL cells 
Our genomic distribution analysis revealed that the majority of Hpall-defined 
accessible sites are located in promoters. Indeed analyzing the chromatin structure of 
HpaII sites revealed all previously reported features of promoter regions (Barski et al., 
2007; Boyle et al., 2008a; Kim et al., 2005) (Figure S4A-E; Supplementary Methods). 
Our analysis also revealed that most differences in accessibility between cell types lie 
in non-promoter regions (Figure 3D). To examine whether these non-promoter regions 
comprise different regulatory elements we proceeded to discriminate subclasses 
of accessible non-promoter regions based on their distinct epigenetic marking. To 
identify different epigenetic signatures we used a clustering program called CATCH 
(Nielsen et al., 2012). As input for CATCH we used the highly accessible NlaIII 
regions (Fisher test, p < 0.0001) (Table 1B) and a wide range of datasets on chromatin 
modification including H2A.Z, H2A.Zac, H3ac, H3K4me3, H3K4me1, H3K9me3, 
DNA methylation, H3K27me3, H4K20me3 and RNAPll. In addition p300 was 
included as a marker to locate enhancer elements. 
CATCH clustering allowed the identification of two distinct clusters (Figure 4). 
Cluster 1 showed significant enrichment for a large variety of epigenetic marks while 
cluster 2, containing over 5000 highly accessible regions, was only marked by H2A.Z 
and H2A.Z acetylation (Figure 4 and Figure S5A-F). Cluster 1 was further divided 
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into sub-clusters based on different characteristic epigenetic patterns. Among these, 
cluster 1a was characterized by increased H3K4me3 levels as well as increased 
levels of H2A.Z, H2A.Zac, H3ac and RNAPII (Figure 4 and Figure S5A). The high 
level of H3K4me3 suggested that this cluster represented the promoter fraction and 
indeed, genomic annotation of these regions revealed their presence at promoter 
regions (data not shown). Independent analysis of all 5270 Nlalll marked promoters 
confirmed this conclusion (Figure S5G) highlighting the robustness of the clustering 
method. In contrast to cluster 1a, genomic annotation of the other four clusters 
(1b,1c,1d,1e) revealed enrichments towards non-promoter regions suggesting that 
these might represent enhancer elements. Interestingly, amongst these, three clusters 
were characterized by p300 enrichment. As several studies have identified p300 as an 
enhancer mark (Heintzman et al., 2009; Visel et al., 2009; Xi et al., 2007), we decided 
to name these three clusters enhancer clusters, which was further suggested by the 
significant presence of H3K4me1 (Heintzman et al., 2009). The differential presence 
of histone modifications, in particular histone acetylation, allowed us to further define 
these three enhancer clusters. Enhancer cluster 1b is marked by high levels of H2A.Z 
and H3 acetylation, while enhancer cluster 1c showed decreased levels of both H3 
and H2A.Z acetylation. The third enhancer cluster 1d is characterized by high levels 
of p300 and low histone acetylation levels (Figure 4 and Figure S5B-D). Functional 
characterization of the associated genes revealed that enhancer cluster 1b is highly 
enriched for genes involved in proliferation, while enhancer cluster 1c is characterized 
by genes involved in signal transduction and communication. In contrast, the enhancer 
cluster 1d showed high enrichment for genes related to apoptosis and regulators of 
cellular differentiation and contained genes like RUNX1 (Figure S5D) and GFI1 
that are important in driving hematopoietic development. The last cluster 1e, was 
characterized by repressive chromatin marking such as DNA methylation, H3K9me3 
and H4K20me3 (Figure S5E). Interestingly, analysis of the RNAPll occupancy in all 
CATCH defined clusters revealed differential enrichments of the RNAPll over different 
clusters. Apart from the promoters, enhancer cluster 1b and 1d were also enriched for 
RNAPll, while enhancer cluster 1c showed less RNAPll marking, comparable to the 
repressive cluster (1e) and cluster 2 (Figure S5H). As mentioned above, cluster 2 was 
distinct in that it did not show any significant enrichment for histone marks, except 
H2A.Z and H2A.Z acetylation (Figure 4 and Figure S5F). Although these results point 
towards H2A.Z as a general mark of chromatin accessibility, the exact role of the 
cluster 2 regions remains unclear.
Altogether, the present functional analysis is in line with previous reports in other 
cell types (Heintzman et al., 2009; Heintzman and Ren, 2009; Visel et al., 2009), 
and allowed the definition of different sets of non-promoter accessible regulatory 
regions as a function of p300 occupancy and specific histone modification patterns in 
a leukemic context.
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Figure 4. Unsupervised clustering of highly accessible regions.
Catch clustering analysis of highly accessible regions in proliferating NB4 cells based on 
profiles of H2A.Z, H2A.Zac, H3ac, p300, H3K4me3, RNAPII, H3K4me1, H3K27me3, 
H3K9me3, H4K20me3 and DNA methylation. The plots represent the average number of tag 
counts in 20bp bins over 5 kb windows for each epigenetic mark in all clusters. Only the 
relevant epigenetic marks are shown in each cluster profile. Gene Ontology (GO) and p-value 
were calculated using the online web tool “DAVID”:Database for Annotation, Visualization, 
and Integrated Discovery (Dennis et al., 2003).
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Oncofusion proteins create a hypoacetylated chromatin environment at accessible 
p300 binding sites
Aberrant recruitment of the epigenetic machinery and disruption of the normal histone 
modification patterns have been suggested as central activities involved in AML-
associated oncofusion protein-mediated leukemogenesis. Our clustering analysis 
of regulatory regions revealed highest enrichment of PML-RARα binding sites in 
enhancer cluster 1d which is characterized by high levels of p300 and low levels 
of acetylation (Figure 5A). These findings are concordant with previous results that 
showed that PML-RARα induces a hypoacetylated chromatin state (Martens et al., 
2010). To investigate whether other oncofusion proteins, such as AML1-ETO harbor 
similar chromatin characteristics we overlapped a previously identified set of high 
confidence AML1-ETO binding sites (Martens and Stunnenberg et al in preparation) 
and the NA-seq accessibility data in SKNO-1 cells. We found a very high enrichment 
of the accessible regions at AML1-ETO binding sites (Figure 5B) further confirming 
that oncofusion proteins, such as PML-RARα and AML1-ETO bind preferentially to 
accessible regions.
To examine whether AML1-ETO binding sites have a similar chromatin signature as 
PML-RARα binding sites and whether such a signature can be used to predict AML1-
ETO binding sites we performed genome-wide ChIP-seq in SKNO-1 cells for p300 
and H2A.Z acetylation, the two characteristic chromatin features of the accessibility 
cluster 1d identified in NB4 cells. We used MACS (Zhang et al., 2008) to call all p300 
binding sites in SKNO-1 cells and analyzed the H2A.Z acetylation status. Correlating 
the acetylation status with AML1-ETO binding revealed that generally accessible 
sites with p300 and high H2A.Z acetylation do not have AML1-ETO binding, while 
accessible sites with p300 and low/intermediate levels of acetylation do have AML1-
ETO binding (Figure 5C&D). Together these results reveal that oncofusion proteins 
such as AML1-ETO and PML-RARα have similar chromatin characteristics and that 
these chromatin characteristics can be used to predict oncofusion protein binding sites.
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Figure 5. PML-RARα and AML1-ETO binding sites share similar chromatin 
characteristics.
(A) Percentage of PML-RARα binding sites in the different CATCH-defined enhancer clusters. 
Clusters 1b, 1c and 1d from figure 4 were examined for their relative PML-RARα presence. 
(B) Enrichment of the accessible regions identified in SKNO-1 cells at AML1-ETO binding 
sites. The plot represents the number of accessible regions enriched over a distance of ±10 kb 
starting from the middle of the AML1-ETO binding sites. (C) H2A.Z acetylation and AML1-
ETO tag density at p300 binding sites in SKNO-1 cells. p300 binding sites were called using 
MACS. (D) Overview of AML1-ETO (red), p300 (green) and H2A.Z acetylation (orange) 
at the PLEKHB2 and ATP2A2 genomic regions showing p300 and AML1-ETO binding but 
H2A.Z hypoacetylation. 
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Discussion
Chromatin structure and the accessibility of the underlying DNA are important 
determinants of proper execution of the regulation of gene expression programs in 
a given cell type (Felsenfeld et al., 1996; Weintraub and Groudine, 1976). Different 
cis-regulatory elements having a crucial role in regulating transcriptional events 
are known to give access to their DNA sequence by having a more open chromatin 
conformation. This suggests that accessible regions of chromatin provide a basic 
scaffold for setting-up a particular epigenomic environment.
In this study we used NA-seq and identified > 100,000 accessible chromatin regions 
in proliferating acute promyelocytic leukemia (APL) cells. Analysis of the accessible 
sites showed that the use of only two different restriction enzymes already gives 
significant insight into accessible regions, encompassing promoters, gene bodies 
and intergenic regions. HpaII preferentially cuts promoters of (most likely) active 
genes as indicated by the fact that 87% of them were RNAPII bound. In contrast 
Nlalll cuts mostly intergenic regions, allowing us to look at putative enhancer regions. 
Additionally, a positive correlation between the accessibility patterns established in 
NB4 cells and an APL patient sample further provides evidence that NA-seq can 
identify high confidence accessible sites.
Comparison of NA-seq and DNaseI data sets revealed a significant overlap between 
these different chromatin accessibility assays, with 78% of DNaseI accessible sites 
located within a 5kb window of NA-seq marked regions. As the NA-seq regions not 
overlapping with DNAseI regions were reproducibly detected, we also regarded these 
as genuine accessible sites. The apparent discrepancies between DNaseI and NA-seq 
may reflect methodology specific variability, as has been reported before (Gargiulo et 
al., 2009; Song et al., 2011). Furthermore, the differential regions are mostly located 
in non-promoter regulatory regions, tending to have lower accessibility signals, which 
may have hampered confident identification by multiple methods. 
PML-RARα expression is the hallmark oncofusion implicated in APL pathogenesis, 
and it has been postulated that PML-RARα binding causes a repressed chromatin 
state at its binding site through recruitment of co-repressor complexes (Saeed et al., 
2011). Interestingly in the present study we found that the majority of PML-RARα 
binding sites are found in accessible chromatin bearing some hallmarks of active 
chromatin, similar to what has been reported recently for the glucocorticoid receptor 
(John et al., 2011). Moreover we found an enhanced accessibility upon ATRA induced 
degradation of PML-RARα on sites which were enriched for classical retinoic acid 
response elements like DR2 and DR5, suggesting that at these locations PML-RARα is 
replaced by the RAR:RXR heterodimer and that it is this heterodimer that is involved 
in chromatin opening. ATRA treatment triggers the process of differentiation in NB4 
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cells (Breitman et al., 1981) allowing the identification of accessibility changes when 
cells go from proliferating to a differentiated state. We identified approximately 5,000 
regions which showed significant differences in accessibility between proliferating 
and differentiated NB4 cells. Genomic annotation analysis showed that upon ATRA 
induced differentiation relatively more promoters are closed while more non-promoter 
regions become accessible, suggesting that non-promoter functional elements are 
important drivers of ATRA mediated APL cell differentiation, consistent with the 
‘repressive’ activities of PML-RARα at non-promoter elements (Martens et al., 2010). 
Like previous studies (Barski et al., 2007; Lee et al., 2004; Weintraub and Groudine, 
1976; Wu, 1980) we found a positive correlation between gene expression and high 
promoter accessibility. However, we found less accessibility changes at promoters 
corresponding to the genes which show changes in expression as the cells go from 
a proliferating to a differentiated state. These results suggest that gene expression 
positively correlates with accessibility, but that the majority of the genes which are 
highly expressed as well as those which are poised for activation have accessibility 
repertoires which are rather stable and therefore that other parameters than accessibility 
per se are involved in fine tuning their expression levels.
Clustering analysis of accessible sites revealed five functional sub-clusters. From 
these, one had the characteristic H3K4me3 ‘active’ promoter mark and showed 
enrichment for RNAPll, indicating a high correlation with transcriptional activity. 
Moreover, in this cluster we found high levels of H2A.Z, H2A.Zac and H3ac over the 
entire region except for a dip in the middle, which likely represents the nucleosome 
free region (Barski et al., 2007). Out of the four remaining clusters, three were marked 
with p300 which is known to bind enhancers (Heintzman and Ren, 2009). We further 
defined these enhancer clusters on the basis of the presence of histone acetylation, and 
found one cluster with high levels of acetylation, one with intermediate levels and one 
with low levels.
Interestingly, cluster 1d with low acetylation and very high p300 binding was enriched 
for PML-RARα binding sites, suggesting that this cluster is actively deacetylated 
through recruitment of histone deacetylase (HDAC) activities by PML-RARα. 
The role of this cluster in leukemia maintenance is further suggested by functional 
examination of the associated genes. This is enriched for genes involved in apoptosis 
and differentiation such as GFI1 and RUNX1, and influencing expression of these 
genes might be crucial for leukemia development.
Extending the analysis to AML1-ETO, another AML-associated oncofusion protein, 
revealed a high enrichment of accessible regions at AML1-ETO binding sites, a 
chromatin characteristic similar to PML-RARα. Moreover, we found a hypoacetylated 
chromatin architecture, and co-localization with p300 at AML1-ETO binding sites 
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and this seems another common feature for both PML-RARα and AML1-ETO. As 
recently the acetylation of AML1-ETO by p300 has been suggested as a key step in 
t(8;21) leukemogenesis (Wang et al., 2011), the colocalization with p300 might also 
indicate a potential role of acetyltransferase activity in regulating the PML-RARα 
complex. 
Based on our analysis, p300 does not seem to fully counteract HDAC activity 
towards histones in the presence of these oncofusion proteins as these are generally 
hypoacetylated. This might be due to a functional difference in that p300 can still 
acetylate AML1-ETO while simultaneously HDACs may deacetylate histones but 
not AML1-ETO. Alternatively, p300 acetylation of AML1-ETO may be restricted to 
particular subsets of genes. The simultaneous presence of histone acetyltransferases 
(HATs) and HDACs is in accordance with the emerging picture of a balanced interplay 
of the antagonistic activities of histone modifying enzymes such as HATs and HDACs 
or methyltransferases and demethylases (Agrawal-Singh et al., 2012; Wang et al., 
2009). Indeed, in a recent study the dynamic balance of histone acetylation levels at 
chromatin regions was shown to be maintained by the activity of HATs/HDACs as 
well as histone demethylase LSD1 containing complexes (Whyte et al., 2012). Based 
on these observations we propose PML-RARα and AML1-ETO oncofusion proteins 
as stabilizers of deacetylase activity at their target regions in leukemic cells. As a 
result, the dynamic balance of the acetylation/deacetylation activity is disrupted and 
an aberrant acetylation profile is observed in these AML cells.
Together, these findings underscore the role of accessible chromatin regions as 
important regulatory elements that are subject to intense regulation by trans-acting 
factors to define cell type identity. Their aberrant regulation in AML at the epigenetic 
level might provide an entry point to test drugs that inhibit chromatin modifying 
enzymes or complexes (Bantscheff et al., 2011) that can lead to proper execution of 
the differentiation program and eradicate the leukemic cells. 
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Figure S1. NA-seq methodology overview. 
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(A) Model showing the workflow of the Nuclease accessible site sequencing (NA-seq) procedure. 
In brief, isolated nuclei (1, 2) were treated with Nlalll and Hpall enzymes (3), purified DNA was 
reduced in size by using Sau3A1 (4) and processed for sequencing. Libraries were ligated to 
specialized adapters A and B (5) having the sticky ends corresponding to Nlalll or HpaII on one 
side and Sau3Al on the other. Size selected fragments (150-600 bp) were purified and Nlalll 
containing fragments were purified by biotin-streptavidin capture. PCR amplified accessible 
libraries were sequenced on the Illumina Solexa platform (6). (B) Correlation of accessibility 
between biological replicates of the NA-seq libraries. In scatter plots the square root of the NA-
seq tag count in 1.2Mb windows was plotted over the whole genome for Nlalll and Hpall libraries 
individually. Upper graphs: scatter plots comparing the biological replicates of the NlaIII (left) 
and HpaII (right) libraries in proliferating NB4 cells. Lower graphs: scatter plots comparing the 
biological replicates of the NlaIII (left) and HpaII (right) libraries in 48 hours ATRA treated NB4 
cells. (C) Overlap between Nlalll and Hpall identified accessible regions in NB4 cells.
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Figure S2. Correlation of expression changes with accessibility.
(A-B) Mean number of accessibility tags plotted as a function of the distance from the 
transcription start site (TSS) for the down- (A) and up-regulated (B) genes following ATRA 
treatment for 48 h. (C) Overview of the CCL2 genomic region showing increased accessibility 
and RNAPll binding after ATRA treatment. RNAPII data is plotted in blue (no ATRA) and red 
(48 h ATRA), NA-seq data is plotted in blue (no ATRA) and green (48 h ATRA). (D) Overview 
of the GFI1 genomic region showing decreased accessibility and RNAPll binding upon ATRA 
treatment. RNAPII data is plotted in blue (no ATRA) and red (48 hrs ATRA), NA-seq data is 
plotted in blue (no ATRA) and green (48 h ATRA).
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Figure S3. Overlap of Nlalll-defi ned promoter regions in SKNO-1 and NB4 cells. 
Enrichment for NlaIII promoter regions defi ned in SKNO-1 cells was examined within a region 
of ± 5kb from the middle of the Nlalll promoter regions defi ned in NB4 cells.
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Figure S4. Analysis of NA-seq defi ned promoters.
(A) Overlap of Hpall and Nlalll NA-seq defi ned promoters in NB4 cells in comparison with all 
ENSEMBL gene promoters. (B) Correlation of all accessible promoters in proliferating NB4 
cells with RNAPll binding before and after 24 or 48 h ATRA treatment. Average tag counts for 
RNAPII are plotted over a distance of 5 kb starting from the middle of the accessible promoter 
regions. (C) Intensity plot showing RNAPll tag density before and after ATRA treatment at NA-
seq defi ned promoters in proliferating NB4 cells. By applying an arbitrary threshold of promoter 
activity at 3 (of log2 tag density; see Supplementary Methods) we identifi ed 87% of all Hpall 
marked accessible promoters as being active in proliferating NB4 cells. (D) Correlation of 
genome-wide binding sites of different epigenetic marks with accessible promoters (n=17,326). 
The number of correlating binding sites was plotted as a function of the distance from the 
middle of the accessible promoter regions. (E) Correlation of promoter accessibility with 
histone modifi cations. The log2 tag density for H3K4me3, H3ac, H2A.Z and H2A.Zac was 
plotted for 1000 accessible promoters of three categories of accessible regions (high, medium, 
low) as well as for random control regions.
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Figure S5. Overview of the CATCH defined clusters.
(A-F) Examples of genomic regions associated with clusters defined by CATCH. Only the 
most relevant profiles for each cluster are shown. (G) Correlation of binding sites of different 
epigenetic marks with Nlalll defined accessible promoters (n=5270). Number of correlating 
transcription marks was plotted as a function of the distance from the middle of the accessible 
promoter regions. (H) Tag count of RNAPll within a 1kb region of all the CATCH defined 
clusters in proliferating NB4 cells.
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Supplementary Methods
Cell culture and preparation of accessible libraries
NB4 cells were cultured in RPMI medium along with 10% FCS at 370C. For 
differentiation cells were treated for 48 hrs with 10µM ATRA. For NA-seq DNA 
regions were isolated essentially as described before (Gargiulo et al., 2009). In brief, 
upon cell harvesting, nuclei were isolated and enzyme treated with Nlalll (NEB, 10,000 
units/ml) and Hpall (NEB, 50,000 units/ml) as described (Gargiulo et al., 2009). After 
the enzyme treatment reactions were stopped using AL buffer (Qiagen) and DNA was 
isolated as described in the kit (Qiagen, DNeasy Blood and Tissue kit). In order to 
reduce the fragment size Nlalll and Hpall treated DNA libraries were further treated 
with Sau3AI (NEB, 4000 units/ml) separately. Reactions were performed at 370C for 
3hrs in Sau3AI buffer supplemented with BSA. Libraries were purified using column 
purification (Qiagen). As a control similar libraries of total genomic DNA were 
prepared. A similar procedure was applied for library preparation of SKNO-1 cells.
Illumina genome analyzer sequencing of accessible libraries
Libraries were ligated to specialized adapters A and B (Supplementary Table S1) 
having the sticky ends corresponding to Nlalll at one side and Sau3Al on the other 
side. The adapter-ligated libraries were loaded on 2% agarose gels and 150-600bp 
fragments were purified. Each of the adapters A and B contained a 20bp PCR 
amplification template. A short PCR reaction of 6 cycles was performed using the 
primers against adapters A and B. The primer against adapter A contained biotin in 
order to add biotin at the beginning of adapter A. Positive selection was made for 
Nlalll containing fragments using a biotin-streptavidin capture method (Basheer et 
al., 2009). Finally before sequencing the accessible libraries were amplified by PCR. 
As the adapters were designed to have a directional ligation to the fragments all the 
sequenced fragments start with the Nlalll recognition motif. For the Hpall libraries the 
same procedure was carried out. The 35bp reads were mapped to the human genome 
HG18 using the eland program. Replicates were also sequenced for each enzyme and 
both plus as well as minus ATRA conditions, and processed in the same manner.
NA-seq computational analysis and defining accessible regions
Accessible regions were defined by merging all the uniquely mapped sequence reads 
within contiguous 300bp windows from all the sequencing runs of Nlalll-Sau3AI 
libraries. Tags were counted in these regions from each of the accessible libraries 
separately as well as of the naked genomic control. For calling the significantly 
accessible regions over the background a Fisher test (Bock et al., 2010; Gu et al., 
2010) was performed. As a result, every region got a p-value. Correction for multiple 
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testing was applied using the q-value method (Storey and Tibshirani, 2003) with q=0.5 
in order to reduce the false positives. Regions having more than a 2 fold difference 
between the accessible libraries over the background were used for further analysis. 
Fisher test along with multiple testing and fold difference was performed using a perl 
script. Biological replicates were generated for all the libraries and the total number of 
accessible regions in proliferating NB4 cells was the added sum of all the replicates. 
Further categorization of Nlalll marked accessible regions was based on p-value. 
Regions having a p-value < 0.0001 were called high accessible, with a p-value < = 
0.005 medium accessible and a p-value > 0.005 were called as low accessible regions. 
For calling the accessible regions in Hpall libraries the same procedure was applied. 
For computing the overlap of NA-seq regions with DNaseI hotspots the q-value 
threshold was lowered down to increase the number of NA-seq regions to 295,218 
which is comparable to DNAseI defined hotspots.
Accessible promoter analysis
Accessible promoters were annotated by using the Genomatix (http://www.
genomatix.de) tool “annotation and statistics” and were overlapped with ENSEMBL 
promoters. For promoter analysis tags were counted from three normalized RNAPll 
data sets taken from (Martens et al., 2010) in all Hpall marked promoter regions. 
Tag density was calculated for all regions by dividing tag count with length of the 
regions and further converted into log2 values. An arbitrary threshold was set at 3 of 
log2 tag density and promoter regions above this threshold were considered as active. 
For example for the GFI1 promoter region we mapped around 500 RNAPll tags in 
proliferating NB4 cells. The log2 of the calculated tag density per 1000bp was 6 and 
therefore this was considered as a highly active promoter region. 
CATCH clustering analysis
Epigenetic marks were clustered using the CATCH clustering algorithm ( http://catch.
cmbi.ru.nl). CATCH performs a hierarchical agglomerative clustering of sets of given 
profile patterns including the alignment of the most similar profiles at every step. 
Clustering was performed using the highly accessible fraction of NA-seq identified 
regions in proliferating NB4 cells. CATCH was run with default settings (scorestyle: 
sum of squared difference, normalization: maximum value, merging: semi average 
merge, use weights: on merge, cut sequence: 1/15, mirroring: allow mirrored 
alignment, min common: 0.20) and a resolution of 20bp. Two major clusters were 
identified. One cluster (cluster 1) was enriched for a variety of epigenetic marks while 
the second cluster (cluster 2) was only marked with H2A.Z and H2A.Zac. Cluster 
1 was further defined into sub clusters by examining the clustering tree within the 
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cluster. Profiles in Figure 4 show the average tag count in 20bp bins over a window 
of 5 kb and gene ontology was performed using the genes annotated at the closest 
distance from the center of the clustered regions.
Differential Analysis between ±ATRA treated NA-seq libraries
To define the regions which showed altered accessibility between ATRA-treated and 
non-treated NB4 cells, accessible regions were further merged within 700bp windows 
which is the average size of accessible regions. Regions were merged in order to look 
at the bigger DNA stretches showing altered accessibility. The Fisher test was applied 
with threshold settings for the q-value of 1e-06 and fold change of greater than 2. The 
same threshold settings were applied for the Nlalll and Hpall libraries.
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Abstract 
Non-specific protective effects against reinfection have been described following 
infection with Candida albicans. Here we show that mice defective in functional T 
and B lymphocytes were protected against reinfection with C. albicans in a monocyte-
dependent manner. C. albicans and β-glucans induced functional reprogramming 
of monocytes, leading to enhanced cytokine production in vivo and in vitro. The 
training required the β-glucan receptor dectin-1 and the non-canonical Raf-1 pathway. 
Monocyte training by β-glucans was associated with stable changes in histone 
trimethylation at H3K4, which suggests the involvement of epigenetic mechanisms in 
this phenomenon. The functional reprogramming of monocytes, reminiscent of similar 
properties of NK cells, has been termed “trained immunity” and may be employed for 
the design of improved vaccination strategies.
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Introduction 
It is a general assumption that the protective effects conferred by vaccines rely 
exclusively on adaptive immunity, i.e., induction of immunological memory mediated 
by T and B cells. However, mechanisms independent of T and B cells may provide 
partial non-specific protection against infection. Adaptive immunity-independent 
protection to reinfection is present in both plants (Durrant and Dong, 2004; Sticher 
et al., 1997) and insects (Pham et al., 2007; Rodrigues et al.). These organisms 
lack specific immunity, but the state of their natural immunity can be enhanced 
by exposure to microbes and their products. In a similar fashion, the function of 
prototypic mammalian innate immune cells such as NK cells can be enforced, leading 
to protection to reinfection with viral pathogens (Cooper et al., 2009; O’Leary et 
al., 2006; Paust et al., 2010; Sun et al., 2009). In this context we proposed the term 
“trained immunity” for the enhanced state of the innate immune responses following 
exposure to certain infectious agents, which may result in an increased resistance to 
reinfection (Netea et al., 2011).
In somewhat forgotten studies performed more than two decades ago, protection 
from infection was demonstrated after a previous infection with avirulent Candida 
species in mice deficient in T and B cells (Bistoni et al., 1986). This protection was 
mediated by macrophages (Bistoni et al., 1986), yet the mechanism responsible for 
this effect remained unknown. Similarly, the β-glucan component of the C. albicans 
cell wall has been known for decades to be a potent immunomodulator, and is used 
in some countries for enhancing immunity against infections and cancer (Brown and 
Williams, 2009; Vetvicka, 2011). 
The aim of the present study was to investigate the “training” effects exerted 
by C. albicans on monocytes and macrophages, cells of innate immunity that are 
responsible for the T/B cell-independent protective effect during secondary Candida 
infection (Bistoni et al., 1986). We demonstrate that C. albicans can protect Rag1-
deficient mice from reinfection, an effect that is dependent on monocytes. C. albicans 
induces functional programming of monocytes that leads to non-specific enhanced 
cytokine production to secondary stimulation. The mechanism of training requires the 
β-glucan receptor dectin-1 and the non-canonical Raf-1 pathway, with a secondary 
role for the complement receptor 3 (CR3). This training of monocytes is associated 
with stable and genome-wide changes in histone H3K4 trimethylation, suggesting a 
putative role of epigenetic programming as an underlying mechanism.
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Methods
Animals
C57BL/6J, B6.129S7-Rag1tm1Mom/J and B6.129S4-Ccr2tm1lfc/J female mice between 8 
and 12 weeks of age were used (Jackson Laboratories). Experiments were approved 
by the Ethics Committee on Animal Experiments of the Colorado University and 
of the University of Athens. Mice were first injected with C. albicans blastoconidia 
(2x104 CFU/mouse) in a 100μl volume of sterile pyrogen-free phosphate-buffered 
saline (PBS) or with PBS alone. 7 days later, mice were infected intravenously with 
a lethal dose of C. albicans blastoconidia (2x106 CFU/mouse). Survival was then 
monitored and kidney fungal burden was assessed 14 days after the second lethal C. 
albicans injection. For the inhibition of Raf-1 during the “training period”, mice were 
orally administrated with 25mg/kg of Sorafenib (as previously described (Bareford et 
al., 2011)), 7 days before and on the day of the low dose of C. albicans blastoconidia 
(2x104 CFU/mouse) injection. For the NK cells depletion experiments, mice were 
either pre-injected intravenously with anti-asialo GM1 antibody (986-10001, Wako 
Pure Chemical Industries Ltd) or an unrelated antibody (control, Rabbit Serum azide 
free, C12SAZ, AbD Serotec) 8 days, 4 days and 0 day prior to inoculation of the lethal 
C. albicans dose. For the endotoxaemia model, mice were first injected intravenously 
with heat-inactivated C. albicans blastoconidia (1x105 CFU/mouse) or with PBS alone. 
7 days later, mice were treated with an intraperitoneal injection of 10µg of purified 
LPS (E. coli serotype 055:B5, Sigma-Aldrich). Blood was collected 90 min later to 
assess the circulating TNFα and IL6 concentrations by electrochemiluminescence 
(ECL) (Netea et al., 2009).
Healthy volunteers 
PBMC were isolated from buffycoats obtained from healthy volunteers (Sanquin 
Bloodbank, Nijmegen, the Netherlands).
Stimulation experiments
PBMCs were diluted to a concentration of 5x106 cells per ml and 100 μl of this 
suspension was added into a well. When required, PBMCs were incubated for 1 
hour at 37°C in 5% CO2 and adherent monocytes were selected by washing out non-
adherent cells with warm PBS. 
CD14+ monocytes, CD4- cell and CD56+ subsets were purified from freshly isolated 
PBMC using MACS microbeads, according to the instructions of the manufacturer 
(Miltenyi Biotec). CD14+ monocytes were diluted to a concentration of 1x106 cells 
per ml and 100 μl of this suspension was put into a flat bottom well plate.
For training, cells were pre-incubated with heat-killed C. albicans 1x104/ml, b-glucan 
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(10µg/ml), mannans (10µg/ml) or E. coli (1x106/ml) for 24 hours. Cells were then 
washed and maintained in RPMI supplemented with 10% human pool serum. After a 
period of 7 days cells were subjected to a second stimulation of cytokine production 
with various stimuli in a volume of 200 μl of medium (LPS 10ng/ml, Pam3Cys 
10µg/ml, heat-killed C. albicans 1x105/ml, M. tuberculosis 1µg/ml). After 24 hours, 
duplicate supernatants were collected, pooled and stored at -20°C until assayed.
In the “inhibition of training” experiments, before the priming with C. albicans or 
with b-glucan, adherent monocytes were pre-incubated for 1 hour with laminarin 
(dectin-1 inhibitor 100µg/ml), anti-CD3 antibody and control anti-IgG (10 µg/ml), 
Syk inhibitor (50nM), Raf-1 inhibitor (1µM), Pargyline (3µM), MTA (1mM). 
For ChIP analysis, adherent monocytes from healthy volunteers were obtained in 150 
mm dishes by incubating 150 x106 PBMCs for 1 hour in a total volume of 20 ml. 
Monocytes were pre-incubated with either cell culture medium (RPMI) or b-glucan 
(10µg/ml) for 24 hours. After a wash-out period of 7 days, adherent monocytes were 
collected and counted before further treatment for chromatin immunoprecipitation.
Chromatin immunoprecipitation
For Chromatin immunoprecipitation (ChIP), adherent monocytes were cultured 
as described above. For the mouse samples, mice were injected intraperitoneally 
with either PBS or 5x103 C. albicans 7 days prior the collection of the peritoneal 
macrophages. ChIP was performed using antibodies against H3K4me3 (Diagenode), 
and H3K27me3 (Millipore). ChIPed DNA was further processed for high throughput 
sequencing using Illumina Genome Analyzer II as described before (Martens et al., 
2010). High quality sequenced reads were uniquely mapped to human hg18 and 
mouse mm9 using ELAND. Data available through the GEO database (GSE34260).
Statistical analysis 
The differences between groups were analyzed using the Wilcoxon signed-rank test 
(unless otherwise stated). The level of significance was defined as a P value of <0.05.
Results
A non-lethal Candida albicans infection induces protection to secondary 
lethal infection through a T/B lymphocyte-independent, monocyte-dependent 
mechanism
Using a low inoculum of C. albicans, we evaluated the potential of a non-lethal 
candidiasis to protect against a second, lethal C. albicans challenge. Pre-injection of 
a low dose of live C. albicans 7 days prior to a second lethal infection increased the 
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survival rate of wild-type mice (Figure 1A). Pilot studies revealed that fungal loads 
in the organs and circulating cytokine concentrations were not measurable on day 
7 after injection of the low inoculum of Candida (data not shown). The protection 
given by pre-infection was also conferred to Rag1-deficient mice, highlighting that 
the conferred protection is not dependent on T and B lymphocytes (Figure 1A, B). 
Interestingly, Ccr2-deficient mice, which fail to recruit monocytes from the bone 
marrow toward the sites of inflammation, could not be protected by the non-lethal C. 
albicans primary infection (Figure 1A). We have also performed experiments in mice 
in which NK cells were depleted by anti-asialo GM1 antibodies (from 7.5% to 0.6%), 
and observed that the protective effect of Candida pre-infection was independent of 
the presence or absence of NK cells (data not shown). Moreover, mice depleted of NK 
cells had a better survival than the mice treated with an unrelated antibody (Figure 
1C), making it highly unlikely that NK cells play an important role in the protection 
conferred against lethal candidiasis. Taken together, these observations emphasize 
the essential role of monocytes, prototypic innate immune cells, in the C. albicans-
conferred protection. 
To assess whether cytokine production may be one of the innate immune functions 
enhanced during this process, we investigated the effect of Candida pre-treatment in 
an endotoxaemia model, which is the prototypical in vivo innate immune response. 
As shown in Figure 1D, induction of pro-inflammatory cytokines by endotoxin 
(lipopolysaccharide; LPS) was indeed enhanced when mice were pre-treated with low 
amounts of heat-killed C. albicans, even though this primary treatment was given one 
week before the LPS challenge. 
Candida albicans primes the production of pro-inflammatory cytokines in 
monocytes 
Mononuclear phagocytes are the main cell population responsible for pro-inflammatory 
cytokine production during infection. We assessed whether priming of human 
peripheral blood mononuclear cells (PBMCs) in vitro with a low dose of C. albicans 
would increase the response of cells to a secondary stimulation with ligands of pattern 
recognition receptors (PRRs), similar to what we observed in vivo. In an experimental 
setting mimicking the in vivo model, PBMCs were pre-incubated with either culture 
medium or heat-killed C. albicans microorganisms for 24 hours, followed by washing 
of the cells. After a wash-out period of 7 days, during which cells were incubated 
solely with culture medium, various pathogen-associated molecular patterns (PAMPs) 
were added as a second stimulus (Figure 2A). Pre-incubation of cells with the low 
dose of heat-killed Candida (104 microorganisms/ml) did not induce measurable 
cytokine production in supernatants collected after 24 hours (data not shown). 
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Figure 1. Non-lethal candidiasis protect mice through T/B cell-independent but 
macrophage dependent mechanism.
(A) Survival rate of wild-type, Rag1-/- and Ccr2-/- mice to an infection with live C. albicans 
(2x106 CFU/mouse) injected intravenously. Mice were either pre-injected intravenously with 
PBS (Control) or a non-lethal dose of C. albicans (2x104 CFU/mouse, Candida, pre-injection) 7 
days prior to inoculation of lethal C. albicans dose (n≥8 per group, 2 independent experiments). 
(B) Fungal burden of kidneys from Rag1-/- mice 14 days after the lethal C. albicans infection. 
(C) Survival rate of wild-type mice to an infection with live C. albicans (2x106 CFU/mouse) 
injected intravenously. Mice were either pre-injected intravenously with anti-asialo GM1 
antibody or an unrelated antibody (control) 8 days, 4 days and 0 day prior to inoculation of 
the lethal C. albicans dose (n≥10 per group). (D) In vivo training of mice (n=5 per group) with 
heat-inactivated C. albicans (black bars), injected intravenously 7 days prior to intraperitoneal 
inoculation of lipopolysaccharide (LPS), enhanced pro-inflammatory cytokines release 
compared to PBS-treated control mice (white bars). *p<0.05 vs control animals.
In contrast, pre-incubation of cells with C. albicans profoundly and significantly 
increased the concentration of the pro-inflammatory cytokines TNFa and IL6 
obtained in the supernatant after the secondary stimulation with PRR ligands or whole 
microorganisms (Figure 2B). Remarkably, C. albicans not only primed the production 
of cytokines induced by a second C. albicans challenge, but also that induced by 
various C-type lectin receptor (CLR) and Toll-like receptor (TLR) ligands or bacteria 
such as LPS, Pam3Cys and sonicated Mycobacterium tuberculosis. This observation 
suggests that the priming of PBMCs by C. albicans is non-specific; therefore, a 
classical T cell-dependent memory for this priming is highly unlikely. 
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Figure 2. Candida albicans and β-glucans prime the production of pro-inflammatory 
cytokines. 
(A) Diagram showing the course of the in vitro pre-incubation experiment. Cells were 
pre-exposed to culture medium or low concentrations of fungal ligands for 24 hours (1st 
stimulation - training). After the 1st stimuli have been washed, the cells were incubated for 7 
days in culture medium supplemented with serum. Afterwards, a second in vitro stimulation (2nd 
stimulation) of cytokine production with various PRR ligands was performed for an additional 
24 hours. (B, C) C. albicans training in vitro using freshly isolated PBMCs (B) or monocytes 
(C). Human PBMCs (B) or adherent monocytes (C) were pre-incubated with RPMI or heat-
killed C. albicans for 24 hours, followed by a wash-out period of 7 days. After this period and 
after a second stimulation of cytokine production for an additional 24 hours, supernatant was 
collected for cytokine measurement (See also Figure S2A and S2B). (D) The training effects 
induced by purified β-glucans (blue), but not with mannans (grey). E. coli pre-incubation 
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induced immune tolerance (red). (E) CD14+ selected monocytes are also primed by β-glucan 
(See also Figure S1A). (F) The priming effect obtained after 1 week of resting period was also 
seen after 2 weeks (See also Figure S1C). (G) Candidacidal activity of cell culture medium 
(Control) or β-glucans pre-incubated monocytes was assessed after 5 hours of incubation with 
1x104CFU of live opsonised C. albicans (n=6). (B-G) *p<0.05. Data are presented as mean ±SD 
(n = 5 to 8). Wilcoxon signed rank test was used to detect significant differences.
To rule out a role for lymphocytes in this effect, we pre-incubated purified monocytes 
in vitro with C. albicans and exposed them to CLRs and TLRs ligands. Similar 
to PBMCs, exposure of monocytes to Candida for 24h enhanced production of 
the pro-inflammatory cytokines TNFa and IL6 one week later (Figure 2C). Of 
note, the induced mechanism of priming was not due to the down-regulation of 
immunoregulatory cytokines such as IL10 (Figure 2B, C). In addition, cell viability 
was identical in all conditions and above 98% (as assessed by LDH release), and 
therefore cannot explain the differences between cells pre-incubated with Candida 
or culture medium. Moreover, microscopic assessment showed no remaining 
intact Candida during the stimulation period, indicating the decomposition of the 
microorganisms by monocytes. 
β-glucans enhance the pro-inflammatory state of monocytes and prime the 
production of pro-inflammatory cytokines 
β-glucan is a major component of the skeletal cell wall of C. albicans, while the 
matrix is mainly comprised of glycosylphosphatidylinositol (GPI)-anchor-dependent 
cell wall proteins that are highly glycosylated with mannans (Netea et al., 2008). The 
priming effects induced by C. albicans could be reproduced with purified β-glucan, 
but not with mannans (Figure 2D). It is important to underline that the training effect 
was specific to C. albicans and β-glucans, as pre-incubation of cells with TLR ligands 
such as LPS or Pam3Cys did not enhance secondary cytokine production, but rather 
inhibited their production consistent with the previously described induction of 
tolerance (Foster et al., 2007) (Figure 2D and data not shown). In order to completely 
exclude an effect of T cells in the priming phenomenon by β-glucans, we performed 
two complementary sets of control experiments: pre-treatment of either positively-
selected CD14+ monocytes or CD4+ T lymphocyte-depleted PBMCs led to similarly 
enhanced production of proinflammatory cytokines (Figure 2E and Figure S1A). In 
contrast to the monocytes, pre-treatment of CD56+-isolated NK cells with either C. 
albicans or β-glucans failed to induce an enhanced production of proinflammatory 
cytokines (data not shown), supporting the in vivo studies that suggest that NK cells 
do not play an important role for trained immunity during candidiasis. Thus, β-glucan 
non-specifically primed the innate cytokine response of monocytes via a T cell-
independent mechanism, in a similar manner as intact C. albicans.
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In a next set of experiments, we assessed the time needed for C. albicans or β-glucan 
to achieve effective training of monocytes. While the most robust effect was seen after 
24 hours of pre-incubation, a priming effect could be detected also when monocytes 
were pre-incubated for shorter periods of time (Figure S1B). Moreover, pre-incubation 
during 24 hours with C. albicans or β-glucans enabled monocytes to enhance their 
production of cytokines for as long as 2 weeks after the training period (Figure 2F 
and Figure S1C). Incubation longer than 2 weeks was not achievable due to the 
death of primary monocytes in these cultures (based on morphology and trypan blue 
exclusion). In order to assess the reactivity of the trained-monocytes, we titrated the 
concentration of the second stimulus used after C. albicans or β-glucan priming. As 
for the classical response of monocytes to the TLR4 ligand, the enhanced production 
of pro-inflammatory cytokine by trained-monocytes upon a second stimulation was 
dose dependent (Figure S2A). Interestingly, the initial dose of C. albicans and of 
β-glucan also influenced the amplitude of the training effect in a dose-dependent 
manner (Figure S2B). 
In a following set of experiments, we investigated whether additional properties of 
the monocytes could be trained by β-glucan pre-incubation. Indeed, we observed that 
besides the production of pro-inflammatory cytokines, 24 hours pre-incubation with 
β-glucans enabled monocytes to enhance their candidacidal activity (Figure 2G) and 
to efficiently inhibit the C. albicans outgrowth after 24 hours of culture (47% ±9% 
more inhibition compared to non-primed control monocytes). Altogether, these data 
demonstrate a reprogramming effect of C. albicans and β-glucans that are able to train 
monocytes, a mechanism that is non-specific and of longer duration than the classical 
priming of cytokine production (Netea et al., 2011). 
The dectin-1/Raf-1 pathway and the complement receptor 3 (CR3) are required 
to induce training of monocytes
The recognition of β-glucan by human cells is dependent on two main receptors, 
dectin-1 and CR3 (Netea et al., 2008). Inhibition of dectin-1 with laminarin inhibited 
the priming by β-glucans (Figure S2C). Similarly, monocytes isolated from a dectin-1-
deficient individual (Ferwerda et al., 2009) could not be effectively trained with 
b-glucan (Figure 3A), underscoring the role of dectin-1 in the training mechanism. 
Only a partial inhibition of the training of monocytes was observed when the CR3 
receptor was blocked (Figure 3B). Dectin-1 activates cellular responses via two 
pathways: one through the spleen tyrosine kinase and caspase-recruitment domain 
protein 9 (Syk/CARD9) (Drummond et al., 2011), and a second independent pathway 
through the serine-threonine kinase Raf-1 (Gringhuis et al., 2009). Inhibition of Syk 
kinase prior to the priming with β-glucan did not influence the training mechanism 
(Figure 3C). In contrast, incubation of monocytes with a Raf-1 inhibitor prior to 
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priming significantly reduced the training by β-glucans (Figure 3D). Moreover, 
in vivo inhibition of Raf-1 in mice during the training period, i.e. when the low dose of 
C albicans is administrated, abolished the protection conferred in wild-type animals 
by the pre-infection (Figure 3E). 
Molecular regulation of trained monocytes
Cellular response to extracellular stimuli is mediated through intracellular signaling 
cascades such as the mitogen-activated protein (MAP) kinase pathways (Zarubin 
and Han, 2005). The MAP kinase p38 is an important intracellular mediator of the 
stimulation of pro-inflammatory cytokine production during innate immune responses 
(Zarubin and Han, 2005). We therefore assessed the kinetics and magnitude of 
activation of the MAP kinase p38 upon β-glucan training of monocytes. Both the 
expression of p38 itself and the magnitude of p38 phosphorylation (i.e. activation) after 
5, 15 and 30 minutes of TLR2 stimulation were stronger in the monocytes primed with 
b-glucan than in the controls (Figure 3F and 3G), suggesting that enhanced signaling 
and/or availability of signaling molecules, participate in the training mechanism of 
monocytes.
β-glucan training of monocytes leads to enhanced production of pro-inflammatory 
cytokines (Figure 2D) when the cells are exposed to PRR ligands. This enhanced 
production is due to increased gene transcription of Tnfα and Il6 mRNA (Figure 
3H, I). The long-lasting effect of the β-glucan pre-treatment on gene expression 
prompted us to investigate whether epigenetic changes are associated with the long-
term training of monocytes. To test this hypothesis, we assessed the role of histone 
methylation, a process recognized in several previous studies to be crucial for the 
long-term regulation of the expression of innate immunity genes (Foster et al 2007; 
Ishii et al 2008; Carson et al 2011). Inhibition of histone demethylases using a specific 
inhibitor prior to priming with C. albicans or β-glucan had no effect on the training 
of monocytes (Figure 3J, K). However inhibition of histone methyltransferases using 
5’-deoxy-5’-methylthio-adenosine (MTA) drastically inhibited the training of the 
monocytes by C. albicans or β-glucan (Figure 3L, M). These observations support the 
hypothesis that epigenetic regulation, more specifically histone methylation, is likely 
to be involved in the training of monocytes.
To confirm this hypothesis, we assessed the genome-wide binding pattern before 
and after β-glucan training of H3K4me3 and H3K27me3, two histone modifications 
that are associated, among others, with the epigenetic regulation of gene expression 
in embryonic stem cells and immune-related gene regulation (Barski et al., 2007; 
Bernstein et al., 2006; Buratowski and Kim, 2010; Foster et al., 2007; Ishii et al., 
2009; Mikkelsen et al., 2007; Min et al., 2011; Pan et al., 2007; Sims et al., 2007; 
Thomson et al., 2010; Wen et al., 2008). 
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Figure 3. The role of β–glucan receptors for monocyte training. 
(A-D) Cytokine production was determined by ELISA in supernatants of adherent monocytes 
primed for 24 hours with either cell culture medium or β-glucans and re-stimulated with 
different PRR ligands in healthy volunteers (control) and cells isolated from a dectin-1 deficient 
volunteer (A, See also Figure S2C); in the presence or absence of anti-CR3 antibody (B) and 
in the presence or absence of Syk kinase inhibitor (C) or Raf-1 inhibitor GW5074 (D). (E) 
Survival rate of wild-type mice to an infection with live C. albicans (2x106 CFU/mouse) 
injected intravenously. All mice were orally treated with a Raf-1 inhibitor 14 days and 7 days 
prior to the lethal C. albicans infection. Mice were either pre-injected intravenously with PBS 
(Control) or a non-lethal dose of C. albicans (2x104 CFU/mouse, Candida, pre-injection) 7 days 
prior to inoculation of lethal C. albicans dose (n≥10 per group). (F) Western blot of total and 
phosphorylated p38 in cells primed with RPMI (controls) or β-glucan and subjected to 5, 15 or 
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30 minutes stimulation with RPMI or Pam3Cys. (G) Quantification of the effect of β-glucan 
priming on the phosphorylation of p38. (H, I) Fold changes in Tnfα (H) and Il6 (I) mRNA 
expression obtained by quantitative real-time PCR in adherent monocytes after stimulation 
with LPS, Pam3Cys, or heat-inactivated C. albicans. Cells were primed with either nutrient 
rich medium (RPMI, Control) or with b-glucan. (J-M) Cytokine production was determined by 
ELISA in supernatants of adherent monocytes primed 24 hours with either cell culture medium 
or C. albicans (J, L) or β-glucans (K, M) and re-stimulated with different PRR ligands in the 
absence or presence of (J, K) the histone demethylase inhibitor pargyline and (L, M) the histone 
methyltransferases inhibitor MTA (5’-deoxy-5’(methylthio) adenosine). (A-D, J-M) The ratios 
of cytokine production by β-glucan primed vs. non-primed monocytes are presented. Data are 
shown as mean ±SD. n=6 for (B, D, J-M), n=5 for (C). Data presented in (A) is mean of 
two independent experiments. n≥6 for (H, I). *p<0.05 for comparison with the corresponding 
values of control cells (RPMI-primed). Wilcoxon signed rank test was used to detect significant 
differences.
Specifically, methylation of H3K4 correlates with transcriptional activation, and 
methylation of H3K27 with gene silencing (Ansel et al., 2006). We completed two 
independent genome-wide ChIP-seq assays (Martens et al., 2010) in monocytes 7 days 
after pre-exposure to either culture medium or β-glucan. ChIP-seq data showed well-
defined H3K4me3 peaks, while H3K27me3 was present in more diffuse blocs (Figure 
S3A). Our analysis revealed a global increase in H3K4me3 signal in monocytes after 
b-glucan treatment (Figure 4A). In contrast, hardly any changes were observed in 
H3K27me3 regions (Figure 4A). 
To validate the physiological relevance of the β-glucan-induced epigenetic 
modifications observed in our in vitro model, we performed additional genome-wide 
ChIP-seq assay for H3K4me3 in peritoneal macrophages recovered from wild-type 
mice 7 days after injection of either saline (control) or a low dose of C. albicans. As 
observed in human monocytes trained in vitro, our analysis revealed a global increase 
in H3K4me3 signal in macrophages after C. albicans training in vivo (Figure 4B). 
Genome-wide ChIP-seq data showed well-defined H3K4me3 peaks (Figure S3B, C) 
and increase in H3K4me3 could be observed at the level of the promoter of genes 
associated with immune signaling pathway e.g. at Myd88 promoter region (Figure 
S3B) and associated with the training mechanism e.g. at Raf-1 kinase promoter region 
(Figure S3C).
For further analysis, we ranked the H3K4me3 peak regions on the basis of signal 
changes between non-trained control and b-glucan-trained monocytes in vitro (Figure 
S3D). We separated 500 peak regions that showed the highest increase in H3K4me3 
occupancy after β-glucan treatment e.g. at TM7SF4 (DC-STAMP) promoter region 
(Figure S3E), and 500 peak regions that showed decrease in H3K4me3 levels 
after treatment e.g. at SYNE2 promoter region (Figure S3F). Of note, even though 
H3K27me3 hardly showed any changes (Figure 4A), we could nevertheless detect 
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some such cases after b-glucan treatment (Figure S3F). We calculated the normalized 
tags density in the separated peak regions. This revealed significant changes for 
H3K4me3 levels, with less alterations for H3K27me3 between trained and non-trained 
monocytes (Figure 4C). More specifically, H3K4me3 was elevated at the promoters 
of important target genes such as the pro-inflammatory cytokines TNFα, IL6 and 
IL18 after β-glucan treatment (Figure 4D-F). Interestingly, β-glucan treatment of 
monocytes also up-regulated H3K4me3 at the promoter of DECTIN-1 (3.3 fold, 
Figure 4G) but also at the promoters of other CLRs and TLRs (Figure 4H). Finally, 
training the monocytes with β-glucan increased the H3K4me3 at the promoter of 
intracellular signaling molecules, such as the adaptor molecule MYD88 (Figure 4I).
In order to find out whether this H3K4me3 signature was set up immediately after the 
exposure to β-glucan and then decayed, or whether it further unfolded upon withdrawal 
of the stimulus, we performed genome-wide H3K4me3 ChIP-seq, before exposure 
(day 0) and 24 hours after exposure (day 1) to either cell culture medium or β-glucan. 
Hierarchical clustering of the top and bottom 500 regions with H3K4me3 variations 
at day 7 (Figure 4C) revealed that many changes noted in day 7 samples were already 
apparent after 24 hours of β-glucan incubation (Figure S4A). Importantly, H3K4me3 
patterns tended to be strengthened after 7 days when compared to 24 hours (Figure 
S4A). This indicates that a stable, β-glucan-induced epigenetic program could be 
maintained for at least a week, e.g. at TM7SF4 (DC-STAMP) promoter region (Figure 
S4B).
Together, these results indicate that H3K4me3 changes in chromatin across 
immunological pathway genes likely participate in the monocyte training induced by 
β-glucans. 
Transcriptome changes in trained monocytes 
To assess whether the increased levels of H3K4me3 lead to genome-wide 
transcriptional changes as well, we performed two independent genome-wide RNA-
sequencing experiments in untreated and β-glucan-trained monocytes. We examined 
the transcriptional changes of the genes associated with the top 500 regions that 
showed the strongest increase in H3K4me3 promoter occupancy and compared 
these with the genes of the bottom 500 regions that showed the largest decrease in 
H3K4me3. This analysis confirmed a strong correlation between the increase in 
H3K4me3 occupancy and the increase in expression (Figure 4J). Importantly, we 
also identified increased gene expression of several histone methyltransferases after 
β-glucan training, including SETD7, which has been previously related to H3K4me3 
(Nishioka et al., 2002) (Figure 4K). Globally, excluding genes with less than 5 
sequence tags, 5804 genes were more than 2-fold up-regulated while only 1494 were 
2-fold down-regulated.
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Thus, exposure of monocytes to β-glucans is coupled with H3K4me3-associated 
epigenetic changes, which correlate with increased expression of pro-inflammatory 
genes in β-glucan-primed monocytes that is the hallmark of trained immunity.
Activation markers in trained monocytes 
Monocytes are known to differentiate into either pro-inflammatory classically-
activated macrophages (M1) or anti-inflammatory alternatively-activated 
macrophages (M2). M1 and M2 macrophages express mRNA encoding for a distinct 
repertoire of molecules. Arginase-1, mannose receptor and CD163 are considered 
M2 markers, while M1 express higher levels of TLR2 and TLR4 receptors (Gordon, 
2003; Mantovani et al., 2004). Transcriptome analysis of b-glucan-trained monocytes 
showed increased RNA level for TNFα and IL6 (Figure 3H, I), and for TLR2 and 
TLR4, but less for ARG-1 (Figure 4L). However, the M2 markers MRC1 (mannose 
receptor) and CD163 mRNA were also up-regulated in the trained monocytes. Beside 
macrophages, monocytes can also differentiate in dendritic cells (DCs). Interestingly, 
TLR2, TLR4 up-regulation and TNFα production are known features of TNF and 
iNOS producing DCs (Tip-DC) that are important for the clearance of Listeria 
monocytogenes bacteria, and influenza virus in mice (Aldridge et al., 2009; Serbina 
et al., 2003). Except for TLR3, transcriptome analysis of b-glucan-trained monocytes 
also showed an increased RNA level for most of the co-stimulatory molecules and 
chemokine receptors associated with Tip-DC phenotypes, and for CD83, DC-LAMP 
that are classical DC differentiation markers (Figure 4M). Thus, b-glucan-trained 
monocytes display increased activation markers for M1 and M2 macrophages, as well 
as for Tip-DC, arguing against simple skewing of macrophage differentiation, and 
more likely for a global pan-activation of the cells.
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Figure 4. β-glucan alters the epigenetic landscape in trained monocytes, and this correlates 
with β-glucan-induced transcriptomal changes.
(A) Box plot of log2 tag density of H3K4me3 and H3K27me3 signal in control versus trained 
monocytes. A global increase of H3K4me3 is observed while H3K27me3 is barely changed 
in trained monocytes (See also Figure S3A, D-F). (B) Boxplot of the log2 tag density for 
genome-wide H3K4me3 enriched regions in peritoneal macrophages retrieved from untreated 
(control, saline) and Candida pre-injected mice, showing a global increase in H3K4me3 
signal in Candida pre-injected mouse macrophages (See also Figure S3B, C). (C) Intensity 
plots showing the normalized tag density for H3K4me3 and H3K27me3 on the 500 H3K4me3 
enhanced and decreased regions (See also Figure S4A, B). (D-I) Genome browser screen 
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shot showing H3K4me3 binding over TNFα (D), IL6 (E), IL18 (F), DECTIN-1 (G) TLR4 (H) 
and MYD88 promoter regions (I), before and after the treatment with b-glucan. (J) Box plot 
showing RNA expression (RPKM) of the genes associated with top and bottom 500 regions 
with H3K4me3 changes. (K) Genome browser screen shot showing H3K4me3 tag density as 
well as RNA-seq expression data over SETD7 histone methyltransferase before and after the 
treatment with b-glucan. (L-M) Histograms showing RPKM values of genes after b-glucan 
treatment of monocytes. The genes are markers of classically- and alternatively-activated 
macrophages (L) and of inflammatory Tip-DCs (M).
Discussion 
The non-specific adaptive features of innate immunity (Bowdish et al., 2007) that 
have been demonstrated in plants, invertebrates and mice (Bistoni et al., 1986; Bistoni 
et al., 1988; Cooper et al., 2009; Durrant and Dong, 2004; O’Leary et al., 2006; Paust 
et al., 2010; Pham et al., 2007; Rodrigues et al.; Sticher et al., 1997; Sun et al., 2009; 
Tribouley et al., 1978; van ‘t Wout et al., 1992) and termed “trained immunity” (Netea 
et al., 2011) have not been investigated mechanistically in mammalian cells, and the 
molecular substrate of “trained immunity” has not yet been identified. In the present 
study, we demonstrate that monocytes can be trained - in vivo as well as in vitro - to 
exhibit an enhanced and lasting response to microbial components after pre-exposure 
to C. albicans. We show that β-glucan, a major structural cell wall component of 
C. albicans, is able to induce training of monocytes. This effect is mainly mediated 
by the dectin-1 receptor and is signaled through the Raf-1 pathway, leading to more 
rapid and effective activation of signaling molecules, which in turn result in enhanced 
cytokine production. 
Firstly, we demonstrated that a non-lethal candidiasis can protect mice toward a 
second lethal C. albicans infection, and this conferred protection was dependent 
on monocytes but not on T and B lymphocytes. On the one hand, Rag1-deficient 
mice that lack a functional adaptive immune response were still partially protected 
against reinfection with C. albicans, and NK cells were not involved in the protective 
effects of Candida vaccination. On the other hand, the protection was lost in Ccr2-
deficient mice, in which no migration of monocytes outside the bone marrow takes 
place, demonstrating the crucial role of monocytes in the protection. Secondly, we 
showed using an in vivo endotoxaemia model in mice that Candida-induced training 
is associated with enhanced innate immune responses, as the production of pro-
inflammatory cytokines was enhanced by pre-treatment of mice with low amounts of 
heat-killed C. albicans one week before the endotoxin (LPS) challenge. 
In order to understand the physiological relevance of monocyte/macrophage training 
in humans, in whom C. albicans is a commensal (Naglik et al., 2008; Pfaller, 1996; 
Pfaller and Diekema, 2007), we have designed an in vitro experimental setting in 
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human primary monocytes that mimics the in vivo training model tested in mice. The 
training effect of Candida was readily reproduced with human primary monocytes. 
This in vitro model of monocyte programming or “training” enabled us to decipher 
the molecular mechanisms responsible for the effect. Both C. albicans and β-glucans 
were shown to be able to drive the functional reprogramming of human primary 
monocytes, resulting in a long-lasting enhancement of the capacity to respond 
to a secondary stimulus. The first step in the priming of monocytes by b-glucans 
is recognition by the b-glucan receptor dectin-1, as demonstrated both by blocking 
this receptor with specific inhibitors and the use of monocytes from individuals 
with complete dectin-1 deficiency (Ferwerda et al., 2009). A secondary role was 
observed for the alternative b-glucan receptor CR3. Regarding intracellular signaling, 
the non-canonical Raf-1 pathway, and not the Syk signaling pathway, was found to 
mediate the training induced by β-glucans. This stimulation leads to enhance gene 
transcription, which correlates with epigenetic changes at the level of H3K4me3, but 
not of H3K27me3. After b-glucan priming, monocytes showed increased level of 
H3K4me3 at the promoter region of pro-inflammatory cytokines, but also of genes 
encoding TLR receptors (e.g., TLR4) and other important pathways of innate host 
defense (such as MYD88). These data were confirmed by in vivo experiments in 
mice, in which macrophages demonstrated similar epigenetic changes after Candida 
challenge. Finally, this combination of signaling and molecular events leads to 
enhanced production of pro-inflammatory cytokines through both CLRs and TLRs. 
The training effect was not due to the down-regulation of anti-inflammatory cytokines 
such as IL10. Interestingly, the functional reprogramming induced by β-glucans does 
not merely program for a shift towards M1 macrophage differentiation, but results in a 
global increase of both M1/M2 macrophages and Tip-DC markers, indicating strongly 
enhanced functional properties.
At this moment, it is important to underscore that the increased resistance to reinfection 
and the higher cytokine release induced by trained immunity is not similar to classical 
immunological memory, as encountered during specific T and B cell responses. In this 
respect, trained immunity reflects an increase in non-specific antimicrobial capacity, 
close to the concept of adaptive characteristics of innate immunity, as described by 
Mantovani et al. (Biswas and Mantovani, 2010; Bowdish et al., 2007).
An important question concerns the molecular mechanism responsible for monocytes 
reprogramming. Firstly, we have identified that signaling pathways such as p38 
activation are increased. p38 is an important signal transduction mediator in many 
biological processes such as inflammation, development, and cell differentiation 
(Zarubin and Han, 2005). Secondly, we have documented changes in the trimethylation 
profile at the level of H3K4. The combination of in vivo and in vitro data suggests 
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that these changes may indeed represent an important component underlying training 
of monocytes. This observation is reminiscent of previously reported epigenetic 
mechanisms mediating LPS- and TNF- induced tolerance (Foster et al., 2007; Park 
et al., 2011). Changes in H3K4me3, H3K27me2 and histone methyltransferase 
complexes have also been proven to regulate the suppression of dendritic cell-
derived IL12 production in a severe peritonitis model (Carson et al., 2011; Wen et al., 
2008). Additionally, chromatin remodeling has been shown to be a key mechanism 
in the regulation of the polarization toward classically- and alternatively-activated 
macrophage subtypes (M1 and M2 macrophages) (Ishii et al., 2009; Takeuchi and 
Akira, 2011).
The identification of adaptive features for the innate immune responses induced in 
mononuclear phagocytes has important conceptual and practical consequences. 
Recently, NK cells, another prototypical type of innate immune cells, have been 
demonstrated to possess memory characteristics (O’Leary et al., 2006; Paust et al., 
2010; Sun et al., 2009). The observation that NK cells and mononuclear phagocytes 
share properties of non-specific immunological memory (or can be “trained”), strongly 
suggest that these features are a fundamental component of host defense (Netea et al., 
2011). At this moment we have no information on the duration of the protection that 
can be provided by trained immunity, even though epigenetic modifications have been 
reported to correlate with long-term maintained mechanisms (Margueron et al., 2005; 
Wen et al., 2008). The conferred protection might be quite long, as epidemiologic 
studies in children have shown that BCG vaccination exerts non-specific protection of 
children from non-mycobacterial infections for at least the duration of early childhood 
(Garly et al., 2003; Rosenthal et al., 1961). Initial data from our laboratory has 
confirmed that phenotypic changes and reprogramming of circulating monocytes are 
present for at least three months after a BCG vaccination (manuscript in preparation). 
If demonstrated to be long-lived, it is to be expected that trained immunity will have 
important consequences for the design of vaccination strategies that may exploit both 
trained immunity and classical T/B lymphocyte-immunological memory.
One may also speculate about the evolutionary aspects of Candida-induced trained 
immunity. The observation that C. albicans can prime and enhance the pro-
inflammatory immune response of monocytes may represent a possible reason why 
C. albicans became a commensal in humans (Naglik et al., 2008; Pfaller, 1996; 
Pfaller and Diekema, 2007). It is tempting to hypothesize that C. albicans not only 
colonizes, but also trains innate immune cells at mucosal barriers, thereby providing 
enhanced immune control at the sites where the host is most often in contact with 
potentially dangerous pathogens. However, this enhanced innate immune response 
might be harmful in individuals with genetic predispositions for autoimmune or 
Chapter 4
96
autoinflammatory conditions. For example, in inflammatory bowel disease such as 
Crohn’s disease, the enhanced pro-inflammatory response induced by C. albicans 
might be deleterious. In this respect, it is interesting to observe that Crohn’s disease 
is characterized by the presence of specific anti-Candida antibodies (McKenzie et al., 
1990; Sutton et al., 2000). 
In conclusion, in the present study we demonstrate that C. albicans, and β-glucans in 
particular, induce epigenetic reprogramming of monocytes through a dectin-1/Raf-1 
pathway, resulting in enhanced cytokine production. The epigenetic modulation of 
innate immune responses is likely to represent an important characteristic of the 
protection to reinfection conferred by what it has been recently described as “trained 
immunity”.
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Figure S1. Candida albicans and β-glucans prime monocytes production of pro-
inflammatory cytokines, related to Figure 2.
 (A) CD4 depleted cells can be primed by β-glucan (n=4). (B) The longer the priming period, 
the stronger the priming effect is (n=4). (C) The priming effect obtained after 1 week of resting 
is also seen after 2 weeks (n=5). *p<0.05 for comparison with the corresponding values of 
control cells (RPMI-primed). Data are presented as mean ± SD.
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Figure S2. Candida albicans and β-glucans prime monocytes properties, related to Figure 
2 and Figure 3. 
(A) Cytokine production was determined by ELISA in supernatants of adherent monocytes 
primed for 24 hours with either cell culture medium, heat-killed C. albicans or β-glucans and 
re-stimulated with different doses of TLR4 ligands (LPS) (n=4). (B) Adherent monocytes were 
primed for 24 hours with either cell culture medium, or different concentrations of heat-killed 
C. albicans or β-glucans and re-stimulated with TLR4 ligands (LPS) (n=4). (C) Cytokine 
production was determined by ELISA in supernatants of adherent monocytes primed for 24 
hours with either cell culture medium or β-glucans and re-stimulated with different PRR ligands 
in the presence or absence of laminarin (n=9). *p<0.05 for comparison with the corresponding 
values of control cells (RPMI-primed). Data are presented as mean ± SD.
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Figure S3. β-glucan and C. albicans training modify 
the H3K4me3 landscape, related to Figure 4. (A, 
E, F) Genome browser screen shots of representative 
regions in human monocytes. 
(A) The view shows enrichment for H3K4me3 signal 
over defined regions and the absence of changes for 
H3K27me3 signal over larger diffused regions (blocs) 
in control (non-trained) and trained monocytes. 
(E) Genome browser screen shot of the TM7SF4 
(DC-STAMP) promoter region, which shows a strong 
induction of H3K4me3 signal upon b-glucan treatment 
(F) Genome browser screen shot of the SYNE2 promoter 
region, showing loss of H3K4me3 signal in trained 
monocytes. Note the (infrequent) concomitant gain of 
H3K27me3. (B-C) Genome browser screen shot of the 
Myd88 and Raf1 promoter regions showing an increase 
in H3K4me3 in macrophages from Candida pre-injected 
mouse. (D) Ranked distribution of the magnitude of 
change for global H3K4me3 enriched regions.
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Figure S4. β-glucan modifies the epigenetic landscape in trained monocytes, related to 
Figure 4.
(A) Hierarchichal clustering of the fold difference in H3K4me3 signal in monocytes before 
training (day 0) versus other time points (day1 and day7). Dynamic H3K4me3 regions (decreased 
and increased 500 regions) defined in control (cell culture medium) versus trained (β-glucan) 
monocytes at day 7 were used in this analysis. (B) Genome browser screen shot of the TM7SF4 
(DC-STAMP) promoter region, which shows a strong induction of H3K4me3 signal already at 
day 1 of the β-glucan treatment and is reinforced in trained monocytes till day 7. 
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Abstract
MicroRNAs (miRNAs) are a distinct class of transcriptional regulators which show 
key involvements in hematopoietic development. However, large scale analysis of the 
miRNAs expressed in a cell is challenging owing to their smaller size and requirement 
for large amount of high quality RNA. The recently developed strand specific RNA-
sequencing (ssRNA-seq) methodology provides an attractive platform for large scale 
transcriptome analysis at a higher resolution and further defines transcribed regions 
based on RNA polarity information. Here, we used the ssRNA-seq methodology for 
the study of primary miRNAs (pri-miRNAs), in AML subtypes expressing PML-
RARα or AML1-ETO oncofusion proteins. To this end, we generated genome-wide 
ssRNA-seq libraries and identified in addition to the protein coding messenger RNAs 
(mRNA), over 100 pri-miRNAs transcribed in the two AML subtypes. Subsequent 
analysis revealed a set of 43 miRNAs being differentially expressed between the two 
cell types and several de-regulated pathways. Altogether, the data provides a detailed 
overview of the pri-miRNAs transcribed in these two AML cells, and their target 
genes and pathways, in addition to supporting the validity of ssRNA-seq for pri-
miRNA detection.
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Introduction
Since their discovery, miRNAs (Lee et al., 1993) have been implicated as key biological 
players in the regulation of multiple cellular pathways. In animals, microRNAs are 
transcribed as long primary transcripts (pri-miRNA) which are initially processed in 
the nucleus by the Drosha RNAse III enzyme into stem loop precursors called pre-
miRNAs (Lee et al., 2003). Further processing of these pre-miRNAs occurs in the 
cytoplasm by the Dicer RNAse III enzyme and as a result mature ~22 nucleotide 
long miRNA molecules are formed (Lee et al., 2004). Processed miRNAs bind to 
their target mRNAs and negatively regulate the expression of the target gene through 
mRNA degradation or translation inhibition. Over 1000 mature miRNA have been 
discovered so far. They are responsible for the regulation of more than half of the 
human genes (Martignani et al., 2011). Deregulation of miRNA function involving 
genetic (mutations, deletions, duplications) or epigenetic mechanisms can lead to 
tumorigenesis and cancer (Agirre et al., 2012). 
Hematopoiesis is a complex lineage system where a high level of regulation is required 
to create specialized blood cells starting from a single hematopoietic stem cell. Several 
studies have investigated the role of miRNA during hematopoiesis and revealed the 
specialized function of several of these miRNAs in normal blood cell formation 
(Schotte et al., 2011; Vasilatou et al., 2009; Yendamuri and Calin, 2009). For example 
mir-181, mir-223 and mir-142 which are among the first described miRNAs, have 
important roles in hematopoietic lineage specification and are differentially expressed 
in different sub-lineages (Chen et al., 2004; Kluiver et al., 2006). Moreover, mis-
regulation of miRNAs has been associated with leukemogenesis (Schotte et al., 2011; 
Yendamuri and Calin, 2009), while their expression pattern has also been suggested 
to have a prognostic value specially in cytogenetically normal leukemia (Eisfeld et al., 
2012; Marcucci et al., 2008).
Different in silico algorithms have predicted a huge number of miRNAs, some of 
them being tested in a functional setup while the role of a large set is still elusive 
(Birney et al., 2007; Dweep et al., 2011). Several methodologies are in use to study 
the expression and function of miRNAs each with its own pros and cons, as reviewed 
before (Jay et al., 2007; Yin et al., 2008). In summary, conventional cloning and 
sequencing of miRNAs (Lagos-Quintana et al., 2002; Takada et al., 2006), and 
more advanced methodologies like RT-PCR (Jiang et al., 2005) and bead based flow 
cytometery (Lu et al., 2005) as well as miRNA based microarrays (Liu et al., 2008) 
are used to detect miRNA expression. Deep sequencing for the detection of the pri-
miRNAs has also been reported (Ryu et al., 2011). However, the use of a large amount 
of starting RNA material, accurate probe/primer design and associated costs makes it 
challenging to implement these technologies in large scale expression analysis. 
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Here, we present the use of strand specific RNA sequencing as a valid method for the 
simultaneous study of protein coding mRNA transcripts as well as other RNA species, 
with the focus on primary miRNA transcripts (pri-miRNA) expressed in different 
AML cell lines. Using strand specific RNA-seq and 250 ng of total RNA as starting 
material, we obtained a high quality ssRNA-seq data set. We could map in addition to 
the protein coding messenger RNAs high quality sequenced tags in various genomic 
regions from where putative RNAs including non-coding RNAs as well as miRNAs 
are expressed. This analysis was first performed in NB4 cells, which represent the M3 
subtype of AML and extended to the AML M2 subtype, allowing identification of a 
set of more than 100 microRNA (MIR) genes in total. Around 43 of these MIR genes 
showed up or down regulated expression when comparing the two AML subtypes. 
Subsequent annotation and validation of the miRNA targets expression allowed 
identification of the pathways which were regulated commonly and differentially 
by these miRNA. Overall the data provides an overview of the transcribed miRNAs 
in PML-RARα and AML1-ETO expressing AMLs and the different pathways (de)
regulated by them, in addition to supporting the validity of ssRNA-seq for primary 
miRNA detection.
Methods
Cell culture and strand specific RNA sequencing
NB4 and SKNO1 cells were cultured in RPMI cell culture medium supplemented 
with FCS. For expression analysis total RNA was isolated from both NB4 and 
SKNO1 cells. DNaseI treatment was performed for 15 min and the concentration was 
measured with a Qubit fluorometer (Invitrogen). A total of 250 ng of RNA was treated 
by Ribo-Zero rRNA Removal Kit (epicentre) to remove ribosomal RNAs according 
to manufacturer instructions. 16 µl of purified RNA was fragmented by addition of 4 
µl 5x fragmentation buffer (200 mM Tris acetate pH 8.2, 500 mM potassium acetate 
and 150 mM magnesium acetate) in a final volume of 20 ml, and incubated at 95°C 
for exactly 90 seconds. After ethanol precipitation, first strand cDNA was synthesized 
from the fragmented RNA with SuperscriptIII (Invitrogen) using random hexamers. 
First strand cDNA was purified by Qiagen mini elute columns and second strand 
cDNA was prepared in the presence of dUTP instead of dTTP for the subsequent 
degradation of the second strand in the next step with USER (Uracil-Specific Excision 
Reagent) enzyme. Double stranded cDNA was purified by Qiagen mini elute columns 
and used for Illumina sample prepping and sequenced according to the manufacturer’s 
instructions. RNA-seq reads were uniquely mapped to the human genome (HG18) 
and used for bioinformatic analysis. RPKM (reads per kilobase of gene length per 
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million reads) (Mortazavi et al. 2008) values for RefSeq genes were computed with 
tag counting scripts and used to analyze the expression level of miRNA in both cell 
types.
Differential miRNA analysis
From the strand specific RNA-seq data set, MIR genes with more than five mapped 
tags were used for further analysis. Reads Per Kilobase of exon model per Million 
mapped reads (RPKM) values for all the transcripts were calculated using a perl 
script. In the subsequent step, the MIR genes with at least a two-fold difference in 
their RPKM values between the NB4 and SKNO1 cell lines were used for intensity 
plots and further analyses. 
miRNA pathway analysis
First, validated targets were extracted for the dynamic miRNAs from a miRNA 
database “miRWalk” (Dweep et al., 2011). Those targets which showed a down 
regulation in the cell line where the miRNA was highly expressed were used for the 
pathway analysis. All the pathway analysis was done using the web-based tool “Gene 
Set Enrichment Analysis (GSEA)” (Subramanian et al., 2005). 
Results
MIR genes detected in NB4 and SKNO1 cell lines
Ribosomal RNA depleted RNA (Roy Sooknanan et al., 2010) from NB4 and SKNO1 
cells was processed for strand specific RNA-seq library using dUTP second strand 
marking (Levin et al., 2010) and sequencing on the Illumina platform. Around 20 
million high quality mapped reads not only gave a comprehensive view of the global 
transcriptome of these AML cells (Figure 1A), but could also detect signal in genomic 
locations giving rise to long non-coding RNAs like MALAT1 (Figure 1B) (Huarte and 
Rinn, 2010) and other putative RNAs including genes encoding microRNAs (Figure 
1C). One example of high expression of primary miRNA (pri-miRNA) transcripts 
was from the MIR17HG gene locus (Figure 1C) which gives rise to a cluster of six 
individual miRNAs whose aberrant expression was reported in various tumors and 
hematopoietic malignancies (Mendell, 2008). Unfortunately the methodology we 
used does not allow the detection of fully processed miRNAs but only of pri-miRNAs, 
since processed mature miRNA are ~ 22 nucleotides long while the size selection 
of the library for sequencing only allowed us to look at fragments greater than 100 
bp. We calculated the RPKM values for all the Refseq gene transcripts including the 
miRNAs and could identify 128 miRNA (MIR) genes or primary transcripts (pri-
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miRNA) which showed significant tag count and RPKM value in either NB4 or 
SKNO1 cells (Table 1). Additional analysis using the miRWalk database (Dweep et 
al., 2011) allowed us to filter out validated targets for 46 of these miRNAs, 80% 
of which showed an overlap with previously described miRNAs involved in AML 
pathway regulation (Figure 1D). These results highlight ssRNA-seq as a valid method 
to study primary miRNA transcripts present in a given cell type.
Table 1. MIR genes identified in NB4 and SKNO1 cells.
RefSeqID Chr Start End Strand Gene Name BaseCount
Tags 
NB4
RPKM 
(NB4)
Tags 
SKNO1
RPKM 
SKNO1
NR_029519 chr20 3846140 3846218 + MIR103A2 78 9 4.73E+00 1 8.70E-01
NR_031722 chr20 3846148 3846210 - MIR103B2 62 9 5.95E+00 1 1.09E+00
NR_029831 chr7 99529551 99529633 - MIR106B 82 3 1.50E+00 4 3.31E+00
NR_031592 chr19 10375133 10375214 - MIR1181 81 5 2.53E+00 2 1.68E+00
NR_031593 chr1 2.29E+08 2.29E+08 - MIR1182 97 3 1.27E+00 7 4.90E+00
NR_031609 chr8 1.29E+08 1.29E+08 + MIR1204 67 4 2.45E+00 7 7.09E+00
NR_031598 chr5 1.79E+08 1.79E+08 - MIR1229 69 0 0.00E+00 8 7.87E+00
NR_036052 chr2 2.32E+08 2.32E+08 + MIR1244-1 82 263 1.31E+02 1 8.28E-01
NR_036262 chr2 2.32E+08 2.32E+08 + MIR1244-2 82 263 1.31E+02 1 8.28E-01
NR_036263 chr2 2.32E+08 2.32E+08 + MIR1244-3 82 263 1.31E+02 1 8.28E-01
NR_031650 chr3 1.88E+08 1.88E+08 + MIR1248 106 20 7.73E+00 1524 9.76E+02
NR_031692 chr12 67953203 67953265 - MIR1279 62 75 4.96E+01 14 1.53E+01
NR_031695 chr15 41873148 41873249 - MIR1282 101 1027 4.17E+02 49 3.29E+01
NR_031623 chr12 47334493 47334580 - MIR1291 87 1 4.71E-01 789 6.15E+02
NR_031639 chr11 93106487 93106578 - MIR1304 91 69 3.11E+01 10 7.46E+00
NR_031706 chr22 18453580 18453665 + MIR1306 85 24 1.16E+01 6 4.79E+00
NR_031707 chr10 1.05E+08 1.05E+08 - MIR1307 149 71 1.95E+01 18 8.20E+00
NR_029683 chr17 53763591 53763678 - MIR142 87 215 1.01E+02 12 9.36E+00
NR_030784 chr21 25868162 25868227 + MIR155 65 5 3.15E+00 1 1.04E+00
NR_001458 chr21 25856327 25869351 + MIR155HG 1474 526 1.46E+01 62 2.85E+00
NR_029485 chr13 49521255 49521338 - MIR15A 83 3 1.48E+00 12 9.81E+00
NR_029663 chr3 1.62E+08 1.62E+08 + MIR15B 98 0 0.00E+00 17 1.18E+01
NR_029486 chr13 49521109 49521198 - MIR16-1 89 3 1.38E+00 32 2.44E+01
NR_029487 chr13 90800859 90800943 + MIR17 84 2 9.76E-01 33 2.67E+01
NR_027349 chr13 90798074 90804830 + MIR17HG 927 318 1.41E+01 114 8.35E+00
NR_027350 chr13 90798074 90804830 + MIR17HG 5018 938 7.66E+00 769 1.04E+01
NR_038975 chr9 1.26E+08 1.27E+08 + MIR181A2HG 617 12 7.97E-01 11 1.21E+00
NR_029612 chr1 1.97E+08 1.97E+08 - MIR181B1 110 0 0.00E+00 33 2.04E+01
NR_029707 chr1 71305901 71305987 - MIR186 86 29 1.38E+01 6 4.73E+00
NR_029488 chr13 90801005 90801076 + MIR18A 71 0 0.00E+00 62 5.93E+01
NR_029489 chr13 90801145 90801227 + MIR19A 82 0 0.00E+00 17 1.41E+01
NR_029490 chr13 90801446 90801533 + MIR19B1 87 0 0.00E+00 6 4.68E+00
NR_029492 chr13 90801319 90801390 + MIR20A 71 0 0.00E+00 7 6.69E+00
NR_029493 chr17 55273408 55273480 + MIR21 72 0 0.00E+00 6 5.66E+00
NR_038262 chr11 555656 558457 - MIR210HG 2303 5 8.90E-02 1 2.95E-02
NR_029635 chrX 45490528 45490638 - MIR221 110 9 3.35E+00 13 8.02E+00
NR_029636 chrX 45491364 45491474 - MIR222 110 1 3.73E-01 27 1.67E+01
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Table 1. (continued)
RefSeqID Chr Start End Strand Gene Name BaseCount
Tags 
NB4
RPKM 
(NB4)
Tags 
SKNO1
RPKM 
SKNO1
NR_029637 chrX 65155436 65155546 + MIR223 110 23 8.57E+00 79 4.87E+01
NR_031754 chr5 92982157 92982250 - MIR2277 93 1 4.41E-01 6 4.38E+00
NR_029495 chr19 13808400 13808473 - MIR23A 73 0 0.00E+00 14 1.30E+01
NR_029498 chr7 99529118 99529202 - MIR25 84 21 1.02E+01 6 4.85E+00
NR_029500 chr2 2.19E+08 2.19E+08 + MIR26B 77 4 2.13E+00 3 2.64E+00
NR_029501 chr19 13808253 13808331 - MIR27A 78 0 0.00E+00 6 5.22E+00
NR_029832 chr1 2.06E+08 2.06E+08 - MIR29C 88 3 1.40E+00 6 4.63E+00
NR_029842 chr17 54583278 54583364 - MIR301A 86 4 1.91E+00 6 4.73E+00
NR_039891 chr17 59927345 59927429 - MIR3064 84 422 2.06E+02 80 6.46E+01
NR_036101 chr7 19711505 19711584 - MIR3146 79 0 0.00E+00 6 5.15E+00
NR_036108 chr9 91116959 91117041 + MIR3153 82 8 4.00E+00 4 3.31E+00
NR_036137 chr16 533277 533367 + MIR3176 90 6 2.73E+00 1 7.54E-01
NR_036149 chr17 25468229 25468304 - MIR3184 75 12 6.56E+00 0 0.00E+00
NR_036152 chr17 77032724 77032809 - MIR3186 85 6 2.89E+00 4 3.19E+00
NR_036154 chr19 764583 764653 + MIR3187 70 25 1.46E+01 22 2.13E+01
NR_039851 chr12 52911447 52911527 - MIR3198-2 80 42 2.15E+01 23 1.95E+01
NR_029896 chr17 7067339 7067422 - MIR324 83 16 7.90E+00 1 8.18E-01
NR_037400 chr1 33570580 33570680 - MIR3605 100 6 2.46E+00 3 2.04E+00
NR_037402 chr5 85952069 85952148 + MIR3607 79 6 3.11E+00 10 8.59E+00
NR_037408 chr17 52323629 52323715 - MIR3614 86 196 9.34E+01 13 1.03E+01
NR_037412 chr22 18453268 18453356 + MIR3618 88 20 9.31E+00 11 8.48E+00
NR_037415 chr1 2.26E+08 2.26E+08 + MIR3620 79 62 3.22E+01 14 1.20E+01
NR_037420 chr16 69120902 69121003 + MIR3647 101 0 0.00E+00 8 5.38E+00
NR_037424 chr9 94094560 94094650 - MIR3651 90 0 0.00E+00 16776 1.27E+04
NR_037425 chr12 1.03E+08 1.03E+08 + MIR3652 131 9 2.82E+00 30 1.55E+01
NR_037426 chr22 28059146 28059256 - MIR3653 110 3 1.12E+00 5 3.08E+00
NR_037429 chr11 1.18E+08 1.18E+08 + MIR3656 69 21 1.25E+01 1 9.84E-01
NR_037431 chr1 1.64E+08 1.64E+08 + MIR3658 56 106 7.76E+01 32 3.88E+01
NR_037434 chr5 1.34E+08 1.34E+08 + MIR3661 96 158 6.74E+01 11 7.78E+00
NR_037435 chr6 1.35E+08 1.35E+08 - MIR3662 95 5 2.16E+00 5 3.57E+00
NR_037438 chr13 77170147 77170252 - MIR3665 105 4 1.56E+00 7 4.52E+00
NR_037447 chr17 8031217 8031302 + MIR3676 85 0 0.00E+00 6 4.79E+00
NR_037453 chr2 53929762 53929846 - MIR3682 84 4 1.95E+00 4 3.23E+00
NR_037480 chr1 2.45E+08 2.45E+08 - MIR3916 94 56 2.44E+01 194 1.40E+02
NR_037482 chr6 1.59E+08 1.59E+08 - MIR3918 93 3 1.32E+00 3 2.19E+00
NR_037505 chr19 6367420 6367522 - MIR3940 102 48 1.93E+01 28 1.86E+01
NR_029945 chr17 25468222 25468316 + MIR423 94 45 1.96E+01 1 7.22E-01
NR_036230 chr2 28072737 28072820 + MIR4263 83 1 4.94E-01 7 5.72E+00
NR_036235 chr3 75870120 75870204 + MIR4273 84 17 8.29E+00 8 6.46E+00
NR_039624 chr2 55314803 55315489 + MIR4426 60 14 9.56E+00 5 5.66E+00
NR_039651 chr4 53273605 53273671 + MIR4449 66 2 1.24E+00 113 1.16E+02
NR_039702 chr10 1.06E+08 1.06E+08 - MIR4482 70 6 3.51E+00 3 2.91E+00
NR_039705 chr11 10486392 10486449 - MIR4485 57 0 0.00E+00 6 7.14E+00
NR_039742 chr16 28877404 28877483 + MIR4517 79 4 2.07E+00 7 6.01E+00
NR_039746 chr17 8030987 8031047 + MIR4521 60 0 0.00E+00 18 2.04E+01
NR_039790 chr6 44329920 44330000 - MIR4647 80 125 6.40E+01 30 2.54E+01
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Table 1. (continued)
RefSeqID Chr Start End Strand Gene Name BaseCount
Tags 
NB4
RPKM 
(NB4)
Tags 
SKNO1
RPKM 
SKNO1
NR_039792 chr7 44116965 44117048 + MIR4649 83 0 0.00E+00 6 4.91E+00
NR_039801 chr7 44887871 44887924 - MIR4657 53 76 5.88E+01 24 3.07E+01
NR_039802 chr7 99592163 99592228 - MIR4658 65 13 8.20E+00 2 2.09E+00
NR_039814 chr9 1.14E+08 1.14E+08 + MIR4668 70 1 5.85E-01 5 4.85E+00
NR_039828 chr10 1.13E+08 1.13E+08 + MIR4680 74 86 4.76E+01 18 1.65E+01
NR_039835 chr11 3833867 3833947 + MIR4687 80 7 3.59E+00 3 2.54E+00
NR_039849 chr12 1.2E+08 1.2E+08 + MIR4700 74 27 1.50E+01 10 9.17E+00
NR_039856 chr14 22495998 22496078 - MIR4707 80 4 2.05E+00 7 5.94E+00
NR_039858 chr14 74016588 74016660 - MIR4709 72 90 5.12E+01 74 6.98E+01
NR_039862 chr15 48439817 48439899 + MIR4712 82 19 9.49E+00 8 6.62E+00
NR_039871 chr16 79976123 79976199 + MIR4720 76 4 2.16E+00 12 1.07E+01
NR_039872 chr16 28762740 28762829 - MIR4721 89 23 1.06E+01 16 1.22E+01
NR_039896 chr1 2.23E+08 2.23E+08 - MIR4742 85 8 3.86E+00 1 7.98E-01
NR_039900 chr19 755931 756023 + MIR4745 92 5 2.23E+00 5 3.69E+00
NR_039906 chr19 55128132 55128206 + MIR4751 74 179 9.91E+01 4 3.67E+00
NR_039918 chr22 18331275 18331357 + MIR4761 82 16 8.00E+00 3 2.48E+00
NR_039934 chr2 2.08E+08 2.08E+08 + MIR4775 75 7 3.82E+00 3 2.71E+00
NR_039964 chr4 2221601 2221681 - MIR4800 80 1 5.12E-01 10 8.48E+00
NR_038310 chr17 6859860 6863697 - MIR497HG 794 229 1.18E+01 17 1.45E+00
NR_039969 chr17 59927793 59927893 - MIR5047 100 199 8.15E+01 99 6.72E+01
NR_030258 chrX 73423663 73423769 - MIR545 106 0 0.00E+00 6 3.84E+00
NR_030282 chr1 1.54E+08 1.54E+08 - MIR555 96 5 2.13E+00 9 6.36E+00
NR_030296 chr3 1.97E+08 1.97E+08 + MIR570 97 26 1.10E+01 8 5.60E+00
NR_030299 chr4 24130912 24131011 - MIR573 99 14 5.79E+00 11 7.54E+00
NR_030321 chr7 73243463 73243560 + MIR590 97 13 5.49E+00 9 6.30E+00
NR_030331 chr9 1.25E+08 1.25E+08 - MIR600 98 5 2.09E+00 1 6.93E-01
NR_030343 chr11 64968504 64968604 + MIR612 100 7 2.87E+00 6 4.07E+00
NR_030352 chr13 40282901 40282997 + MIR621 96 16 6.83E+00 17 1.20E+01
NR_030359 chr15 70666611 70666708 + MIR630 97 9 3.80E+00 1 7.00E-01
NR_030366 chr17 72244126 72244225 - MIR636 99 13 5.38E+00 8 5.48E+00
NR_030371 chr19 45480289 45480388 - MIR641 99 10 4.14E+00 1 6.86E-01
NR_030386 chr20 26136821 26136914 - MIR663 93 1 4.41E-01 278 2.03E+02
NR_030407 chr7 1.51E+08 1.51E+08 + MIR671 118 10 3.47E+00 2 1.15E+00
NR_029605 chr9 85774482 85774592 - MIR7-1 110 3 1.12E+00 19 1.17E+01
NR_031580 chr1 52074603 52074662 - MIR761 59 7 4.86E+00 3 3.45E+00
NR_031576 chr16 30812724 30812807 + MIR762 83 5 2.47E+00 2 1.64E+00
NR_030615 chr6 30660087 30660173 + MIR877 86 16 7.62E+00 6 4.73E+00
NR_030627 chr3 1.99E+08 1.99E+08 - MIR922 81 8 4.05E+00 9 7.54E+00
NR_029508 chr13 90801568 90801646 + MIR92A1 78 4 2.10E+00 8 6.96E+00
NR_029510 chr7 99529326 99529406 - MIR93 80 1 5.12E-01 17 1.44E+01
NR_030635 chr8 1.46E+08 1.46E+08 - MIR939 82 2 9.99E-01 7 5.79E+00
NR_030641 chr4 1957908 1958002 - MIR943 94 16 6.97E+00 0 0.00E+00
NR_029476 chr9 95978059 95978139 + MIRLET7A1 80 0 0.00E+00 11 9.33E+00
NR_027033 chr22 44860540 44888472 + MIRLET7BHG 4717 6 5.21E-02 107 1.54E+00
NR_029483 chr9 95978449 95978536 + MIRLET7F1 87 6 2.83E+00 4 3.12E+00
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Figure 1. MIR genes identifi ed in NB4 and SKNO1 cell lines.
(A) Genome browser screen shot of the ssRNA-seq data at a chromosome 17 locus in SKNO1 
and NB4 cells. (B) Genome browser screen shot of the ssRNA-seq data at the chromosome 11 
locus bearing the MALAT1 long non-coding RNA. (C) Genome browser screen shot of the 
ssRNA-seq SKNO1 and NB4 cell data for the MIR17HG gene locus on chromosome 13 which 
bears miRNA cluster mir-17-92a. (D) Overlap of the miRNAs detected in NB4 and SKNO1 
cells with 237 miRNAs associated with the AML pathway according to the miRWalk database. 
miRNAs are dynamically expressed in NB4 and SKNO1 cells
Various studies, mostly based on qRT-PCR and microarray data, have shown the 
differential expression of miRNA in different leukemic subtypes (Dixon-McIver et 
al., 2008; Li et al., 2008; Votavova et al., 2011). In order to look at the MIR genes 
which showed altered expression between the two leukemic cell types, we calculated 
ratios of RPKM values and identifi ed 43 MIR genes which showed more than two-
fold expression difference between the two cell types (Figure 2A) and (Table 2). 
Among these, 20 showed overlap with previously described miRNAs linked to acute 
myeloid leukemia (AML) and acute promyelocytic leukemia (APL) (Figure 2A) in 
the miR2disease database (Jiang et al., 2009). Among these is mir-142, one of the 
fi rst identifi ed miRNAs associated with hematopoiesis (Chen et al., 2004), which is 
highly expressed in NB4 cells but not in SKNO1 cells (Figure 2 A,B), confi rming a 
previous report of high expression of this miRNA in APL patients (Dixon-McIver et 
al., 2008). In contrast, expression of mir-663 was completely abolished in NB4 cells 
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whereas it was highly expressed in SKNO1 cells (Figure 2 A,C), in line with recent 
studies in which mir-663 has been shown to have variable expression among different 
leukemic cell lines (Yang et al., 2011). Interestingly, in the leukemic cell line HL-
60, mir-663 expression is reported as upregulated upon retinoic acid treatment and 
cellular differentiation (Jian et al., 2011) suggesting that its low expression in NB4 
cells is linked to the inability of this class of AMLs to differentiate. Alltogether, the 
differential expression of these miRNAs in our experiments is in line with previous 
reports and further supports the validity of the ssRNA-seq approach to detect miRNAs.
Table 2. MIR genes differentially expressed between NB4 and SKNO1 cells.
Ref Seq ID  Chr Start End Strand Gene Name RPKM NB4
RPKM 
SKNO1
miRNA Name
NR_029612 chr1 1.97E+08 1.97E+08 - MIR181B1 0.00E+00 2.04E+01 hsa-mir-181b-1
NR_029707 chr1 71305901 71305987 - MIR186 1.38E+01 4.73E+00 hsa-mir-186
NR_029832 chr1 2.06E+08 2.06E+08 - MIR29C 1.40E+00 4.63E+00 hsa-mir-29c
NR_030282 chr1 1.54E+08 1.54E+08 - MIR555 2.13E+00 6.36E+00 hsa-mir-555
NR_031707 chr10 1.05E+08 1.05E+08 - MIR1307 1.95E+01 8.20E+00 hsa-mir-1307
NR_038262 chr11 555656 558457 - MIR210HG 8.90E-02 2.95E-02 hsa-mir-210
NR_029485 chr13 49521255 49521338 - MIR15A 1.48E+00 9.81E+00 hsa-mir-15a
NR_029486 chr13 49521109 49521198 - MIR16-1 1.38E+00 2.44E+01 hsa-mir-16-1
NR_029487 chr13 90800859 90800943 + MIR17 9.76E-01 2.67E+01 hsa-mir-17
NR_029488 chr13 90801005 90801076 + MIR18A 0.00E+00 5.93E+01 hsa-mir-18a
NR_029489 chr13 90801145 90801227 + MIR19A 0.00E+00 1.41E+01 hsa-mir-19a
NR_029490 chr13 90801446 90801533 + MIR19B1 0.00E+00 4.68E+00 hsa-mir-19b-1
NR_029492 chr13 90801319 90801390 + MIR20A 0.00E+00 6.69E+00 hsa-mir-20a
NR_029508 chr13 90801568 90801646 + MIR92A1 2.10E+00 6.96E+00 hsa-mir-92a-1
NR_030359 chr15 70666611 70666708 + MIR630 3.80E+00 7.00E-01 hsa-mir-630
NR_029683 chr17 53763591 53763678 - MIR142 1.01E+02 9.36E+00 hsa-mir-142
NR_029493 chr17 55273408 55273480 + MIR21 0.00E+00 5.66E+00 hsa-mir-21
NR_029842 chr17 54583278 54583364 - MIR301A 1.91E+00 4.73E+00 hsa-mir-301a
NR_029896 chr17 7067339 7067422 - MIR324 7.90E+00 8.18E-01 hsa-mir-324
NR_029945 chr17 25468222 25468316 + MIR423 1.96E+01 7.22E-01 hsa-mir-423
NR_038310 chr17 6859860 6863697 - MIR497HG 1.18E+01 1.45E+00 hsa-mir-497
NR_029495 chr19 13808400 13808473 - MIR23A 0.00E+00 1.30E+01 hsa-mir-23a
NR_029501 chr19 13808253 13808331 - MIR27A 0.00E+00 5.22E+00 hsa-mir-27a
NR_030371 chr19 45480289 45480388 - MIR641 4.14E+00 6.86E-01 hsa-mir-641
NR_029519 chr20 3846140 3846218 + MIR103A2 4.73E+00 8.70E-01 hsa-mir-103-2
NR_030386 chr20 26136821 26136914 - MIR663 4.41E-01 2.03E+02 hsa-mir-663
NR_030784 chr21 25868162 25868227 + MIR155 3.15E+00 1.04E+00 hsa-mir-155
NR_027033 chr22 44860540 44888472 + MIRLET7BHG 5.21E-02 1.54E+00 hsa-let-7b
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Table 2. (continued)
Ref Seq ID  Chr Start End Strand Gene Name RPKM NB4
RPKM 
SKNO1
miRNA Name
NR_027033 chr22 44860540 44888472 + MIRLET7BHG 5.21E-02 1.54E+00 hsa-let-7a-3
NR_029663 chr3 1.62E+08 1.62E+08 + MIR15B 0.00E+00 1.18E+01 hsa-mir-15b
NR_031598 chr5 1.79E+08 1.79E+08 - MIR1229 0.00E+00 7.87E+00 hsa-mir-1229
NR_029831 chr7 99529551 99529633 - MIR106B 1.50E+00 3.31E+00 hsa-mir-106b
NR_029498 chr7 99529118 99529202 - MIR25 1.02E+01 4.85E+00 hsa-mir-25
NR_030407 chr7 1.51E+08 1.51E+08 + MIR671 3.47E+00 1.15E+00 hsa-mir-671
NR_029510 chr7 99529326 99529406 - MIR93 5.12E-01 1.44E+01 hsa-mir-93
NR_031609 chr8 1.29E+08 1.29E+08 + MIR1204 2.45E+00 7.09E+00 hsa-mir-1204
NR_030331 chr9 1.25E+08 1.25E+08 - MIR600 2.09E+00 6.93E-01 hsa-mir-600
NR_029605 chr9 85774482 85774592 - MIR7-1 1.12E+00 1.17E+01 hsa-mir-7-1
NR_029476 chr9 95978059 95978139 + MIRLET7A1 0.00E+00 9.33E+00 hsa-let-7a-1
NR_029635 chrX 45490528 45490638 - MIR221 3.35E+00 8.02E+00 hsa-mir-221
NR_029636 chrX 45491364 45491474 - MIR222 3.73E-01 1.67E+01 hsa-mir-222
NR_029637 chrX 65155436 65155546 + MIR223 8.57E+00 4.87E+01 hsa-mir-223
NR_030258 chrX 73423663 73423769 - MIR545 0.00E+00 3.84E+00 hsa-mir-545
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Figure 2. miRNAs up and down regulated in NB4 and SKNO1 cells.
(A) Intensity plot of the ratios of RPKM values showing the differentially expressed miRNAs 
in the NB4 and SKNO1 cell lines. Highlighted miRNAs (bold) also show an overlap with AML 
and APL associated miRNAs listed in the mir2disease database. (B-C) Genome browser screen 
shots depicting examples of differential expressed miRNA in NB4 and SKNO1 cell lines, hsa-
mir-142 (B) and hsa-mir-663 (C).
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Biological pathways targeted by differentially expressed micro-RNAs in AMLs
As miRNAs have a very important role in the maintenance of normal hematopoiesis as 
well as in the onset of leukemogenesis (Kluiver et al., 2006; Vasilatou et al., 2010) we 
analyzed the biological pathways which are being affected by the target genes of these 
dynamically expressed miRNAs. To this end we first extracted the validated target 
genes of these miRNAs using the “miRWalk” data base. Next we analyzed whether 
the genes have an inverse correlation with miRNA expression in the respective cell 
line where they are targeted (Figure. 3A-D). Many genes (around 300), targeted by 
highly expressed miRNAs in NB4 cells showed decreased expression in NB4 cells as 
compared to SKNO1 cells (Figure 3A) e.g. CD69 gene which is targeted in NB4 cells 
(Figure 3B), and the opposite was true for genes (around 1000), targeted in SKNO1 
cells (Figure 3C) e.g. JAG1 gene (Figure 3D). Interestingly, most of the genes targeted 
by miRNAs in NB4 cells also showed a similar pattern of decreased expression in 
AML M3 patients as compare to AML M2 as assessed from the (Verhaak et al., 2009) 
data set (Figure 3E) and similarly genes targeted by miRNAs in SKNO1 cells showed 
a decreased expression in AML M2 patients as compare to AML M3 (Figure 3F). We 
used a gene set enrichment analysis (GSEA) tool (Subramanian et al., 2005) for the 
pathway analysis (see methods) and found a very significant enrichment of different 
cancer-associated pathways (Table 3A& B). Moreover, we found many pathways 
which are affected in the two cells lines but by different sets of genes (Table 3A&B). 
For example “p53 signaling pathway” was affected in both the cell lines. Furthermore, 
we found a major deregulation of the cell cycle pathways, specifically the cell cycle 
checkpoint-associated targets, which were down regulated in both cell lines (Table 
3A&B). These results further suggest that at the miRNA level different leukemic 
subtypes broadly affect the same pathways to set up their leukemic program.
Table 3
A. Pathways effected by miRNA targets in SKNO1 cells.
Pathways effected in SKNO1 cells p-value
p53 Signaling Pathway 2.23 e-5
RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage 4.06 e-5
Chaperones modulate interferon Signaling Pathway 1.03 e-4
Pathways in cancer 1.14 e-4
Genes involved in Cyclin A1 associated events during G2/M transition 1.3 e-4
Influence of Ras and Rho proteins on G1 to S Transition 2.26 e-4
Regulation of transcriptional activity by PML 3.37 e-4
Cell Cycle: G1/S Check Point 4.26 e-4
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Table 3. 
A. Pathways effected by miRNA targets in SKNO1 cells. (continued)
Pathways effected in SKNO1 cells p-value
Expression of cyclins regulates progression through the cell cycle by activating 
cyclin-dependent kinases. 4.38 e
-4
Chronic myeloid leukemia 4.48 e-4
Cyclins and Cell Cycle Regulation 4.89 e-4
Telomeres, Telomerase, Cellular Aging, and Immortality 5.1 e-4
Acute myeloid leukemia 5.15 e-4
Cell cycle 6.28 e-4
MAPKinase Signaling Pathway 1.21 e-3
IGF-1 Signaling Pathway 1.48 e-3
Genes involved in Apoptosis 1.67 e-3
IL 6 signaling pathway 2 e-3
TNFR1 Signaling Pathway 2.67 e-3
Genes involved in Intrinsic Pathway for Apoptosis 2.67 e-3
Melanoma 2.92 e-3
FAS signaling pathway ( CD95 ) 3.37 e-3
Cell Cycle: G2/M Checkpoint 3.49 e-3
Genes involved in Death Receptor Signaling 3.57 e-3
Genes involved in p75NTR signals via NF-kB 3.57 e-3
TNF/Stress Related Signaling 4.48 e-3
IL-2 Receptor Beta Chain in T cell Activation 4.56 e-3
Genes involved in TRAF6 Mediated Induction of the antiviral cytokine IFN-
alphaeta cascade 5.31 e
-3
p38 MAPK Signaling Pathway 6.53 e-3
E2F1 Destruction Pathway 7.92 e-3
Apoptosis 8.72-3
B. Pathways effected by miRNA targets in NB4 cells.
Pathways effected in NB4 cells p-value
Pathways in cancer 9.11 e-9
Chronic myeloid leukemia 2.03 e-6
Inhibition of Cellular Proliferation by Gleevec 5.16 e-6
Acute myeloid leukemia 2.73 e-5
Toll-Like Receptor Pathway 9.37 e-5
NFkB activation by Nontypeable Hemophilus influenzae 1.06 e-4
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Table 3. 
B. Pathways effected by miRNA targets in NB4 cells. (continued)
Pathways effected in NB4 cells p-value
Influence of Ras and Rho proteins on G1 to S Transition 1.59 e-4
Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar 
Macrophages 1.92 e
-4
p53 signaling pathway 5 e-4
p38 MAPK Pathway 6.78 e-4
Genes involved in NF-kB is activated and signals survival 9.2 e-4
Apoptotic Signaling in Response to DNA Damage 9.41 e-4
IL-2 Receptor Beta Chain in T cell Activation 9.98 e-4
Integrin Signaling Pathway 1.05 e-3
B Cell Antigen Receptor 1.13 e-3
Regulation of eIF4e and p70 S6 Kinase 1.32 e-3
Glioma 2.08 e-3
Genes involved in p75NTR signals via NF-kB 2.1 e-3
Apoptosis 2.13 e-3
Cell Cycle: G1/S Check Point 2.39 e-3
Bone Remodelling 2.63 e-3
CD40L Signaling Pathway 3.24 e-3
TACI and BCMA stimulation of B cell immune responses. 3.24 e-3
The TrkA receptor binds nerve growth factor to activate MAP kinase pathways 
and promote cell growth. 3.24 e
-3
Melanoma 3.26 e-3
EGF Signaling Pathway 3.51 e-3
PTEN is a tumor suppressor that dephosphorylates the lipid messenger 
phosphatidylinositol triphosphate. 3.92 e
-3
PDGF Signaling Pathway 3.95 e-3
PI3K Pathway 4.42 e-3
Genes involved in TRAF6 Mediated Induction of the antiviral cytokine IFN-
alphaeta cascade 4.46 e
-3
PTEN dependent cell cycle arrest and apoptosis 5.55 e-3
TGF beta signaling pathway 6.49 e-3
Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha) 6.56 e-3
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Figure 3. Biological pathways targeted by differentially expressed miRNAs in AMLs.
 (A) Box plot of the genes targeted by highly expressed miRNAs in NB4 cells. The plot shows 
RPKM expression values of the genes in NB4 versus SKNO1 cells. (B) Genome browser 
screen shot of the CD69 gene targeted in NB4 cells. (C) Box plot of the genes targeted by highly 
expressed miRNAs in SKNO1 cells. The plot shows RPKM expression values of the genes in 
NB4 versus SKNO1 cells. (D) Genome browser screen shot of the JAG1 gene which is targeted 
in SKNO1 cells. (E-F) Box plot showing the expression of the differentially targeted genes in 
patients using the (Verhaak et al., 2009) dataset. The plot shows the averaged log2 expression 
values of the relevant genes from different M2 and M3 AML patients.
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miRNA clusters down regulated in NB4 cells
In our analysis we found two major clusters of miRNAs on chromosome 13 which 
showed altered expression between SKNO1 and NB4 cells. These clusters included 
mir-15a-mir-16-1 and mir-17-mir92a (Figure 4A&B). The mir15-16 cluster normally 
acts as a tumor suppressor and is found deleted or down regulated in various cancers, 
including leukemia (Aqeilan et al., 2010; Bandi et al., 2009; Bonci et al., 2008; 
Calin et al., 2008). The mir15-16 cluster is a negative regulator of the anti-apoptotic 
gene BCL2 and thereby increases apoptosis by targeting its transcript (Cimmino 
et al., 2005). Interestingly, we found a down regulation of this cluster in NB4 cells 
as compared to SKNO1 cells as well as a complementary up regulation of BCL2 
expression (Figure 4C). Contrary to the mir-15-16, the mir-17-92a cluster has been 
shown as overexpressed in different cancers and is linked to enhanced cell proliferation 
(Hayashita et al., 2005). Moreover, in a recent report this cluster was also shown 
to affect the hematopoietic compartment by targeting p53 (Li et al., 2012). In our 
study we noticed a major increase in its expression in SKNO1 cells as compared to 
NB4 cells and a complementary decrease of p53 expression in SKNO1 cells (Figure 
4D). Moreover, decrease of the mir-17-92a cluster in NB4 cells is also in line with 
previous miRNA expression studies where the mir-17 and mir-20a components of 
this cluster were shown to be down regulated in t(15,17) APL cases (Marcucci et 
al., 2011). Together these results suggest that the two leukemic cell lines exploit the 
leukemogenic potential of these two miRNA clusters rather differently to disturb the 
balance of gene expression in their own way.
Combinatorial effects of miRNAs and PML-RARα AML1-ETO oncofusion 
proteins
PML-RARα and AML1-ETO are the two hallmark oncofusion proteins associated with 
AML M3 and M2 subtypes and are expressed in NB4 and SKNO1 cells, respectively. 
These two oncofusion proteins are thought to create a repressive chromatin environment 
where they bind in the genome (Martens and Stunnenberg, 2010). Interestingly the 
genome-wide binding data of these oncofusion proteins previously generated in our lab 
revealed that the two miRNAs, mir-142 and mir-663 differentially expressed in NB4 
and SKNO1 cells (Figure 2 B,C) also showed an inverse correlation with the binding 
of the respective oncofusion protein. mir-142, which was found highly expressed in 
NB4 cells as compare to SKNO1 cells, showed AML1-ETO binding sites close to 
this regions in SKNO1 cells (Figure 5A), while mir-663, which was high in SKNO1 
cells as compared to NB4 cells, showed binding by PML-RARα in NB4 cells (Figure 
5B). These results suggest that apart from mRNA-coding target genes, there may exist 
an important role for the repressive activity of these oncofusion proteins in directly 
targeting and regulating the expression of miRNAs. 
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Figure 4. miRNA clusters down regulated in NB4 cells.
(A-B) Genome browser screen shots of the mir15-16 and mir17-92a miRNA clusters showing 
altered expression between NB4 and SKNO1 cells. (C) Bar chart showing the RPKM 
expression values of the MIR15-16 cluster and BCL2 gene in NB4 and SKNO1 cells. (D) Bar 
chart showing the RPKM expression values of the MIR17-92 cluster and of the TP53 gene in 
NB4 and SKNO1 cells.
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Figure 5. Combinatorial effects of miRNAs and PML-RARα AML1-ETO oncofusion 
proteins.
(A) Genome browser screen shot of the mir-142 genomic region. The plot shows low mir-142 
expression in SKNO1 cells versus NB4 cells, and strong binding of AML1-ETO in SKNO1 
cells close to this region, while no PML-RARα binding could be detected close by in NB4 cells. 
(B) Genome browser screen shot of the mir-663 genomic region. The plot shows high mir-663 
expression in SKNO1 versus NB4 cells, and correlating strong binding of PML-RARα in NB4 
cells close to this region, while no AML1-ETO binding was detected in SKNO1 cells.
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Conclusions and future prospective
Over the past years miRNAs have been known as one of the core factors regulating gene 
expression, and they have been extensively investigated in normal hematopoiesis and 
hematopoietic malignancies. However, miRNAs show diverse mechanisms of action 
due to overlapping target genes for different miRNAs and sometimes the presence of 
binding sites for several miRNAs within one gene. In most of the miRNA expression 
studies use of the RT-qPCR based assay is prevalent, whereby the accuracy of the 
determined expression level is dependent upon primer efficiency and specificity. It is 
therefore difficult to properly carry out a large scale miRNA expression analysis using 
RT-qPCR. Apart from that, microarrays are used for large scale expression analysis in 
miRNA studies. However, the use of a large amount of high quality RNA, accuracy 
and the cost of probe design are the major challenges that hamper the wide-spread 
use of this technique for genome-wide studies of miRNA expression. Collectively, all 
this adds to the methodology-specific complexities in investigating the expression and 
exact function of miRNAs in different cell types. 
Here in our study, we propose strand-specific RNA sequencing as a potential method 
for the simultaneous study of the mRNA and miRNA. Moreover, use of low amounts 
of RNA, between 100-250 ng as a starting material, highlights the major advantage of 
this technique. We detected more than 100 pri-miRNA transcripts which are expressed 
in two myeloid leukemic cell lines NB4 and SKNO1 respectively, harboring the PML-
RARα and AML1-ETO translocations. Further analysis revealed 43 miRNAs which 
showed altered expression in the two cell lines, including the previously identified mir-
223, mir-142 and mir-663. Interestingly, our pathway analysis showed that mainly the 
same pathways are affected by the two AML cell types. However, within the same 
pathways we observed the involvement of different miRNA and targeting of different 
members of the same pathway. Interestingly, we found examples of PML-RARα and 
AML1-ETO binding to differentially expressed miRNAs, suggesting that they might 
have a repressive effect on the expression of these miRNAs in their respective cell lines.
Detection of more than 100 pri-miRNA transcripts as well as the validation of 80% 
of them at the hand of published datasets further supports the possibility of using ss-
RNA-seq to study miRNA transcripts expressed in a particular cell type. Additionally, 
the low amount of starting material that is needed makes it a more appropriate 
methodology to study RNA expression in patient samples where only low amounts of 
material are available. In the future, selection of smaller sized fragments to generate the 
sequencing libraries may yield more exclusive results on the presence of fully mature 
miRNAs. Overall, in line with previous investigations, our results also emphasize the 
fact that miRNAs should be taken into account as additional factors to study the full 
leukemogenic program. Functional screening of these miRNA can help us to better 
comprehend the extent of their involvement in development or maintenance of leukemia 
and may provide a better set of prognostic markers for as yet poorly defined leukemias.
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Discussion
All the regulatory factors entering a cell nucleus encounter particular chromatin states 
that allow or prohibit their biological activity. As a result, alterations in the chromatin 
compaction are described as indispensible in the process of cellular development and 
differentiation (Graf and Enver, 2009; Thomas et al., 2011). Hematopoiesis is one of the 
best characterized and complex animal cell differentiation system where progressive 
restriction of the cellular fate is achieved by a highly coordinated interaction of lineage 
specific transcription factors and different epigenetic modifications. 
Mutations and genetic perturbations of transcription factors are known to interfere 
with the hematopoietic differentiation program. However, it is now evident that 
along with genetic lesions involving transcription and signaling proteins, epigenetic 
factors also cooperate to aberrantly regulate cell functioning, ultimately leading to 
disease progression (Bhalla, 2005). In a cell, chromatin compaction accommodates 
all DNA in the nucleus, however, at the same time it should allow the different 
transcriptional events to take place (Felsenfeld and Groudine, 2003). This process 
is governed by a wide range of chromatin modifiers that make the chromatin more 
accessible and open for other factors to exert their function or restrict their interaction 
with the DNA template. In a given cell type the accessible chromatin environment 
at regulatory chromatin regions such as promoters and enhancers is suggested to 
function as a primary scaffold for all the nuclear events to take place that regulate 
the gene expression programs (Boyle et al., 2008; Giresi and Lieb, 2009). Despite 
the important role of accessibility, chromatin architecture is much more extensively 
studied in terms of histone modifications as compared to the chromatin scaffold itself 
(Barski et al., 2007; Chi et al., 2010; Neff and Armstrong, 2009). 
The role of histone modifications and epigenetic enzymes in leukemia development 
is extensively investigated (Galm et al., 2006; Gronbaek et al., 2007). However, the 
exact roles of aberrant chromatin accessibility structure in leukemia progression is 
still unclear. This highlighted the need for more in-depth studies towards a better 
characterization of the chromatin accessibility state during leukemia development. 
This can help in comprehending the complex nature of the packaged genome and 
the importance of chromatin structure in regulating normal transcriptional activities 
during differentiation and development.
Chromatin landscape and (de)regulation of nuclear activities
The major aim of the project was to map the chromatin landscape of the acute myeloid 
leukemia (AML) genome by performing genome-wide chromatin accessibility 
mapping. In addition, an attempt was made to uncover the changes in chromatin 
architecture when the differentiation block of the leukemic cells is released, i.e. 
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when leukemic cells are forced to differentiate. To this end we generated genome-
wide chromatin accessibility maps of AML subtypes and patient blasts. We used a 
novel technique called nuclease accessible site sequencing (NA-seq) which couples 
conventional restriction enzyme treatment of the nuclei with next generation 
sequencing (NGS). NA-seq methodology and the use of two restriction enzymes 
with cutting preferences for different genomic regions gave us the first genome-wide 
“snapshots” of the functional DNA elements present in the leukemia genome (Chapter 
3). This resulted in the identification of over 100,000 accessible regions in both 
proliferating and all trans retinoic acid (ATRA) treated NB4 cells. NB4 cells represent 
acute promyelocytic leukemia (APL) cells, a distinct subtype of AML characterized by 
expression of the oncofusion protein PML-RARα. Our analysis highlighted NA-seq 
as an accurate methodology to capture accessible chromatin regions. This led to novel 
descriptions of the genome-wide chromatin accessibility landscape in AML cells and 
of the accessibility dynamics when leukemic cells are forced to differentiate such as 
in case of ATRA treatment of APL cells. Different clusters of accessible functional 
elements having distinct epigenetic repertoires were delineated and chromatin features 
associated with binding sites of AML-related oncofusion proteins were identified. 
Finally, correlations of accessibility patterns with gene expression could be drawn.
Functional elements and accessibility dynamics in APL genome 
APL is characterized by a differentiation block at the promyelocytic stage caused 
by PML-RARα. ATRA can release the blockage by causing degradation of PML-
RARα, thereby triggering the process of differentiation (Parmar and Tallman, 
2003). Identification of the dynamic chromatin regions during the process of cellular 
differentiation can help to unravel different molecular factors involved in cell fate 
decisions (Waki et al., 2011). In APL cells we found around 5000 regions which 
showed a change in accessibility from proliferating to differentiating cells after ATRA 
treatment (Chapter 3). Genomic annotation of these dynamic regions revealed that 
upon differentiation, around 83% of the regions which showed increased accessibility 
were non-promoter elements while only 17% were promoters. In contrast the regions 
which showed decrease in accessibility upon differentiation, 46% of them were the 
promoter elements. Increased accessibility of the non-promoter regulatory regions is 
suggestive of their important role in setting up the differentiation program of these 
leukemic cells. Accessible chromatin architecture and high RNAPII occupancy 
is suggested as a read out for genes that are either active or poised for activation 
(Song et al., 2011). We found a positive correlation between the highly accessible 
promoters identified by our assay and high RNAPII binding. This indicates that by 
using restriction enzymes we are able to identify accessible promoters associated with 
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genes that are either active or poised for activation. Furthermore, the presence of 
more non-promoter regions in ATRA treated APL cells point towards a transcriptional 
reprogramming which is tightly regulated through non-promoter regulatory elements 
leading to differentiation induction (Chapter 3). Motif analysis showed an enrichment 
for core ETS factor binding motif in the regions which showed increased accessibility 
upon ATRA treatment. ETS (E-twenty-six) is a large family of transcription factors 
that show specific DNA interactions using their common DNA binding domains while 
functional divergence of different members is attained through the rest of the protein 
sequence (Sharrocks, 2001). Many studies have shown a central role of the ETS 
factor proteins in hematopoietic lineage development and their deregulation has been 
reported in several leukemias (Kastner and Chan, 2008; Martens, 2011). Enhanced 
accessibility of the ETS factor core motif when the differentiation block is released 
indicates an important role of the ETS factors (de)regulation in APL pathogenesis. 
More detailed future studies can help to unravel the key member of the ETS factor 
family whose deregulation contributes to the disease pathogenesis. 
Epigenetic hallmarks of the regulatory regions in APL
Packaging of the DNA into chromatin makes it challenging for the cis-regulatory 
elements to be accessible and hence for trans-acting factors to interact with them. 
Consequently this epigenetic setting of the chromatin plays a pivotal role in regulating 
DNA-associated processes in normal to diseased state of a cell. In leukemia, apart from 
genetic defects, other features including a perturbed chromatin architecture governed 
through epigenetic changes histone modifications, DNA-methylation and microRNA 
mediated transcriptional regulation also underscore leukemia development (Chen et 
al., 2010). Subsequently chromatin landscape is found perturbed in several leukemias. 
The advent of state-of-the-art high throughput sequencing has made it possible for 
us to study at a global scale, changes in the patterns of these different epigenetic 
modifications and the underlying chromatin state. 
In order to study the chromatin architecture of the APL genome we performed 
genome-wide profiling of a large set of histone modifications and regulatory factors 
like p300 in NB4 cells (Chapter 3). Deposition pattern of the post translational histone 
modifications and their crosstalk with other chromatin modifiers are considered as 
deterministic factors in compartmentalization of the chromatin into hetero- and 
euchromatin domains (Suganuma and Workman, 2011). In our study, genome-wide 
profiling followed by unsupervised clustering of these epigenetic marks uncovered 
specific subsets of highly accessible functional elements in the APL genome, each 
subset with a characteristic epigenetic makeup. H2A.Z appeared enriched over 
more than 80% of the clustered regions. H2A.Z is an evolutionary conserved H2A 
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histone variant which has been linked with gene activity as it spreads over the TSS 
of active genes (Barski et al., 2007; Valdes-Mora et al., 2011). H2A.Z presence at the 
majority of our accessible regions suggests that H2A.Z is a broad-spectrum hall mark 
associated with accessible functional elements. We could also identify three distinct 
clusters having varying levels of histone acetylation and p300, an acetyltransferase 
protein. p300 is considered as an enhancer marker (Heintzman and Ren, 2009; Visel et 
al., 2009) and enhancers are known to have a critical role in regulating transcriptional 
events in a cell by acting as docking sites for different co-activator or repressor 
complexes. Histone acetylation is so far considered as one of the major disruptions 
of the histone code in the context of PML-RARα and AML1-ETO induced AML 
(Martens et al., 2010; Martens and Stunnenberg, 2010). Therefore in our study the 
presence of these heterogeneous p300 marked clusters and their association with 
key hematopoietic transcription factors suggest that they encompass sets of distinct 
functional elements involved in setting the stage for AML leukemogenesis. 
PML-RARα and AML1-ETO chromatin binding paradigms
AMLs are often characterized by chromosomal translocations that give rise to 
oncofusion proteins. The most frequent fusions involve AML1 or RARα as partner 
genes (Look, 1997). Expression of the resultant fusion products are hallmark of AML 
pathogenesis and translate into aberrant chromatin modifying activities and perturbed 
chromatin landscape. A wide spread paradigm for their mechanism of action is 
the recruitment of co-repressive complexes like NCoR, SMRT including histone 
deacetylases (HDACs) in a rather constitutive manner (Chapter 2). This creates a 
relatively stable repressive state of chromatin at the genes important for myeloid 
development. Interestingly, we found that the majority of the PML-RARα binding 
sites are at accessible chromatin regions. Moreover, the binding sites were enriched 
with high p300 and low acetylation levels (Chapter 3). This epigenetic pattern which 
we found on PML-RARα binding sites is consistent with its repressive activities at 
non-promoter regulatory regions. Our study shows the binding of the PML-RARα at 
accessible chromatin regions and suggests that these regions are actively deacetylated 
through recruitment of HDAC activities by PML-RARα. Functional examination of 
these regions showed affiliation with several key myeloid differentiation regulators 
such as GFI1 and RUNX1, and an influence on the expression of these genes might 
be crucial for leukemia development. Another important aspect of the PML-RARα 
functioning is its binding preference at retinoic acid response elements in a rather 
constitutive manner in place of the wild type RAR:RXR complex, (Kamashev et al., 
2004). Moreover, on a genome-wide scale this binding repertoire shows an expanded 
preference for the variable length and spaced DR motifs (Martens et al., 2010). When 
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pharmacological doses of ATRA were applied to degrade PML-RARα, we found an 
enhanced accessibility at classical retinoic acid response elements such as DR2 and 
DR5 which are preferred RAR:RXR heterodimer binding sites. This suggests that 
at these locations PML-RARα is replaced by the wild type RAR:RXR heterodimer, 
supporting the involvement of RAR:RXR heterodimer complex in rendering the 
chromatin environment more accessible at these response regions. 
Another important oncofusion protein is AML1-ETO, which is associated with the 
M2 subtype of AML. Although belonging to distinct subtypes of AMLs, both AML1-
ETO and PML-RARα proteins share several similar molecular features including their 
chromatin affinities and the downstream pathways which they target (Martens and 
Stunnenberg, 2010). To investigate whether similarities can be extended to chromatin 
architecture, we extended our chromatin accessibility mapping to the AML1-ETO 
expressing SKNO-1 cell line. Analysis revealed the preferential binding of AML1-
ETO to accessible chromatin regions similar to what we found for PML-RARα. 
Genome-wide binding patterns of both oncofusion proteins show a high preference 
for intergenic enhancer elements. In our study we found a characteristic pattern of 
hypoacetylated chromatin being associated with mutually shared AML1-ETO and 
p300 binding sites. This feature seems to be a common characteristic of both PML-
RARα and AML1-ETO and also derives the notion that HAT activity of p300 does 
not counteract the aberrant deacetylated environment induced by PML-RARα or 
AML1-ETO through their interactions with HDACs (Figure 1). The balance of the 
antagonistic functions of the HATs and HDACs has been proposed to play a pivotal 
role in attaining the active or inactive states of genes (Wang et al., 2009). Moreover, 
this dynamic cycle of gene (in)activation also requires additional factors like RNAPII, 
co-activators and repressor molecules (Peserico and Simone, 2010). Based on these 
findings and our data we can suggest that these oncofusion proteins function as 
stabilizers of the HDAC molecules in AML cells by inducing an imbalance of the 
acetylation/deacetylation activity, hence giving rise to a hypoacetylated chromatin 
environment. Intriguingly in a recent study, acetylation of AML1-ETO by p300 was 
suggested as a key event activating AML1-ETO-induced up-regulation of the self 
renewal associated genes in hematopoietic cells (Wang et al., 2011). This apparent 
discrepancy might be due to a functional divergence in that p300 can still acetylate 
AML1-ETO while simultaneously HDACs deacetylate histones but not AML1-
ETO, or that activity of the acetylated AML1-ETO is required for the regulation of 
a particular subset of genes. Overall our study demonstrates that two major AML 
associated oncofusion protein bind to open chromatin regions but that additional factors 
such as hematopoietic transcription factors, co-activator and repressor complexes are 
required for the transcriptional regulation instigated by these etiologically important 
oncofusion proteins.
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Figure 1. Genome browser screen shot of the chromosome 19 locus showing the binding 
pattern of different epigenetic marks. The regions bound by PML-RARα and AML1-ETO show 
a reduced level of acetylation
MicroRNAs functional relevance to AML pathogenesis 
Apart from deregulated gene expression, deregulation of non-coding RNAs has also 
been associated while full transformation of leukemic cells. In the last couple of years 
miRNAs, which are small non coding RNA molecules, appeared as new paradigms for 
gene expression regulation in normal cell development as well as in the pathogenesis 
of leukemia. 
Amongst miRNAs miR-142s, miR-181a and miR-223, were the first identified murine 
hematopoietic tissue specific miRNAs which show expression in a lineage specific 
manner (Chen et al., 2004). MicroRNAs are often located at fragile genomic loci 
and their deregulation can contribute to the onset of leukemia. In some expression 
studies distinct miRNA patterns are shown associated with different subtypes of AML 
(Cammarata et al., 2010; Garzon et al., 2008; Jongen-Lavrencic et al., 2008). However, 
it is still challenging to perform large scale analysis of miRNA profiles because of 
their less abundance and the requirement of large amount of starting material. In 
our study we performed genome-wide strand specific RNA-seq (ss-RNA-seq) with 
a very low amount of total RNA (~250ng). Furthermore, sequencing and the data 
analysis not only gave a comprehensive view of the protein coding messenger RNA, 
but also identified other non-coding RNAs like primary microRNAs (pri-miRNAs). 
We analyzed pri-miRNA expression to identify putative miRNAs expressed in 
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the AML M2 SKNO-1 and M3 NB4 cell lines. We found more than 100 miRNA 
transcripts with significant tag counts and RPKM values, where by 43 of them display 
differential expression between M2 and M3 AML subtypes (chapter 5). We observed 
high expression of several miRNAs such as mir-142 in APL cells while miR-663 
and miR-223 were down-regulated in NB4 cells. MiR-663 and miR-223 activity is 
suggested to be positively regulated by ATRA and known to play an important role in 
differentiation (Garzon et al., 2007; Jian et al., 2011). This discriminatory expression 
of these miRNAs between NB4 and SKNO-1 cell lines suggests unique functions in 
APL pathogenesis. Our downstream pathway analysis of the genes targeted by these 
miRNAs revealed many common biological pathways that are affected between the 
M2 and M3 AML subtypes. This suggests a similar mechanism of action between the 
two AML subtypes by exploiting the leukemogenic potential of different miRNAs. 
Overall these results propose ssRNA-seq as a robust method for studying pri-miRNAs, 
starting with very low amounts of total RNA and emphasize the biological relevance 
of these miRNAs for AML. 
Epigenetic effects on immunological reprogramming 
Along the lineage commitment hierarchy of the hematopoiesis, white blood cells 
are a diverse group of cell types which make-up the immune system of the body. In 
higher organisms, the immune system is very well segregated into memory-specific 
(adaptive) and non-specific (innate) immune systems. Monocytes and macrophages 
are part of the innate immune system of the body (Geissmann et al., 2010; Parkin 
and Cohen, 2001). A rapid and non-specific response generated against any foreign 
pathogen is the widely accepted paradigm for their mechanism of action. However, 
there is a handful of studies which also point towards memory based properties in the 
cells of the innate immune response (Netea et al., 2011; Sun et al., 2011). Exploiting 
this aspect of the innate immunity we could show (chapter 4) an enhanced memory-
based response of primary monocytes against reinfection with Candida albicans 
after priming with C.albicans or β-glucans. Monocytes trained first with either 
C.albicans or β-glucans showed increased production of pro-inflammatory cytokines 
upon re-infection. Genome-wide ChIP-seq analysis showed a mechanism involving 
epigenetic changes in the chromatin architecture of the trained monocytes. We found 
a global increase in H3K4me3 over the trained monocytes as compared to the wild 
type, while H3K27me3 remained constant. Moreover, at the transcriptomal level we 
found up-regulation of several genes involved in the immune response. Our time 
course experiments revealed the induction of this epigenetic programming upon the 
first stimulation of monocytes with β-glucans for 24h. Furthermore, this epigenetic 
pattern was stable over a period of at least seven days. This global increase of the 
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H3K4me3 and thereby a permissive chromatin environment upon β-glucans treatment 
at regions including pro-inflammatory cytokines and receptor molecules like TLRs 
(TLR4) suggests the key involvement of an epigenetic setup in memory retention of 
the monocytes. 
Conclusions and future prospects
The work presented in this thesis provides new insights into the involvement 
of epigenetic changes in the regulatory hematopoietic hierarchy, ranging from 
proliferating leukemic cells to terminally differentiated cells of the immune system. 
By using state-of-the-art high throughput sequencing approaches (NA-seq, ChIP-
seq) and an extensive bio-informatic analyses we were able to present a detailed and 
comprehensive view of the chromatin landscape in M2 and M3 subtypes of AML. For 
example, our genome-wide chromatin accessibility data showed a large repertoire of 
open chromatin regions in proliferating and differentiating AML associated cell lines 
and patient blasts. In addition we mapped many other chromatin features associated 
with the aberrant epigenome of the AML cells, ranging from post-translational histone 
modifications, like histone acetylation and methylation to the transcription-associated 
histone variant H2A.Z as well as enhancer-associated protein p300. Altogether, this 
study adds a new and important additional layer of information regarding the status 
of the genome-wide chromatin landscape in AML subtypes. We anticipate that this, 
together with ongoing detailed characterizations of chromatin stretches and associated 
genes in proliferating and differentiating hematopoietic cells can help to better 
comprehend the molecular pathways affected in leukemia and possibly other diseases 
with an epigenetic etiological components. 
Our studies also revealed that two hallmark AML-associated oncofusion proteins, 
PML-RARα and AML1-ETO, show preferential binding to the accessible chromatin 
region with a particular epigenetic makeup, allowing us to predict an epigenetic 
signature for the binding sites of both oncofusion proteins. Further exploration of 
the epigenetic patterns associated with PML-RARα and AML1-ETO, but also other 
oncofusion protein-bound regions can help to further characterize the regulatory 
regions involved in AML leukemogenesis. As a large number of AML patients do 
not harbor detectable chromosomal translocations it would be interesting to expand 
the chromatin accessibility maps to different AML patients in order to have detailed 
information on the extent of variability in the epigenetic landscape between different 
AML cells. This extended analysis of chromatin accessibility dynamics and other 
associated epigenetic features can not only be expected to have a possible diagnostic 
value for characterization of different leukemias, but might ultimately also allow 
the discovery of potential (epigenetic) drugs that can cure the disease (Lohrum et 
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al., 2007). In this thesis we also showed the involvement of epigenetic chromatin 
environment in generating specific responses by the terminally differentiated cells of 
the immune system. Our genome-wide studies of the epigenetic features in monocytes 
revealed an involvement of the epigenetic programming in inducing memory 
characteristics in innate immune cells upon a re-infection. H3K4me3 appeared as an 
important histone modification which showed an increased deposition in the fungally 
trained monocytes as compare to the untreated controls. Given the importance of the 
innate immune system as the first line of defense, our study brings forward a novel 
aspect of epigenetic regulation in modulation of the innate immune cells to generate 
memory properties. In future it will be of great interest to further investigate the role 
of epigenetic factors in developing immune response memory which can help to 
improve the development of future vaccination protocols.
Overall, detailed knowledge of the chromatin architecture and the epigenetic features 
associated with it has been, and in future will be, proven as an effective tool in 
unraveling the molecular mechanisms underlying normal cell homeostasis as well 
as of those underlying the disease state of a cell. Moreover, this will further uncover 
novel entry points and insights that can ultimately form the basis for future drug 
development.
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Summary
Chromatin compaction allows accommodation of the entire genome, which consists 
of over 3 billion DNA base pairs, in the nucleus of a cell. It involves series of events 
starting with deposition of histone proteins on the DNA template to form nucleosomes, 
higher order folding of the chromatin as well as post translational histone modifications. 
However, this chromatin compaction is not static and developmental progression 
requires alterations in chromatin conformation for different nuclear events to take 
place. Therefore, knowledge of the chromatin architecture is of crucial importance to 
fully understand the regulatory events taking place in a cell. This thesis focuses on 
the hematopoietic system and aims to decipher the epigenetic chromatin landscape 
in acute myeloid leukemia (AML) and in terminally differentiated blood cells of the 
myeloid compartment. 
In AML, a large number of cases are caused by non-random chromosomal 
translocations giving rise to oncofusion proteins. In many cases these genetic 
alterations have important prognostic value for the selection of appropriate therapy. 
One of the most prevalent chromosomal translocation associated with 95% of acute 
promyelocytic leukemia (APL) cases is between chromosome 15 and 17 and gives rise 
to the PML-RARα oncofusion protein. Recent genome-wide studies have suggested 
perturbed epigenetic signatures associated with PML-RARα binding in APL cells and 
patient blasts. In chapter 2 we have discussed in detail these functional characteristics 
associated with global PML-RARα binding as well as the essential pathways and 
genes targeted. In chapter 3 we extended these analysis and performed genome-wide 
chromatin accessibility assays to identify the open chromatin regions in the APL 
genome as well as in other AML subtypes and patient blasts. Our study provides 
comprehensive maps of accessible chromatin regions of different AML cells and 
gives insight into the dynamics of accessibility in APL cells going from proliferating 
to differentiated states. Further bioinformatic analysis revealed specific clusters of 
accessible functional elements with different epigenetic make-up in terms of histone 
modifications, DNA methylation and regulatory factors like p300. Our results 
show that the PML-RARα and AML1-ETO oncofusion proteins bind to accessible 
chromatin regions and that chromatin accessibility together with p300 binding and 
histone acetylation can serve as landmarks to predict AML1-ETO and PML-RARα 
binding. 
In chapter 5 we further focused on the AML cells and performed genome-wide strand 
specific RNA-seq (ssRNA-seq) analysis to identify the pri-miRNAs that are expressed 
in NB4 and SKNO-1 cells, which represent AML M3 and M2 subtypes respectively. 
In this study we identified a set of > 100 pri-miRNA transcripts, 43 of them showed 
expression changes between these two cell types. Further bioinformatic analysis 
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based on the validated target genes of these miRNAs gave us a comprehensive list 
of the miRNA (de)regulated pathways in PML-RARα and AML1-ETO expressing 
subtypes of AML. 
Together, the above mentioned studies provide comprehensive information on the 
global chromatin landscape and gene regulation in AML cells. Moreover, these 
findings can serve as an entry point for the further characterization of the aberrantly 
regulated regions in AML to better comprehend the molecular pathways affected. 
In chapter 4 we performed genome-wide analysis of the epigenetic signatures in 
monocytes (innate immune cells) untreated and C.albicans trained. This study shows 
that C.albicans and beta-glucans induce functional reprogramming of monocytes, 
leading to enhanced cytokine production in vivo and in vitro. We found an association 
of monocyte training and stable changes in histone H3K4me3 levels. Our results 
suggest involvement of an epigenetic mechanism in the functional reprogramming 
of the monocytes facilitating memory retention. This study brings forward a novel 
aspect of the epigenetic regulation with respect to memory retention properties of 
the innate host defense. Given the importance of the innate immune system as first 
line of defense against infections further characterization of the epigenetic etiological 
components in generating memory properties can open new research horizons for 
developing future vaccines. 
Together, this thesis provides important novel insights into the epigenetic processes 
that orchestrate the chromatin landscape in healthy as well as disease blood cell types.
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Samenvatting
Door middel van chromatine condensatie past het hele genoom, wat bestaat uit 3 
miljard DNA base-paren, in de celkern. Deze condensatie bestaat uit verschillende 
gebeurtenissen, waaronder de afzetting van histon eiwitten op het DNA waardoor 
nucleosomen worden gevormd, post-translationele histon modificaties en hogere 
orde vouwing van het chromatine. Chromatine condensatie is echter niet statisch 
en de cel vereist aanpassingen in chromatine conformatie tijdens de ontwikkeling 
zodat verschillende nucleaire processen plaats kunnen vinden. Daarom is kennis 
van de chromatine structuur van cruciaal belang om de regulerende processen in een 
cel volledig te kunnen begrijpen. Dit proefschrift richt zich op het hematopoëtisch 
systeem en stelt zich als doel om het epigenetische landschap in acute myeloïde 
leukemie (AML) en uit-gedifferentieerde bloed cellen van het myeloïde compartiment 
te ontcijferen.
Een groot aantal gevallen van AML wordt veroorzaakt door chromosomale 
translocaties die leiden tot onco-fusie eiwit expressie. In veel gevallen hebben deze 
genetische veranderingen een belangrijke prognostische waarde voor de selectie van 
een geschikte behandeling. Eén van de meest prevalente chromosomale translocaties, 
geassocieerd met 95% van alle gevallen van acute promelocytische leukemie (APL), 
is tussen chromosoom 15 en 17 en leidt tot expressie van het PML-RARα onco-
fusie eiwit. Recente genoom-brede onderzoeken suggereren dat een verstoorde 
epigenetische signatuur geassocieerd is met PML-RARα binding in APL- en patiënten 
cellen. In hoofdstuk twee hebben we deze functionele karakteristieken geassocieerd 
met globale PML-RARα binding en de hierdoor beïnvloede genen en essentiële 
pathways besproken. 
In hoofdstuk drie hebben we deze analyse uitgebreid met genoom-brede chromatine 
toegankelijkheids proeven om de regio’s met open chromatine te identificeren in het 
APL genoom en in andere AML subtypes. Ons onderzoek heeft uitgebreide kaarten 
van toegankelijk chromatine in verschillende AML cellen opgeleverd en biedt inzicht 
in de toegankelijkheids dynamiek van prolifererende en differentierende APL cellen. 
Verdere bio-informatische analyse onthulde specifieke clusters van toegankelijke 
functionele elementen met verschil in epigenetische opmaak wat betreft histon 
modificaties, DNA methylatie en regulatoire factoren als P300. Onze resultaten 
tonen aan dat de PML-RARα en AML1-ETO onco-fusie eiwitten aan toegankelijke 
chromatine regio’s binden en dat chromatine toegankelijkheid, samen met P300 
binding en histon acetylatie, als baken voor identificatie van  AML1-ETO en PML-
RARα binding kan dienen.
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In hoofdstuk 5 verdiepten we ons verder in de AML cellen en voerden genoom-
brede streng specifieke RNA-seq (ssRNA-seq) proeven uit om de pri-miRNA’s te 
identificeren die tot expressie komen in NB4 (AML M3) en SKNO-1 (AML M2) 
cellen. In dit onderzoek identificeerden we een set van >100 pri-miRNA transcripten, 
waarvan er 43 een verandering in expressie tussen de twee cel typen toonden. Verdere 
bio-informatische analyse, gebaseerd op de gevalideerde target genen van deze 
miRNA’s, gaf ons een uitgebreide lijst met ge(de)reguleerde pathways in de PML-
RARα en AML1-ETO AML subtypes. 
Samenvattend bieden de boven genoemde onderzoeken uitgebreide informatie 
over het globale chromatine landschap en gen regulatie in AML cellen. Daarnaast 
kunnen deze bevindingen als invalshoek voor verdere karakterisatie van afwijkend 
gereguleerde regio’s in AML dienen, zodat de geaffecteerde pathways beter kunnen 
worden begrepen. 
In hoofdstuk 4 voerden we genoom-brede proeven uit op de epigenetische signatuur 
van monocyten (cellen van het aangeboren immuun systeem), onbehandeld en 
getraind met C. Albicans. Dit onderzoek toont aan dat C. Albicans en beta-glucanen 
functionele herprogrammering van monocyten induceren, wat leidt tot verhoogde 
cytokine productie in vivo en in vitro. We vonden een associatie tussen monocyte 
training en stabiele veranderingen in het niveau van histon H3K4me3. Ons resultaat 
suggereert betrokkenheid van een epigenetisch mechanisme in de functionele 
herprogrammering van monocyten, wat geheugen retentie faciliteert. Deze studie 
brengt een nieuw facet van epigenetische regulatie wat betreft eigenschappen van 
geheugen retentie en de aangeboren afweer naar voren. Gezien het belang van het 
aangeboren immuun systeem als eerste verdedigingslinie tegen infecties kan verdere 
karakterisatie van de epigenetische etiologische componenten in het genereren 
van geheugen eigenschappen nieuwe mogelijkheden openen voor onderzoek naar 
toekomstige vaccins.
Samengenomen biedt dit proefschrift belangrijke nieuwe inzichten in de epigenetische 
processen die het chromatine landschap arrangeren in zowel gezonde als zieke bloed 
cel types. 
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